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Saccharomyces cerevisiae Arv1p (ARE2 required for viability 1) is an endoplasmic reticulum 
(ER)-localized, functionally conserved protein that was initially observed to mediate subcellular 
sterol distribution, and has since been implicated in the movement of multiple lipid species.  In 
this thesis, we examined the role of ARV1 in S. cerevisiae and mammalian systems by two 
approaches.  In yeast, we used gene deletion to access loss of Arv1p function.  In mammalian 
cells we utilized antisense oligonucleotides (ASOs) to decrease ARV1 expression in vitro and in 
vivo.  In the yeast model, loss of Arv1p function results in sensitivity to modulators of sphingolipid 
homeostasis and aberrant accumulation of exogenous sterols.  Transcription microarrays 
demonstrated that ARV1 deletion impacts ER homeostasis and activates the transcription factor 
HAC1, a component of the unfolded protein response (UPR) signaling cascade in yeast.  
Moreover, arv1Δ strains exhibited constitutive UPR induction, mediated by the unfolded protein 
sensor Ire1p.  Genetic interaction studies revealed that the arv1Δ ire1Δ homozygous haploid 
strain is inviable, suggesting the UPR protects the cell from arv1Δ-mediated stress.  In order to 
assess the stimulus for arv1Δ-mediated UPR induction, arv1Δ ire1Δ heterozygous diploids were 
transformed with mutated Ire1p core luminal domains (cLDs) that are sufficient to transmit the 
signal for UPR induction but are defective in sensing unfolded proteins in the ER lumen.  The 
mutant cLDs were able to rescue the lethality of the arv1Δ ire1Δ haploid.  These strains exhibited 
increased UPR induction that was independent and additive with protein misfolding.  
Furthermore, ARV1 deficiency in murine macrophages activated PERK-mediated UPR induction, 
particularly an upregulation of the cell death effector, CHOP.  ARV1 deficiency also caused 
apoptosis, likely due to prolonged UPR induction, a phenomenon that was exacerbated by 
inhibiting cholesterol esterification at the ER.   
  In murine and human models, ARV1 is implicated in intracellular cholesterol 
homeostasis and bile acid metabolism.  ASO-mediated decreases in ARV1 expression in vivo 
occurred primarily in the liver and adipose.  ARV1 ASO-treated animals did not exhibit UPR 
activation but were hypercholesterolemic and had increased levels of hepatic and plasma bile 
acids.  Consequently, accumulating bile acids transiently activated FXR-regulatory pathways, 
including target genes SHP, CYP7α1, NTCP and ABCB11.  Furthermore, knockdown of ARV1 
expression in hepatocytes established a role for human ARV1 in intracellular cholesterol 
distribution.  ARV1 ASO-treated HepG2 cells exhibited accumulation of ER cholesterol, 
decreased SREBP processing and decreased expression of SREBP targets, suggesting that 
human ARV1 may mediate cholesterol export from the ER.   
In summation, loss of ARV1 has a profound impact on lipid homeostasis in yeast and 
metazoans.  Various sterol detoxification pathways are activated in order to offset the loss of 
ARV1.  In a hepatocyte, cholesterol biosynthesis is decreased and bile acid secretion is 
increased, in response to ARV1 deficiency.  In yeast and macrophage models, where conversion 
of excess sterols into bile acids is not possible, the UPR is activated in order to compensate for 
loss of ARV1 function.  Taken as a whole, these studies reflect the role of ARV1 in ER sterol 
distribution and trafficking, and the profound impact of decreased ARV1 expression on 
intracellular sterol homeostasis.  
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CHAPTER 1: LITERATURE REVIEW 
 
Part I.  The sterol moiety. 
 
Significance and structure.  Cholesterol is an essential molecule that is implicated in many 
aspects of physiology.  The conversion of cholesterol into bile acids in the liver is necessary for 
absorption of essential dietary nutrients and the major route of cholesterol excretion in the body.   
Conversion of cholesterol into steroid hormones regulates physiological processes, such as salt 
and water balance, stress responses, as well as reproduction.  In a cellular context, cholesterol is 
essential for proper membrane fluidity, permeability and activity of membrane-bound proteins.  
Nonetheless, the critical functions of this molecule are undermined by the slew of diseases 
caused by its misregulation.   
The significance of sterols in membrane physiology is largely due to its unique structure.  
The structural unit of cholesterol is a tetracyclic carbon skeleton containing a double bond 
between C5 and C6 and a hydroxyl group at C3 (Figure 1-1) [1,2].  The single hydroxyl group on 
the cholesterol molecule confers an amphipathic nature.  The planar ring structure of the steroid 
molecule allows for efficient packing between the fatty acyl chains of membrane phospholipids; 
thus, sterols function as a rigidity factor in cell membranes, providing proper conformation for 
integral membrane proteins and foci for signaling machinery [3].   
In contrast to mammalian cells, the prominent sterol in fungi is ergosterol, which differs 
from cholesterol by two additional double bonds at C7 and C22, and a methyl group at C28 [4].  
However, in vitro esterification assays in S. cerevisiae demonstrate that yeast are able to 
metabolize various substrates, including ergosterol, cholesterol and 7-dehydrocholesterol [5].  
Thus, S. cerevisiae is a suitable model system for the study of sterol metabolism, despite 
differences in endogenous sterols. 
 
Sterol biosynthesis.  The synthesis of cholesterol (mammals) and ergosterol (fungi) involves a 
complex series of over 20 enzymatic reactions [6] that occur primarily in the endoplasmic 
reticulum (ER) [7].  Sterol biosynthesis in eukaryotes can be thought of as two pathways 
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occurring in sequence.  The first, called the isoprenoid or mevalonate pathway, involves the 
formation of farnesyl pyrophosphate (FPP) from 2 molecules of acetyl-CoA [8] (Figure 1-2).  At 
this point, the pathway diverges to generate both sterol and non-sterol end products including 
hemeA [9], quinones [10], dolichols [11] and farnesylated proteins [8].  Not surprisingly, enzymes 
of the isoprenoid pathway that function downstream of mevalonate are essential in yeast [4].  The 
mevalonate pathway includes the conversion of HMG-CoA to mevalonate by HMG-CoA 
reductase, the rate-limiting step in sterol biosynthesis.  This reaction is catalyzed by HMG-CoA 
reductase in mammalian cells and by the functionally conserved isozymes encoded by HMG1 
and HMG2 in S. cerevisiae.  The second pathway, the cholesterol- or ergosterol-dependent 
branch, involves the generation of the sterol end product.  Three reactions after the generation of 
FPP, the sterol biosynthetic pathways of yeast and mammalian systems diverge in order to 
generate their respective sterol end products [12].  Thus, the sections to follow will cover the 
reactions of the mevalonate pathway through the generation of lanosterol, as they pertain to both 
yeast and mammals, followed by individual descriptions of the respective sterol-specific 
pathways.   
The first step in the mevalonate pathway is the condensation of 2 molecules of acetyl-
CoA to form acetoacetyl-CoA, catalyzed by the enzyme acetoacetyl-CoA thiolase (Erg10p in 
yeast) [4,13].  This is followed by the condensation of a third molecule of acetyl-CoA to form 
HMG-CoA, catalyzed by HMG-CoA synthase (Erg13p in yeast).  Next, the conversion of HMG-
CoA to mevalonate is catalyzed by the action of HMG-CoA reductase.  Isopentenyl 
pyrophosphate (IPP), the 5-carbon molecule that serves as the structural basis of isoprenoid 
species, is generated from mevalonate, catalyzed by a series of phosphorylations and 
decarboxylations (Erg12p, Erg8p and Erg19p in yeast).  IPP then polymerizes to form the 10-
carbon geranyl pyrophosphate (GPP) (yeast Idi1p), followed by its conversion to the 15-carbon 
FPP (yeast Erg20p) [4,8].  Condensation of FPP by the action of squalene synthase (yeast 
Erg9p) results in the 30-carbon molecule squalene, the first step dedicated to sterol biosynthesis.  
The linear squalene molecule then undergoes cyclization and several intramolecular 
rearrangements to form the four-ring cyclopentanophenanthrene nucleus (steroid nucleus) of 
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lanosterol, common to all natural steroids [14].  Subsequent demethylation steps yield the 27-
carbon molecule, cholesterol [8]. 
Ergosterol synthesis diverges from cholesterol synthesis after the formation of lanosterol.   
Lanosterol cannot support the sterol viability requirement in S. cerevisiae; thus, lanosterol C-14 
demethylase (Erg11p) is essential [4].  This enzyme is also the target of azoles, a class of 
antifungals used to treat fungal infections in humans [15].  Following the subsequent formation of 
4,4-dimethylzymosterol by Erg24p, Erg25p-Erg26p-Erg27p catalyzes two subsequent 
demethylations on C4.  Finally, the terminal steps of ergosterol biosynthesis facilitate the 
conversion of zymosterol to ergosterol [4].   
 
Distribution and partitioning.  The heterogeneous arrangement of sterols in subcellular and 
plasma membranes reflects the role of this lipid species (Figure 1-3).  The molar fraction of 
sterols in the ER is low [16], increases along the secretory pathway, and is highly enriched in the 
plasma membrane.  This is particularly important for the regulation of cholesterol synthesis; 
experiments in purified ER membranes demonstrate that transcriptional activation of cholesterol 
biosynthesis is subject to a particular threshold of ER cholesterol (below 5 mol% activates 
SREBP-2 processing) [16].  Moreover, the proper distribution of free sterols in membranes is 
critical for protein trafficking [17,18], and it is hypothesized that sterol depletion alters the 
formation of sphingolipid-sterol microdomains.   
Until recent advancements in microscopy and spectroscopy which demonstrated that 
membrane microdomains exist on the nanoscale, the concept that sterols and sphingolipids 
associate into lipid-ordered self-associating microdomains was controversial [19].  The 
association of sterols and sphingolipids into cold, non-ionic detergent resistant membrane 
microdomains (lipid rafts) suggests that lateral segregation of these lipid species in membranes 
may facilitate biological function.  Lipid rafts demonstrate selectivity for receptors, scaffolding 
molecules and secondary signal transducers.  One type of raft-associated protein are 
glycophosphatidylinositol (GPI)-anchored proteins, a class of soluble proteins covalently attached 
to an insoluble lipid moiety required for membrane scaffolding [20].  Fluorescence anisotropy 
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experiments demonstrate that the GPI-anchored folate receptor associates with detergent-
resistant membranes and that this association is disrupted upon cholesterol depletion [21].  This 
suggests an intimate link between cholesterol partitioning, raft formation and protein trafficking. 
  
Part II.  Cholesterol homeostasis in mammalian systems. 
 
Overview.  This section covers the many facets of cholesterol homeostasis in a mammalian 
system.  In order to understand the impact of ARV1 deficiency in mammalian cells, it is important 
to understand all aspects of cholesterol homeostasis.  Cholesterol homeostasis can be broken 
down into four categories, all of which are described in sections below:  
• Cholesterol biosynthesis: Transcriptional and post-transcriptional regulation 
• Cholesterol trafficking: Extracellular and intracellular cholesterol movement  
• Storage: Cholesteryl ester formation 
• Metabolism: Conversion of cholesterol into bile acids and steroid hormones  
Topics that are more relevant to the research in this thesis are covered in greater depth 
(transcriptional regulation of cholesterol biosynthesis, lipoproteins and extracellular cholesterol 
trafficking, intracellular cholesterol trafficking, cholesterol esterification and bile acids), while the 
remaining topics (post-transcriptional regulation of cholesterol biosynthesis and steroid hormone 
synthesis) are summarized in brief. 
 
Regulation of cholesterol biosynthesis.   
Transcriptional regulation 
Regulation of cholesterol biosynthesis in mammalian cells is primarily mediated by negative 
feedback inhibition due to subcellular cholesterol accumulation.  Transcriptional activation of 
cholesterol biosynthesis in a sterol-depleted state occurs through the proteolytic processing and 
membrane release of sterol regulatory-element binding proteins (SREBPs).  SREBPs are basic 
helix-loop-helix leucine zipper transcription factors that regulate cholesterol and fatty acid 
biosynthesis by binding to sterol regulatory elements (SREs) in the promoters of target genes.  
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There are three isoforms of SREBP encoded by two separate genes.  SREBP-2, encoded by the 
SREBP-2 gene, preferentially activates genes involved in cholesterol biosynthesis, including 
HMG-CoA reductase, farnesyl diphosphate synthase and squalene synthase [22].  SREBP-1c 
and SREBP-1a are encoded by alternate splicing of the first exon of the SREBP-1 gene.  
SREBP-1c (also called ADD1) preferentially regulates genes involved in fatty acid biosynthesis, 
including acetyl-CoA carboxylase and fatty acid synthase [22,23,24].  SREBP-1a regulates all 
SREBP target genes [22].   
SREBP is embedded in the ER membrane in a hairpin fashion so that both the N- and C-
termini face the cytosol.  Under conditions of cholesterol abundance, SREBP remains in the ER 
bound to SREBP cleavage-activating protein (SCAP) through its C-terminus [12].  SCAP serves 
the dual function of escorting SREBP to the Golgi for processing and sensing cellular levels of 
cholesterol.  Cholesterol binds to the N-terminal sterol-sensing domain (SSD) of SCAP 
(transmembrane segments 2-6) [12,25], facilitating ER retention of the SREBP-SCAP complex.   
The Insig-1 and Insig-2 proteins (collectively referred to as Insig) also interact with the SSD of 
SCAP, anchoring the SREBP-SCAP complex in the ER when sterols accumulate [12,26].  Upon 
cholesterol depletion, SCAP undergoes a conformational change and the SREBP-SCAP complex 
dissociates from Insig.  The SREBP-SCAP complex then travels to the Golgi in COPII vesicles 
[27] where SREBP undergoes regulated intramembrane proteolysis by site 1 and site 2 proteases 
(S1P and S2P).  S1P and S2P consecutively cleave SREBP, releasing the active transcription 
factor from the membrane.  S1P cleavage occurs after the RXXL consensus sequence in the 
luminal loop of SREBP, followed by S2P cleavage, which releases the soluble transcription factor 
[12].  The soluble SREBP transcription factor then travels to the nucleus where it activates 
transcription of cholesterol and fatty acid biosynthetic genes.   
 
Post-transcriptional regulation 
 In mammalian cells, the post-transcriptional regulation of cholesterol biosynthesis is 
mediated primarily though degradation of HMG-CoA reductase (HMG-R) in response to flux 
through the mevalonate pathway.  Immunoblot experiments indicate that HMG-R expression 
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increases under sterol-replete conditions.  In contrast, rapid degradation of HMG-R occurs when 
sterols accumulate [28].  The 888-residue HMG-R protein contains two domains:  An N-terminal 
domain consisting of 8 TM segments, including a SSD, embedded in the ER and a C-terminal 
cytosolic, catalytically active domain [29].  Early observations indicate that the N-terminal domain 
of HMG-R is important for degradation [30], while the C-terminal domain is not [31].  Importantly, 
Insigs bind to the SSD domain of HMG-R in a sterol-dependent manner [32].  Subsequent 
experiments demonstrate that the accumulation of the sterol intermediate 24,25-dihydrolanosterol 
stimulates the ubiquitination and degradation of HMG-R [33].  Sterol accumulation induces Insig 
binding to the membrane domain of HMG-R [34].  Insigs are associated with the membrane-
bound ubiquitin ligase gp78 [34], which binds to the ubiquitin-conjugating enzyme Ubc7 [35].  
Thus, 24,25-dihydrolanosterol accumulation triggers the binding of the Insig-gp78 complex to 
HMG-R and facilitates its ubiquitination by Ubc7.  HMG-R is then extracted from the membrane 
and degraded in the 26S proteasome.   
 
Lipoproteins and extracellular cholesterol trafficking.  Lipoproteins particles are the major 
carrier of plasma lipids.  Lipoproteins are macromolecular complexes consisting of a hydrophobic 
core rich in neutral lipids such as triglyceride (TG) and cholesteryl ester (CE).  In contrast, the 
surface of the lipoprotein consists of amphipathic phospholipids and hydrophilic free cholesterol.  
Lipoproteins are classified as chylomicrons, very low-density lipoproteins (VLDL), low-density 
lipoproteins (LDL), intermediate-density lipoproteins (IDL), high-density lipoproteins (HDL) and 
lipoprotein(a) (Lp(a)) by their densities, their lipid composition and the apolipoproteins present on 
their surface [36].  One role of lipoproteins is to deliver energy in the form of TG to peripheral 
tissues. Lipoproteins also deliver cholesterol to peripheral tissues for membrane biogenesis and 
steroidogenesis, and back to the liver for bile acid biosynthesis and excretion.   
Dietary cholesterol and TG are absorbed in the intestine and packaged into chylomicrons 
for circulation.  In circulation, TGs are hydrolyzed by lipoprotein lipase, releasing fatty acids for 
uptake into muscle (for energy) and adipose tissue (for storage).  The remaining chylomicron 
remnant (containing cholesterol) is taken up into the liver.  In the hepatocyte, TG and cholesterol 
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are packaged into VLDL particles and secreted into circulation.  In circulation, VLDL undergoes 
further loss of TG, primarily through the action of hepatic lipase, and is converted to LDL.  LDL is 
a pro-atherogenic lipoprotein comprised mainly of cholesteryl esters that facilitates delivery of 
cholesterol to peripheral tissues via uptake by the LDL receptor [36].  
In contrast to LDL-mediated delivery of cholesterol to peripheral tissues, cholesterol from 
extrahepatic tissues is effluxed and trafficked back to the liver in a process termed reverse 
cholesterol transport.  HDL-mediated reverse cholesterol transport is athero-protective, as high 
plasma HDL levels have an inverse relationship with the development of atherosclerosis [37].  
Cholesterol efflux occurs by two distinct mechanisms.  The first involves passive diffusion of 
cholesterol to HDL particles in contact with the cell surface.  The second involves energy 
dependent, ABCA1-mediated efflux of cholesterol and phospholipids to lipid-poor apolipoprotein 
A-I on the nascent HDL particle.  ABCA1 is widely expressed and its deficiency is causal in 
Tangiers disease [38].  Lecithin:cholesterol acyltransferase (LCAT) present in the plasma 
esterifies cholesterol within the nascent HDL particle, producing mature HDL.  The mature HDL 
functions as the cholesterol acceptor from peripheral cells, mediated by another ATP-binding 
cassette (ABC) transporter, ABCG1, which is highly expressed in macrophages [39].  Finally, the 
HDL receptor SR-BI mediates selective uptake of the mature HDL particle into the liver and 
steroidogenic cells for utilization and excretion [40]. 
 
Intracellular cholesterol trafficking.  While lipoprotein-mediated cholesterol trafficking is well 
characterized, how cholesterol is transported within cells is not fully understood. The underlying 
properties of the cholesterol molecule (single hydroxyl group, planar structure and short alkyl 
chain) [41] confers relatively low free energy in comparison to other lipid species [42], making it 
possible for cholesterol to flip-flop between membrane leaflets.  In theory, passive diffusion of 
cholesterol through the cytosol could occur, but the low solubility of this molecule makes this 
unlikely.  The heterogeneous distribution of cholesterol within subcellular membranes 
necessitates trafficking from one membrane to another.  Vesicular routes mediate only a small 
fraction of intracellular cholesterol trafficking.  In mammalian cells, pulse-chase experiments 
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followed by cyclodextrin removal of sterols demonstrate that brefeldin A treatment, which causes 
dissociation of the Golgi complex and inhibits vesicular trafficking [43], reduced the transport of 
newly synthesized ER cholesterol to the plasma membrane by 20% [44]. This finding is supported 
by experiments in S. cerevisiae, which demonstrated loss of the vesicular trafficking machinery 
had no impact on sterol transport [45].  Thus, the majority of intercellular cholesterol trafficking in 
mammalian systems (and yeast) occurs through nonvesicular transport.  As such, the remainder 
of this section will focus on candidate lipid transfer proteins. 
 Sterol carrier protein 2 (SCP-2) is a ubiquitously expressed, non-specific lipid transfer 
protein that has a high affinity for cholesterol [46].   SCP-2 is formed by the excision of either 
SCP-x or pro-SCP-2, which are encoded by the same gene (SCP-x/SCP-2) under the control of 
two different promoters.  SCP-x, also encoded by the SCP-x/SCP-2 gene, is a fusion protein 
between a thiolase domain and SCP-2.  SCP-2 contains a peroxisome localization sequence but 
is also found in the cytosol.  SCP-2 binds cholesterols at a single site and has also been 
demonstrated to bind fatty acids, fatty acyl CoAs and phospholipids [47].  Overexpression of 
SCP-2 in McA-RH7777 cells increased the rate of cholesterol transfer to the plasma membrane 
and the internalization of plasma membrane cholesterol [48], demonstrating that SCP-2 enhances 
cholesterol trafficking between the plasma membrane and internal sites. However, SCP2-/- 
knockout mice exhibited no changes in serum cholesterol, liver cholesterol or liver cholesteryl 
esters, but did exhibit peroxisome proliferation, hypolipidemia, impaired body weight control, 
neuropathy and impaired catabolism methyl-branched fatty acyl CoAs. [49].  Thus, the exact role 
of SCP-2 in cholesterol homeostasis is still unknown [50]. 
 Another candidate for nonvesicular sterol transport are caveolins.  Caveolae are 
invaginations of the plasma membrane (60-100 nm in diameter) that are enriched in free 
cholesterol and sphingomyelin [51].  Caveolins are the membrane coat proteins of caveolae.  The 
three Caveolin proteins (Caveolins-1, -2 and -3) possess N- and C-termini in the cytosol and a 
long putative hairpin intramembrane domain [52].  In vitro binding assays demonstrate that 
Caveolin-1 (CAV1) binds at least one mol of cholesterol per mole of protein [53].  Moreover, 
CAV1 binds to fatty acids [54] and is found in lipid droplets [55], consistent with the finding that 
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caveolae are profuse in specialized lipid-storing cells such as adipocytes [52].  Overexpression of 
CAV1 in hepatocytes led to an increase in the free cholesterol content of the plasma membrane 
and increased cholesterol efflux [56].  These data suggest that CAV1 stimulates cholesterol efflux 
by incorporating free cholesterol in microdomains on the plasma membrane.  Subsequent studies 
demonstrate that the addition of cholesterol to adipocytes stimulates caveolar budding. 
Furthermore, lipid droplets from adipocytes of CAV1-/- mice contain reduced levels of cholesterol 
[57].  These data suggest a role for CAV1 in lipid sensing and trafficking at the PM and for 
storage in the lipid droplet. 
 Exogenous cholesterol is taken up by LDL receptors in the form of CEs in the LDL particle 
or chylomicron remnant.  CEs are hydrolyzed in the late endosomes and lysosomes and then 
trafficked to organelles throughout the cell.  The mechanism by which free cholesterol exits the 
lysosome is not understood.  Much of our knowledge on this transport pathway has come from 
the study of Neimann-Pick Type C (NPC) disease, a fatal, autosomal recessive disorder 
characterized by lysosomal accumulation of LDL-derived free cholesterol and subsequent 
neurodegeneration.  Subcellular accumulation of sphingomyelin, sphingosine and complex 
glycosphingolipids also occurs in NPC disease, but whether this is causal or just a consequence 
of cholesterol accumulation is controversial.  NPC disease is caused by a mutation in one of two 
genes: NPC1 or NPC2.  NPC1 is a large (1278 residues) thirteen-transmembrane domain protein 
that localizes to the late endosomes and lysosomes.  In contrast, NPC2 is a small (131 residues) 
soluble intralysosomal protein.  Mutations in NPC1 are responsible for 95% of NPC cases, while 
mutations in NPC2 account for only 5% of NPC cases. Consistent with neurodegeneration seen 
in human NPC patients, loss of NPC1 in a mouse model causes purkinje cell death and 
cerebellar degeneration [58].  Mutations in either NPC1 or NPC2 result in the same cellular and 
biochemical characteristics.  It is possible that the two proteins may function in a coordinated 
manner, though no physical interactions have been demonstrated and overexpression of one 
NPC protein does not complement the loss of the other [59].  Both NPC1 and NPC2 contain lipid-
interaction motifs, a SSD and a MD-2-related lipid-recognition (ML) domain, respectively [59].  
NPC1 and NPC2 bind cholesterol and various oxysterols in vitro [60,61,62,63], further implicating 
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cholesterol as the pathogenic lipid in this disease. Thus, it is likely that both NPC1 and NPC2 act 
as lysosomal cholesterol transporters, though the mechanism by which they do so remains 
unknown. 
As its name implies, oxysterol binding protein (OSBP) was initially identified to bind 25-
hydroxycholesterol and other oxysterols in murine fibroblasts [64].  OSBP was later cloned by 
Brown and Goldstein, who re-confirmed its oxysterol-binding capacity [65,66].  This protein family 
is highly conserved in eukaryotes, with humans possessing 12 OSBP-related proteins (ORP) [67].  
Evidence that this family of proteins mediates intracellular sterol transport comes from studies 
examining the S. cerevisiae OSBP homologue (OSH), Osh4p.  Osh4p was crystallized in 
complex with cholesterol, ergosterol and various oxysterols [68].  Furthermore, molecular 
dynamic simulations of Osh4p suggest that cholesterol is bound in lid-covered cholesterol binding 
pocket that is docked on donor and acceptor membranes.  The lid opens upon sterol depletion 
[69], allowing lipid transfer between closely associated membranes [70].   
Another well-studied lipid transporter is the steroidogenic acute regulatory protein (StAR) 
and its StAR-related lipid transfer (START)-domain containing counterparts. StAR is implicated in 
steroidogenesis and is reviewed in the steroid hormone synthesis section of this thesis. 
 
Cholesterol esterification. 
Biological context and the esterification reaction 
 Exogenous cholesterol is taken up by the LDL receptor and trafficked through the 
endosomal system to the ER.  Accumulation of free cholesterol in the ER is toxic; thus, 
mechanisms to rid the ER of excess free cholesterol are necessary.  Free cholesterol is 
converted into its neutral lipid form, CE, through the action of the acyl-coenzyme A (CoA): 
cholesterol acyltransferase (ACAT) enzymes (Figure 1-4).  The resulting CE has several fates.  In 
extrahepatic cells, it can be stored in lipid droplets, functioning as a substrate repository for 
steroidogenesis and membrane biogenesis.  In the hepatocyte, CEs are packaged into the core 
of a VLDL particle for circulation and delivery.   
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ACAT enzymes catalyze the conjugation of the hydroxyl group on the cholesterol moiety 
to the carboxylate group of a long-chain fatty acyl CoA, thereby forming an ester linkage [71].  
ACATs are multispaning membrane-bound proteins that localize to the ER [72,73].  They are 
members of the membrane-bound O-acyltransferase (MBOAT) enzyme family, all of which 
catalyze the conjugation of a fatty acyl CoA to a hydrophobic substrate [74].  In mammalian cells, 
the ACAT reaction is catalyzed by two isozymes, ACAT1 and ACAT2.   
 
The ACAT enzymes: Gene, protein, expression and regulation  
The human ACAT1 gene is unusual in that it is located on two different chromosomes, 
each containing a distinct promoter [75].  Moreover, there are three splice variants of human 
ACAT1 mRNA.  Two variants, under the control of one promoter, account for 70-80% of ACAT1 
mRNA and translate into a single 50-kDa ACAT1 protein; this is the major ACAT1 isoform in 
human tissues.  In contrast to humans, the murine ACAT1 gene is located only on one 
chromosome .  The human ACAT2 gene was identified based on sequence homology to ACAT1 
[76,77,78], and encodes a single protein. ACAT1 and ACAT2 lack SREs in their promoter regions 
and cholesterol loading experiments demonstrate that ACAT1 and ACAT2 are allosterically 
regulated by cholesterol [79,80].   
The human ACAT1 and ACAT2 proteins are 44% identical to each other with the majority 
of conservation in the C-terminus [76,77].   Both ACAT1 and ACAT2 contain a highly conserved 
FYXDWWN motif, likely involved in fatty acyl-CoA binding, and a MKXXSF motif, required for 
ACAT activity [71].  Although both ACAT1 and ACAT2 are ER-resident membrane proteins, their 
topographies vary.  To date, neither protein has been crystallized; thus, the structure of these 
proteins has been characterized through biochemical methods [81,82,83,84,85].  The current 
model of ACAT1 structure suggests it is a nine transmembrane (TM) domain protein with the 
active site located in TM domain seven [81].  Moreover, the N-terminus is cytosolic while the C-




Human ACAT1 and ACAT2 exhibit different expression patterns.  ACAT1 is widely 
expressed in cells and tissues including the liver, adrenal glands, macrophages, and kidneys but 
not in the intestine [86].  Moreover, immunodepletion experiments suggest that ACAT1 accounts 
for more than 80% of the total ACAT enzyme activity in vitro [74].  Consistent with high ACAT1 
expression in macrophages, immunohistochemical localization experiments demonstrate that 
ACAT1 is highly expressed in atherosclerotic lesions, suggesting that ACAT1 is the major 
contributor to foam cell formation [87].  In contrast, human ACAT2 is expressed exclusively in the 
liver and intestine [86].  However, immunodepletion studies demonstrate that ACAT1 accounts for 
the majority (85-90%) of activity in the human liver [88], while ACAT2 accounts for the majority of 
activity in the intestines [86]. In a mouse model, ACAT2 is the major isozyme in both the liver and 




Bile acids are incorporated into bile where they emulsify dietary lipids, cholesterol and fat-
soluble vitamins in the gut.  The synthesis of bile acids from cholesterol is the major pathway of 
cholesterol catabolism in the body.  In the adult liver, approximately 500 mg of cholesterol is 
converted into bile acids daily; this accounts for 90% of actively metabolized cholesterol (10% for 
steroidogenesis).  As such, defects in components of bile acid biosynthesis cause dysregulation 
of cholesterol homeostasis.   
 The conversion of cholesterol into bile acids involves 17 reactions and can be broken down 
into four parts: (1) initiation of synthesis by 7α-hydroxylation of cholesterol and oxysterols, (2) ring 
structure modification, (3) oxidation and shortening of the side chain and (4) conjugation to an 
amino acid.  The conversion of cholesterol to 7α-hydroxycholesterol by the cytochrome P-450, 
cholesterol 7α-hydroxylase (CYP7α1), is the first and rate-limiting step in classical bile acid 
biosynthesis.  This pathway accounts for 75% of bile acids synthesized [90].  Thus, CYP7α1-/- 
mice exhibit high mortality rates, mainly due to liver failure and malabsorption [91].  Conversely, 
overexpression of CYP7α1 causes enlarged bile acid pools [92].  Moreover, liver-specific 
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overexpression of CYP7α1 caused a mark reduction in diet-induced obesity and hepatic steatosis 
[93].  Oxysterols can also serve as substrates for bile acid synthesis.  27-hydroxycholesterol is 
synthesized from cholesterol by sterol 27-hydroxylase (CYP27α1).  The 7α-hydroxylation of 27-
hydroxycholesterol by oxysterol 7α-hydroxylase (CYP7B1) to form bile acid precursors accounts 
for 25% of total bile acids [91].  Next, the 7α-hydroxylated intermediates undergo ring 
modification by 3β-hydroxy-Δ5-C27-steroid oxidoreductase (HSD3B7).  HSD3B7 is essential for 
the formation of all bile acids.  The products of this reaction can then take two routes in the 
formation of primary bile acids.  The first involves 12α-hydroxylation by sterol 12α-hydroxylase 
(CYP8B1) and subsequent ring modifications, ultimately resulting in the formation of cholic acid.    
Alternatively, the HSD3B7 product can undergo ring modifications without 12α-hydroxylation, 
resulting in the formation of bile acids such as chenodeoxycholic acid (CDCA) (humans) and 
muricholic acid (mice).  The products of ring modification then undergo progressive oxidation of 
the sterol side chain catalyzed by CYP27α1. Thus, all bile acid intermediates, regardless of their 
origin (cholesterol or oxysterol), are acted upon by CYP27α1.  The products of CYP27α1 
oxidation then undergo shortening of the sterol side chain and an additional oxidation reaction, 
providing the proper substrate for amino acid conjugation.  The terminal step in bile acid 
biosynthesis involves glycine- or taurine-conjugation to C24, catalyzed by bile acid coenzyme 
A:amino acid N-acyltransferase.  Conjugation of bile acids increases their amphipathic nature and 
solubility, making them impermeable to membranes [91,94].  Ergo, a complex transport system is 
necessary to move bile within enterohepatic circulation. 
 
Transport 
 Bile acid transport involves a network of proteins required to mediate bile flow through 
enterohepatic circulation and excretion of bile in the kidneys.  As such, transport of bile salts has 
been an area of extensive study (reviewed in [95,96]).  The description of bile salt transport in this 
section of the thesis will focus primarily on hepatocellular transport, given its relevance to the data 
reported in this thesis. 
 Recycling of bile salts is an extremely efficient process.  Approximately 95% of bile salts 
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secreted into bile are taken up from enterohepatic circulation.  Hepatic uptake of bile salts from 
the portal blood is facilitated by two groups of transporters: the Na+ taurocholate cotransporting 
polypeptide (NTCP) and by members of the organic anion transporting polypeptide (OATP) 
family.  OATPs facilitate basolateral uptake of a small fraction of bile salts in addition to other 
amphipathic organic compounds [96].  In contrast, NTCP facilitates uptake of 75% of all 
conjugated bile salts. NTCP (encoded from the SLC10A1 gene) is a 349-residue membrane 
glycoprotein that functions as a sodium-solute cotransporter (moves 2 Na+ ions per molecule of 
solute).  NTCP expression is regulated by substrate availability, cytokines, liver injury, hormones 
and nuclear receptors.  Consistent with this finding, NTCP expression is down-regulated in 
cholestasis [97]. 
 Transport of bile salts out of the hepatocyte into the bile caniculi for secretion into bile is 
mediated by two ABC transporters: ABCB11 (the bile salt export pump or BSEP) and ABCC2 
(multidrug resistance-associated protein 2 or MRP2).  ABCC2 is a 190-kDa glycoprotein that 
mediates the secretion of many anionic substrates across the canicular membrane, including 
conjugated bilirubin, glutathione conjugates and sulfated and glucuronidated bile acids.   
Moreover, defects in ABCC2 results in Dubin-Johnson syndrome, characterized by chronic 
jaundice [98].  ABCB11 is a liver-specific 160-kDa glycoprotein that displays high affinity for the 
transport of conjugated bile acids.  ABCB11 is the major canalicular bile acid efflux pump; thus, 
mutations in ABCB11 are causal in progressive familial intrahepatic cholestasis, a hepatic 
disorder characterized by a severe reduction in biliary bile acid concentrations.  ABCB11 
expression is regulated by the nuclear receptor FXR (see below) in response to bile acid 
accumulation in the hepatocyte [97]. 
 Similar to transport of bile salts, cholesterol efflux into the bile is mediated by two ABC 
transporters: ABCG5 and ABCG8.   Both ABCG5 and G8 localize to the apical membrane of 
enterocytes and the canicular membrane of hepatocytes.  ABCG5 and G8 are LXR-regulated 
(see below) transporters that form heterodimers with each other to mediate cholesterol flux 
[99,100].  Moreover, mutations in ABCG5 and G8 are causal in β-sitosterolemia, an autosomal 
recessive disorder characterized by a buildup of sitosterol (a plant-derived sterol) and cholesterol 
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in plasma and tissues.  β-sitosterolemia patients exhibit increased absorption of dietary neutral 




 Regulation of bile acid homeostasis is mediated primarily through feedback inhibition of 
CYP7α1 and CYP8B1 in response to bile acid and cholesterol accumulation.  This regulation is 
controlled by nuclear receptors (Figure 1-5).    Suppression of bile acid synthesis is initiated when 
bile acids bind to and activate the farnesoid X receptor (FXR).  Targets of FXR include IBABP, 
ABCB11, NTCP, and SHP, all of which serve to decrease hepatic bile acid accumulation by 
means of inhibiting transport or synthesis [91,97].  Consistent with this finding, FXR-/- mice 
express high levels of CYP7α1 and CYP8B1 mRNA and have increased bile acid biosynthesis 
[101].  Bile acids exhibit varying potencies as FXR ligands.  FXR reporter assays demonstrate 
that cholic acid is a strong FXR agonist, while muricholic acid is a less potent activator [102].  
CYPB8B1-/- mice exhibit unregulated bile acid biosynthesis, suggesting that the formation of 
cholic acid is necessary to regulate FXR and that derivatives of muricholic acid cannot function as 
the primary FXR ligand in mice [103].   
 FXR is an activator; thus, FXR suppresses bile acid biosynthesis indirectly, by activating 
the transcriptional repressor short heterodimer partner (SHP).  FXR regulates SHP transcription 
though an FXR response element in the SHP promoter.  SHP then binds to and suppresses liver 
receptor homologue 1 (LRH-1), a transcriptional activator of CYP7α1 and CYP8B1.  The SHP 
promoter also contains a LRH-1 response element.  This allows for the fine-tuning of bile acid 
biosynthesis, where SHP-mediated suppression of bile acid biosynthesis is regulated through 
feedback inhibition of SHP transcription as LRH-1 is inhibited.  This elegant system of regulation 
allows bile acids to remain at homeostatic levels in response to both their accumulation and 
synthesis [91]. 
 Liver X receptor (LXR), another nuclear hormone receptor, upregulates bile acid 
biosynthesis in response to cholesterol accumulation.  There are two LXR genes in mammals: 
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LXRα and LXRβ.  LXRα is highly expressed in the liver and is the primary regulator of bile acid 
synthesis in response to cholesterol.   LXRα controls the expression of CYP7α1, which contains a 
LXRα response element in its promoter, but not CYP8B1.  Moreover, LXR activates the 
transcription of the bile acid transporters ABCG5 and ABCG8 [91].  Oxysterols, such as the bile 
acid intermediates 7α-hydroxycholesterol and 25-hydroxycholesterol, are the ligands for LXRα 
[104].  As such, LXRα-/- mice eventually die when fed a high-cholesterol diet [105].  In the context 
of bile acid regulation, cholesterol accumulation stimulates LXRα-mediated transcription of 
CYP7α1 but not CYP8B1.  In mice, this pushes the bile acid pool towards the formation of 
muricholic acid, rather than cholic acid.  Cholic acid is a potent activator of FXR in mice; thus, 
cholesterol-induced LXR activation serves to limit FXR-mediated suppression of bile acid 
biosynthesis, allowing for the conversion of excess cholesterol into bile acids. 
 
Steroid hormone synthesis.  Steroid hormones regulate various aspects of physiology including 
reproduction (androgens, estrogens, progestogens), salt and water balance (mineralocorticoids) 
and stress responses (glucorticoids).  The cytochrome P450 side chain cleavage enzyme 
(P450scc, encoded by CYP11A1) is expressed in steroidogenic cells (adrenal cortex and gonads) 
where it converts cholesterol to pregnenolone, the rate-limiting step in the biosynthesis of all 
steroid hormones [106].  P450scc resides on the inner mitochondrial membrane; the transport of 
cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane, where 
it has access to P450scc, is critical for steroidogenesis.  Transport of cholesterol to P450scc is 
facilitated by StAR [107].  StAR is a mitochondrial-localized protein that contains a 210-residue 
START domain that facilitates cholesterol binding in vitro [108].  While the crystal structure of 
StAR has not been solved, structures of other START domain-containing proteins 
(STARD3/MLN64, STARD4 and STARD5) demonstrate specificity for cholesterol [109].  
Mutations in the StAR protein are causal in lipoid congenital adrenal hyperplasia (CAH) [110,111] 
an autosomal recessive disorder characterized by impaired adrenal and gonadal steroidogenesis, 
male pseudohermaphroditism and lipid deposits within steroidogenic tissues.  Consistent with 
adrenocortical insufficiency in humans, both male and female StAR knockout mice exhibit female 
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external genitalia and die within 1-2 days after birth unless supplemented with corticosteroids 
[112].  These studies demonstrate the importance of cholesterol homeostasis, in the context of 
mitochondrial cholesterol trafficking and steroidogenesis, in human physiology.  
 
Part III. Lipotoxicity and the unfolded protein response. 
 
The unfolded protein response (UPR).  The ER is the major site of protein folding and 
maturation for both secretory and transmembrane proteins. Molecular chaperones reside within 
the ER lumen, facilitating proper protein folding and conformation.  The demand on the ER to fold 
proteins fluctuates in response to transcriptional activation and repression, environmental cues 
and cell differentiation.  This necessitates a quality control system that serves to restore ER 
homeostasis in response to increased demand.  The first observation that a signal transduction 
cascade is linked to the dynamic ER environment comes from experiments examining the effect 
of malfolded forms of the influenza virus haemagglutinin (HA) on the transcription of the ER-
resident chaperone BiP (GPR78).  Simian cells expressing mutant forms of HA exhibited 
increased BiP expression that was also increased upon inhibition of N-linked glycosylation [113].  
The pathway that mediates signal integration from the ER to the nucleus in response to misfolded 
proteins, called ER stress, is aptly named the unfolded protein response (UPR).  ER stress 
occurs when the capacity of the ER to fold proteins becomes inundated, including conditions of 
improper protein folding and aggregation, alterations in ER calcium homeostasis, glucose 
deprivation, hypoxia and defective protein secretion or degradation [114].  The UPR restores ER 
homeostasis by reducing general protein translation in combination with selective activation of 
ER-resident chaperones and proteins involved in ER-associated degradation (ERAD) [115].  In 
mammalian cells, prolonged ER stress activates the cell death effector C/EBP homologous 
protein (CHOP) [116], causing the cell to undergo apoptosis when ER homeostasis cannot be 
restored. 
 The fundamental components of the UPR have been elucidated in S. cerevisiae.  Inositol-
requiring protein-1 (Ire1p in yeast, IRE1 in mammalian cells) is a conserved type 1 ER-resident 
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transmembrane protein consisting of a luminal domain and cytosolic kinase and RNase domains 
[117].  Ire1p is required to activate transcription of KAR2 (the yeast orthologue of BiP) and the 
ER-resident chaperone protein disulfide isomerase, PDI1 [118].  Ire1p recognizes unfolded 
proteins in the ER lumen by either direct binding [119] or by titration of BiP away from the Ire1p 
luminal domain [120].  This initiates Ire1p trans-autophosphorylation [121] and non-conventional 
splicing of the HAC1 transcript [122], the only known substrate for Ire1p.  Spliced HAC1 is then 
translated into an active transcription factor, translocates to the nucleus and binds to the UPR 
response element [123], thereby activating the transcription of UPR target genes.  The crystal 
structure of the yeast Ire1p luminal domain demonstrates that a MHC-like groove and protein 
interfaces are important for protein binding and dimerization/oligomerization, respectively [119].  
This is in contrast to human IRE1, which has a luminal domain that is too small to facilitate 
peptide binding [124].  Furthermore, the RNase domain of mammalian IRE1 splices the XBP1 (x-
box binding protein-1) transcript, rather than HAC1, in response to ER stress [125].  Though there 
are differences in protein structure and the downstream components of IRE1-mediated UPR 
induction, this protein mediates bifunctional kinase and ribonuclease functions in both yeast and 
mammalian cells. 
 While Ire1p mediates all UPR effector functions in yeast [126], UPR induction in 
mammalian cells is more complex.  Mammals possess additional ER stress transducers, mainly 
protein kinase RNA (PKR)-like ER kinase (PERK) and activating transcription factor-6 (ATF6), 
that mediate both differential and functionally redundant effects on ER homeostasis in 
combination with IRE1.  Like IRE1, PERK is a type 1 ER-resident transmembrane protein with a 
luminal ER stress-sensing domain and a cytosolic kinase domain.  In response to protein 
accumulation in the ER, PERK oligomerizes and trans-autophosphorylates.  PERK 
phosphorylates the α-subunit of eukaryotic translation initiation factor-2 (eIF2α) at serine 51 [127].  
Phosphorylated eIF2α inhibits the guanine nucleotide exchange factor eIF2B, a complex 
responsible for recycling eIF2 back to its active GTP-bound form; thus, PERK activation results in 
attenuation of protein translation [117].  Moreover, conditions of limiting eIF2α stimulate 
translation initiation of activating transcription factor-4 (ATF4) and its downstream target CHOP 
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[116].  Consistent with the mechanism of PERK activation and its downstream effects, mice 
lacking PERK are sensitized to ER stress-inducing agents [128], while CHOP-/- fibroblasts are 
protected from ER stress-associated cell death [129]. 
 ATF6 is a bZIP transcription factor that is retained in the ER lumen by BiP binding [130].  
Upon accumulation of unfolded proteins in the ER lumen, the precursor form of ATF6 
translocates to the Golgi where it undergoes regulated intramembrane proteolysis by S1P and 
S2P, the same proteases that cleave SREBP [131].  The active ATF6 transcription factor then 
translocates to the nucleus where it activates transcription of UPR target genes.  The scope of 
ATF6 target genes is not fully characterized but includes ER-resident chaperones and 
components of ERAD [132].   
   
ER stress and lipid dysregulation.  The link between UPR induction and lipid metabolism is 
compelling.  Both protein folding/processing and lipid synthesis occur in the ER.  Thus, 
dysregulation of either of these processes is likely to impact the other.  In yeast, cells lacking 
Ire1p are inositol auxotrophs [133], a vital component of many phospholipids.  Many of the genes 
upregulated upon UPR induction in yeast encode proteins involved in phospholipid biosynthesis 
and lipid homeostasis [126].  Moreover, a downstream effect of UPR induction is expansion of the 
ER compartment, suggesting that increasing the phospholipid:free cholesterol ratio of the ER 
membrane can restore ER homeostasis [117].   In mammalian cells, ER stress has been 
implicated in a variety of pathologies (reviewed in [134]), including neurodegenerative diseases, 
obesity, cancer, diabetes and atherosclerosis. On the cellular level, lipid accumulation contributes 
to ER stress and apoptosis of macrophages and pancreatic β-cells, which contribute to the 
development of atherosclerosis and type 2 diabetes, respectively. [135,136].  As such, there is an 
intimate connection between the triad of lipid metabolism, ER stress and disease progression. 
 The impact of free fatty acid (FFA) accumulation on UPR induction and apoptosis in 
yeast and mammalian cells has been well characterized.  In general, both saturated (SFAs) and 
unsaturated fatty acids (UFAs) are toxic to cells, although effects vary based on concentration 
and cell type.  UPR reporter assays in S. cerevisiae demonstrate that the accumulation of either 
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endogenous SFAs (mutants lacking fatty acid desaturase function) or exogenous SFAs induces 
the UPR, and that this phenomenon is synergistic with sterol accumulation [137].  In contrast, 
yeast lacking the ability to synthesize any neutral lipid species (triglyceride or steryl esters) exhibit 
UPR induction in the presence of exogenous UFAs, an effect attributed to the inability of these 
strains to funnel UFAs into phospholipid species [138].  Since lipid accumulation has been 
associated with β-cell death and the development of type 2 diabetes, several groups have 
examined the role of UPR in the pathogenesis of this disease.  Prolonged palmitate treatment in 
INS-1 pancreatic β-cells increased protein levels of phospho-PERK, phospho-eIF2α, ATF4 and 
CHOP. Which was not seen upon exogenous oleate treatment [139].  Similar experiments in 
MIN6 pancreatic β-cells demonstrated s time-dependent increases in the expression of ER-stress 
markers XBP1, ATF4 and CHOP in response to palmitate, but not oleate, treatment [140].  
Specificity studies conducted by Cunha, et al. demonstrated that INS-1 cells are protected from 
palmitate-induced apoptosis when CHOP expression is reduced, further implicating the UPR in 
lipid-mediated β-cell death [141].  Conversely, prolonged infusions of oleic acid induce ER stress 
and inhibit hepatic apoB100 secretion in vitro and in vivo [142], suggesting the impact of FFAs on 
UPR induction and apoptosis differs among cell types. 
Dysregulation of sphingolipid homeostasis is also linked to ER stress.  In S. cerevisiae, 
loss of the ER-resident proteins Orm1p and Orm2p causes an accumulation of long-chain bases 
and UPR induction.  Furthermore, the Orm proteins physically interact with the yeast serine 
palmitoyltransferase enzymes (the rate-limiting step in sphingolipid biosynthesis), coordinating 
sphingolipid homeostasis with ER quality control in yeast [143].  In mammalian cells, 
downregulation of ceramide synthase-6 or -2 results in UPR induction [144,145].  Moreover, in 
human breast adenocarcinoma MCF7 cells, downregulation of sphingosine-1-phosphate 
phosphohydrolase-1, an enzyme responsible for the degradation of sphingosine-1-phosphate, 
results in ER-stress and autophagy that was not associated with ceramide accumulation [146].  
Experiments in HCT-116 cells demonstrate that knockdown of COL4A3BP, the gene encoding 
the ceramide transport protein CERT, or pharmacological CERT inhibition by HPA-12 increased 
PERK phosphorylation and CHOP expression [147]. These data suggest that disruption of 
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sphingolipid homeostasis contributes to ER stress, although the contributions of individual 
sphingolipid species to UPR induction are not understood. 
 Our understanding of sterol-mediated ER stress has largely come from research in the 
field of atherosclerosis.  Macrophage apoptosis is a key event in the development of advanced 
atherosclerotic lesions and ER stress has emerged as a contributing factor to macrophage death 
[136].  Thus, the molecular mechanisms implicating chronic ER stress in the development of 
atherosclerosis have been an area of extensive study.  Cell types of the atherosclerotic plaque 
include macrophages, endothelial cells and smooth muscle cells.  Data garnered from the latter 
two cell types (reviewed in [136]) are not critical to understanding the work in this thesis.  
Therefore, this review will focus on studies examining ER-stress induced macrophage apoptosis 
upon sterol accumulation.  The first body of evidence that subcellular cholesterol retention can 
induce a stress response comes from work by Feng, et al.  Macrophages treated with a modified 
form of LDL cholesterol (acetylated LDL) in combination with an ACAT inhibitor (58035) exhibited 
ER stress and CHOP-mediated apoptosis [148].  In this context, cholesterol loading caused 
depletion of ER calcium stores, which was later attributed to inhibition of the ER calcium pump 
sarcoplasmic-endoplasmic reticulum calcium ATPase-2b (SERCA2b) [149].  These findings are 
supported by work in apoE-/- mice, which demonstrated that cholesterol accumulation in lesional 
macrophages of aortic root sections is associated with BiP (GRP78) and phospho-PERK 
expression, XBP1 splicing and CHOP-mediated apoptosis [150].  Moreover, experiments by 
Myoishi et al. demonstrate that the oxysterol 7-ketocholesterol can also induce ER stress-
associated cell death in vitro [151], suggesting that LDL-derived cholesterol is not the only pro-
atherogenic sterol species.  Further experiments have demonstrated that free-cholesterol 
mediated ER stress and apoptosis requires the activation of pattern recognition receptors, 
specifically the type A scavenger receptor in combination with toll-like receptor 4 [152,153].  
Overall, these studies suggest a multi-hit model where accumulation of atherogenic sterol species 
induces ER stress, which, in combination with activation of pattern receptors, triggers 
macrophage apoptosis.  Recent evidence implicates additional lipid species, including oxidized 
phospholipids and SFAs, and pattern recognition receptors, including CD36 and toll-like receptor 
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2, in the multi-hit model [154].  Altogether, these data demonstrate that the stimuli for ER stress-
induced macrophage apoptosis encompass both sterols and other lipid species. 
 
Part IV.  Sterol homeostasis in S. cerevisiae. 
 
Yeast as a model system for the study of sterols.  Saccharomyces cerevisiae is a powerful 
model system in molecular genetics due to its short generation time, ease of genetic manipulation 
and the complete elucidation of the genome [155].  Efficient homologous recombination allows 
researchers to create gene deletions in weeks, versus years in mammalian systems.  
Additionally, yeast can exist in either a haploid or diploid state.  This is particularly useful for 
studying of genetic interactions, which help to elucidate how genes coordinately function to carry 
out biological processes.  Moreover, researchers have access to genome-wide collections of 
deletion mutants and epitope-tagged strains making it possible to examine genetic and protein-
protein interactions on a large scale [156,157].   
In the context of lipid metabolism, classical genetic approaches in yeast have provided 
valuable insight into the regulation of sterol homeostasis.  One example of this is the identification 
of the second ACAT enzyme.  Lipid labeling of deletion strains demonstrated that ACAT activity in 
S. cerevisiae is mediated by two acyltransferases, Are1p and Are2p [158].  This led to the 
subsequent identification, cloning and characterization of a second ACAT (ACAT2) in mammals, 
[76,77,78].  The final product of endogenous sterol biosynthesis in yeast is ergosterol, rather than 
cholesterol [4].  However, many features of sterol regulation, esterification, synthesis and 
trafficking are evolutionarily conserved [7], making yeast an effective system for the study of 
sterol disorders.   
 
Transcriptional regulation of sterol biosynthesis.  S. cerevisiae exhibit aerobic sterol 
exclusion and thus are fully dependent on endogenous sterol biosynthesis when grown 
aerobically.  Even though S. cerevisiae lack any membrane-bound orthologs of SREBP and 
SCAP, transcriptional regulation of ergosterol biosynthesis in yeast is subject to sterol flux [7].  
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This finding primarily comes from experiments that examined the effects of ergosterol 
biosynthetic gene (ERG) mutations or sterol inhibitory drugs, such as statins and antifungals, on 
expression of ERG genes [159,160,161].  Transcriptional regulation of ergosterol biosynthesis in 
S. cerevisiae is mediated by the activity of two members of the Zn(II)2-Cys6 binuclear cluster 
family of fungal transcription factors, Ecm22p and Upc2p.  Ecm22p and Upc2p bind to SREs in 
the promoters of ERG genes (specifically ERG1, ERG2, ERG3, ERG7, ERG25, ERG26 and 
ERG27), activating their transcription upon sterol depletion [162,163].  This finding is supported 
by recent evidence that both Ecm22p and Upc2p exhibit increased localization to perinuclear foci 
upon fluconazole-mediated sterol depletion [164], suggesting a role in transcriptional regulation of 
sterol biosynthesis. 
 Both ergosterol and heme biosynthesis are oxygen-dependent processes; it has been 
suggested that heme acts as a measure of oxygen levels in the cell.  Thus, it is not surprising that 
the heme-responsive transcriptional activator, Hap1p, and repressor, Rox1p, regulate ergosterol 
biosynthetic genes such as the HMG-CoA reductase orthologs, HMG1 and HMG2, and the 
ergosterol biosynthetic gene, ERG11 [165].  Additionally, Hap1p has been demonstrated to 
activate expression of ERG2 in an Ecm22p-dependent and Upc2p-independent manner [166].  
Thus, there is an intimate connection between oxygen availability, heme-sensing and ergosterol 
biosynthesis. 
 
Post-transcriptional regulation of sterol biosynthesis.  Like mammalian cells, post-
transcriptional regulation of sterol biosynthesis is primarily mediated by HMG-R degradation, a 
process that has been elucidated through the work of Hampton and colleagues.  Yeast possess 
two isozymes of HMG-CoA reductase, Hmg1p and Hmg2p.  Hmg1p is a stable protein, with a 
half-life exceeding eight hours [167].  In contrast, regulated degradation of Hmg2p is subject to 
flux through the mevalonate pathway.  Pulse-chase and immunoblotting experiments have 
demonstrated that inhibition of HMG-CoA reductase with statins stabilized Hmg2p while inhibition 
of squalene synthase steps with zaragozic acid, thereby accumulating FPP, caused rapid Hmg2p 
degradation [168,169].  Thus, accumulation of FPP is the signal for Hmg2p degradation in yeast.  
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This finding is supported by studies that HRD (HMG-R required for degradation) mutants, 
identified in a screen for defective Hmg2p degradation, encode components of the 26S 
proteasome [170] and a ubiquitin ligase [171], consistent with a role for these proteins in ERAD.  
Because HRD mutants encode for components of general protein degradation, a second screen 
was performed to isolate mutants specific for the stability of HMG-R.  This screen identified 
mutants that exhibited constitutive HMG-R degradation, designated COD (control of HMG-R 
degradation), upon lovastatin treatment [172].  One gene of interest is COD1/SPF1, a P-type 
calcium ATPase responsible for ER calcium transport that induces the unfolded protein response 
when lost [173].  All together, this work implicates sterol homeostasis as a key regulator of ER 
quality control in yeast. 
 
Sterol esterification. The conjugation of toxic free sterols to a fatty-acyl CoA, thereby forming a 
neutral steryl ester, is an important component of subcellular sterol homeostasis.  This conserved 
process is catalyzed by the yeast orthologs of the ACAT enzymes, Are1p and Are2p.  Are1p, a 
610-residue protein, was identified based on sequence homology to human ACAT1 (23% identity, 
49% similarity).    Surprisingly, loss of Are1p only had a small impact on sterol esterification.  This 
lead to the idea that perhaps there was another mediator of sterol esterification in yeast.  Are2p, a 
643-residue protein, was identified based on sequence homology to Are1p (the proteins are 49% 
identical).  Sterol esterification in the are2Δ mutant was drastically reduced by 65-74%, 
demonstrating that this isozyme confers the majority of acyltransferase activity in yeast.  The 
are1Δ are2Δ strain exhibited a complete loss of acyltransferase activity and a significant (almost 
complete) reduction in steryl ester formation [158,174].  Though viable, it should be noted that 
loss of Are1p and Are2p impacts sporulation efficiency [174] and down-regulates endogenous 
sterol biosynthesis [175].  Fluorescent microscopy experiments of GFP-fusion proteins 
demonstrate that both Are1p and Are2p localize to the ER [176], the hub of lipid metabolism in 
yeast.  In vivo substrate specificity experiments show that both Are1p and Are2p prefer oleate 
(16:1) and palmitoleate (18:1) as fatty-acyl donors.  In contrast, Are1p preferentially esterifies 
25 
 
sterol precursors (mainly lanosterol), as well as ergosterol, while Are2p preferentially esterifies 
ergosterol [176,177].  
The established regulation of primarily Are2p-mediated sterol esterification during aerobic 
conditions is altered during anaerobiosis.  Lipid labeling experiments by Valachovič, et al. 
demonstrate that under hypoxic conditions, Are1p contributes to the majority of steryl ester 
formation [178].  This is consistent with microarray findings that expression of ARE1 is 
upregulated more than 8-fold during anaerobiosis [179].  Moreover, expression of both ARE1 and 
ARE2 are regulated by the oxygen-responsive transcriptional repressor, Rox1p [177], suggesting 
that oxygen availability is key to regulation of these enzymes.  Importantly, expression of ARE1 
was induced during heme deficiency, while expression of ARE2 was repressed [180].  Heme is 
an oxygen-dependent cofactor required for the latter steps of ergosterol biosynthesis [181].  
These findings suggest an intriguing model for the upregulation of ARE1 expression during 
anaerobiosis, the time at which sterol precursors accumulate, while Are2p mediates esterification 
of the ergosterol end product when oxygen is available.  
 
Sterol uptake.  Ergosterol biosynthesis is an oxygen-dependent process [12].  For example, the 
conversion of squalene to squalene epoxide catalyzed by squalene epoxidase (Erg1p) requires 
oxygen [181].  As such, anaerobic growth in S. cerevisiae confers sterol auxotrophy.  Uptake of 
exogenous sterols is controlled by Upc2p (uptake control 2) [182], which serves a dual function in 
regulating endogenous sterol biosynthesis under aerobic conditions and exogenous sterol uptake 
under hypoxic conditions.  Anaerobic conditions allow for little experimental manipulation, 
precluding the analysis of sterol uptake in yeast.  Thus, a gain-of-function mutation in UPC2, 
designated upc2-1, confers aerobic sterol uptake in addition to maintaining endogenous sterol 
biosynthesis [183,184].   
Sterol influx is mediated by the two members of the yeast ABC-transporter super family, 
Aus1p (ABC protein involved in uptake of sterol 1) and Pdr11p (pleiotropic drug resistance 11).  
AUS1 was indentified in a screen for transcriptional targets upregulated upon upc2-1 expression; 
PDR11 was identified based on sequence homology to AUS1.  Loss of Ausp1 and Pdr11p 
26 
 
decrease sterol uptake by ~85% and ~60%, respectively.  The aus1Δ pdr11Δ strain completely 
abolishes sterol uptake in a upc2-1 background or during anaerobiosis. Moreover, energy 
depletion with sodium azide markedly decreased sterol uptake in a upc2-1 hi background [184].  
These data demonstrate that uptake of exogenous sterols in yeast is an energy-dependent 
process. 
 
Subcellular sterol trafficking.  Intracellular movement of sterols is not well understood.  Some 
insight into subcellular trafficking of exogenous sterols has come from the study of the yeast 
NPC1 orthologue, Ncr1p.  Ncr1p exhibits 35% identity to the human NPC1 protein and localizes 
to the vacuole, the yeast equivalent of the endosomal-lysosomal system in mammalian cells.  
Importantly, expression of Ncr1p in NPC mutant CT60 CHO cells abrogated cholesterol and 
sphingolipid accumulation [185].  Surprisingly, ncr1Δ in yeast has no impact on sterol uptake, 
trafficking or esterification, does not display sensitivity to the polyene antibiotic nystatin and 
exhibits no defects in endocytic transport [185,186].  However, NCR1Y718D, which encodes an 
Ncr1p with a dominant mutation in the region corresponding to the SCAP-SSD, conferred 
sensitivity to modulators of sphingolipid homeostasis [185].  These data suggest that Ncr1p 
performs a primitive function that underlies the sterol transport defects associated with NPC 
disease, but its primary role may be in the regulation of sphingolipid trafficking.  Thus, the putative 
sterol transport function of Ncr1p still eludes researchers.   
Cyclodextrin-based capture assays demonstrate that trafficking of newly synthesized 
sterols to the plasma membrane in yeast occurs primarily through nonvesicular transport [45]; 
thus, the identification of candidate sterol transport proteins has been an area of much research.   
Yeast oxysterol binding protein homologues (OSHs) consist of a family of seven proteins (Osh1p-
Osh7p) implicated in the maintenance of subcellular sterol composition.  While no single OSH 
mutant is lethal, deletion of all seven OSH (osh1-7Δ) proteins is inviable [187], suggesting that 
they function in a redundant fashion.  OSHs are defined by the presence of a ~150-200 residue 
sub-domain within the conserved oxysterol binding protein-related domain [188].  Deletion 
combinations of several OSHs conferred nystatin resistance and lovastatin sensitivity [187], 
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suggesting they alter both plasma membrane and ER sterol content.  Moreover, conditional osh1-
7Δ disrupted subcellular sterol distribution and endocytosis, and caused vacuolar fragmentation 
[189].  This finding is supported by evidence that demonstrated that both exogenous sterol 
transport from the plasma membrane (PM) to the ER [190] and transfer of newly synthesized 
sterols from the ER to the PM [191] is diminished in a osh1-7Δ expressing an inducible osh4-1(ts) 
mutation.  As previously discussed, Osh4p was crystallized in complex with cholesterol, 
ergosterol and various oxysterols [68], further implicating this protein family in subcellular sterol 
maintenance.   
Additional studies have examined the role of sterol uptake and transport in a upc2-1 
background using tritium suicide selection and during anaerobiosis. Anaerobic screening 
implicated the mitochondria in subcellular sterol transport, although no new sterol-trafficking 
proteins were identified [192]. Recent studies using tritium suicide selection of exogenous 
[3H]cholesterol identified Det1p (decreased ergosterol transport 1) as a component of sterol 
transport and Mot3p as a regulator of Aus1p and Pdr11p expression.  Cells lacking Det1p exhibit 
decreased uptake of exogenous cholesterol and slowed trafficking of newly synthesized sterols 
back to the PM [193], demonstrating a role for Det1p in bidirectional (PM-to-ER and ER-to-PM) 
sterol movement. In the next section, we will discuss the identification and subsequent 
characterization of another putative sterol transporter, Arv1p, which mediates anterograde sterol 
movement. 
 
Part V.  Are2 Required for Viability 1 (ARV1): A putative lipid transport protein 
 
Identification and characterization of Arv1p.  Akin to mammalian cells, sterol esterification in 
yeast is an important process to rid the ER of cytotoxic free sterols.  Deletion of both S. cerevisiae 
orthologues of the ACAT enzymes, Are1p and Are2p, is viable and grows normally despite the 
inability to esterify sterols [158].  As such, there must exist either a compensatory or parallel 
detoxification pathway responsible for removing accumulating free sterols.  A genetic screen was 
performed by random mutagenesis of are1Δ are2Δ strains expressing ARE2 on a plasmid.  ARV1 
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was the most frequently mutated gene dependent on a functional Are2p for viability [194].  Thus, 
the Arv1 protein was identified as the factor that compensates for the loss of sterol esterification 
in yeast.   
ARV1 encodes a 321 amino acid protein containing six predicted transmembrane 
domains and a putative zinc-binding motif (Figure 1-6).  The spacing of the cysteine residues in 
the N-terminal portion of the protein is characteristic of a zinc ribbon (Cys-X2-Cys-X20-Cys-X2-
Cys), which has been suggested to mediate DNA-protein and protein-protein interactions.  
Further characterization of the ARV1 mutant in yeast suggests it functions to mediate sterol 
trafficking from the ER to the plasma membrane.  Strains lacking Arv1p accumulate subcellular 
free ergosterol at the expense of the plasma membrane and, consequently, exhibit increased 
sterol esterification.  Additionally, ARV1 mutants are sensitive to nystatin and anaerobiosis, a 
condition in which yeast are auxotrophic for exogenous sterols [194].  These phenotypes reflect 
the importance of Arv1p function in proper sterol distribution and uptake, respectively. 
 
Arv1p and sphingolipid transport.  Subsequent studies have established a role for Arv1p in 
generalized lipid trafficking and homeostasis (Table 1-1) [187,194,195,196,197].  Swain, et al. 
demonstrated that arv1Δ strains accumulate phytosphingosine-derived ceramides at the expense 
of complex sphingolipid formation (IPC, MIPC and MIP2C) [197], suggesting a role for Arv1p in 
mediating ER-to-Golgi ceramide trafficking, where the enzymes responsible for complex 
sphingolipid formation reside.   This finding is supported by experiments demonstrating that arv1Δ 
mutants are sensitive to aureobasidin A, a potent inhibitor of the IPC synthase, Aur1p [196].  It is 
important to note that these findings were exacerbated by growing arv1Δ mutants at restrictive 
temperatures (37°C), another condition that is growth limiting in these strains [194].   
  
Arv1p and GPI-anchor maturation.  Arv1p has also been implicated in the maturation of the 
GPI moiety.  In order for proper formation and anchoring to proteins, early GPI intermediates that 
reside on the cytoplasmic side of the ER leaflet must translocate into the ER lumen for 
mannosylation and protein attachment.  In yeast, the preferred substrate for the first 
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mannosylation reaction in the ER lumen, mediated by GPI-mannosyltransferase (GPI-MT), is 
glucosaminyl-acyl-phosphatidylinositol (GlcN-acylPI) [198].  Uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc) labeling studies by Kajiwara, et al. suggested that Arv1p 
mediates the flipping of GlcN-acylPI to the inner leaflet of the ER where it is acted upon by GPI-
MT for mannosylation, subsequent processing and attachment to proteins.  In support of this 
finding, arv1Δ strains exhibit delayed maturation of GPI-anchored proteins such as Gas1p and 
Yps1p, though there are no defects in glycosylation.  More importantly, ceramide accumulation, 
decreased complex sphingolipid formation and increased subcellular sterols appear to be 
common among arv1Δ strains and GPI biosynthetic/anchoring mutants [196]. 
 
Conservation of ARV1 function.  Yeast Arv1p contains a 61-residue N-terminal region that is 
conserved throughout eukaryotic evolution.  This region is made up of the putative zinc-binding 
motif in addition to a conserved block of 33 resides, collectively termed the ARV1 homology 
domain (AHD) [194] (Figure 1-6, Figure 1-7).  Structure-function experiments in yeast and plants 
suggest that the C-terminal portion of the AHD is required for proper ARV1 function [199,200].  To 
date, ARV1 localizes to the ER in all organisms examined [197,200,201], supporting the idea that 
it mediates lipid movement out of this organelle.  Human ARV1 (hARV1) is predicted to encode a 
271 amino acid protein (Figure 1-6).  Expression of hARV1 in yeast rescues all phenotypes of a 
yeast arv1Δ mutant [194].  Functional homologs of Arv1p have also been reported in A. thaliana, 
and M. musculus [200,201], underlying the importance of ARV1 function in the cell.  
 
Part VI.  The aims and findings of this thesis.  The purpose of this thesis is to obtain a better 
understanding of how ARV1 regulates subcellular lipid homeostasis.  We use yeast and 
mammalian model systems to further characterize the effects of loss or down-regulation of ARV1, 
respectively.  In Chapter 2, we examine the role of Arv1p in regulating subcellular lipid distribution 
and induction of the unfolded protein response.  We demonstrate that loss of Arv1p in yeast 
causes ER stress and that a component of UPR induction in arv1Δ mutants is independent of 
protein misfolding, presumably due to alterations in the lipid content of the ER membrane.  To 
30 
 
support previous findings on the functional conservation of ARV1, we go on to demonstrate that 
decreased ARV1 expression in a murine macrophage model presents with similar phenotypes to 
the yeast mutant.  In Chapter 3 we explore the down-regulation of human and murine ARV1 in 
vitro and in vivo, respectively.  Our findings indicate that ARV1 impacts various levels of sterol 
homeostasis including endogenous SREBP-mediated biosynthesis, bile acid metabolism and 
plasma lipid composition.   Finally, in Chapter 4, we discuss possible mechanisms of ARV1 
function and propose future experiments to gain a better understanding of how ARV1 regulates 
the subcellular trafficking and homeostasis of multiple lipid species. 
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Table 1-1.  Comprehensive overview of arv1Δ phenotypes in S. cerevisiae 
Phenotype Reference 
Sterol Homeostasis and Trafficking  
• Inviability in the absence of sterol esterification proteins [194] 
• Increased free sterols in subcellular membranes [194]§ 
• Increased sterol esterification [194] 
• Accumulation on sterol intermediates [197] 
• Nystatin sensitivity [194,195] 
• Lovastatin sensitivity [195] 
• Anaerobic inviability [194] 
• Vacuolar fragmentation [187] 
Sphingolipid Biosynthesis and Trafficking  
Defects in complex sphingolipid formation [196,197] 
Ceramide accumulation [197] 
Aureobasidin A sensitivity [196] 
Fatty Acid and Phospholipid Homeostasis  
Lipid droplet accumulation [195] 
Decreased fatty acid biosynthesis [197] 
Altered phospholipid composition [197] 
GPI-Anchor Biosynthesis and Trafficking  
Accumulation of early GPI-anchor precursors [196] 
Delayed maturation of GPI-anchored proteins [196,202] 
Weakened membrane association of GPI-anchored proteins [196] 
Defective GPI-anchoring [196] 
Sensitivity to calcofluor white [196] 
Other  
Temperature sensitivity (37°C) [194] 
Defective fluid-phase endocytosis [187] 
Kar2p secretion [202] 
UPR induction [203] 
Defective mating [199] 
 












































Figure 1-1.  The predominant membrane sterols in yeast and mammalian cells.  Chemical 


































Figure 1-2.  Sterol biosynthesis in S. cerevisiae and mammalian cells.  Early sterol 
biosynthetic steps are similar but the pathways diverge after the formation of lanosterol.  Figure 







Figure 1-3.  Distribution of cholesterol in mammalian cells.  Cholesterol is heterogeneously 
distributed among subcellular and plasma membranes.  Only 0.5-1% of total cellular cholesterol is 
found in the endoplasmic reticulum [204], while 60-80% of total cellular cholesterol is found in the 
plasma membrane [205].  Distribution is maintained by the combined impact of various input and 
output mechanisms.  Input mechanisms include endogenous cholesterol synthesis in the 
endoplasmic reticulum and LDL receptor-mediated uptake of exogenous cholesterol.  Output 
mechanisms include storage of steryl esters in lipid droplets and vesicular/nonvesicular transport 
of cholesterol to the plasma membrane.  ER, endoplasmic reticulum; PM, plasma membrane; 





























Figure 1-4. The ACAT reaction.  The mammalian ACATs (ACAT1, ACAT2) and their S. 
cerevisiae orthologues (Are1p, Are2p) catalyze the conjugation of a sterol hydroxyl group to the 
carboxylate group of a long-chain fatty acyl CoA, thereby forming an ester linkage.  The resulting 




Figure 1-5. The regulation of bile acid biosynthesis by nuclear hormone receptors. Black 
arrows indicate the conversion of cholesterol into bile acids.  Gray arrows indicate positive 










Figure 1-6. Putative structure of Arv1p in S. cerevisiae and H. sapiens.  The ARV1 coding 
sequence predicts a 321 amino acid protein in yeast and a 271 amino acid protein in humans, 









Figure 1-7. ARV1 conservation in various organisms.  ClustalW2 multiple sequence alignment 
of the N-terminal portion of ARV1 in various model organisms.  The S. cerevisiae AHD is 
highlighted in gray; the  putative zinc-binding motif is underlined.  Identical (*), strongly conserved 
(:) and weakly conserved (.) residues are indicated.  NCBI protein queries are GI:21312118 (M. 
musculus), GI:157818753 (R. norvegicus), GI:12232479 (H. sapiens), GI:62858267 (X. 
tropicalis), GI:6323271 (S. cerevisiae), GI:46445164 (C. albicans) and GI:79332834 (A. thaliana). 
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CHAPTER 2: LOSS OF SUBCELLULAR LIPID TRANSPORT DUE TO ARV1 DEFICIENCY 
DISRUPTS ORGANELLE HOMEOSTASIS AND ACTIVATES THE UNFOLDED PROTEIN 







This body of work has been published in the Journal of Biological Chemistry [206].  As such, 
the data illustrated here have been adapted from the original publication for presentation in this 
thesis.  Contributions from co-authors are described.  Arthur Tinkelenberg performed the 
experiments in Figures 2-3A and 2-3B.  Annette Henneberry and Lisa J. Wilcox performed the 
microarray studies described in Appendix 3.  Annette Henneberry performed the experiment in 
Figure 2-5C and first suggested the involvement of the unfolded protein response in lipid 
homeostasis in ARV1 mutants.  Eunjee Lee and Mina Fazlollahi performed the experiments 
described in Table 2-1 and Appendix 4, respectively.  Andrew Munkacsi performed the 
experiment described in Figure 2-5D.  Tracie Seimon and Ira Tabas provided guidance and 
reagents for the macrophage experiments.  Caryn Shechtman performed the experiments 
described in Tables 2-2, 2-3 and Appendix 5, as well as Figures 2-1, 2-2, 2-3D, 2-4, 2-5(A-B), 2-
6, 2-7, 2-8, 2-9, 2-10, 2-11, 2-12, 2-13 and 2-14.  Stephen Sturley and Caryn Shechtman wrote 








The ARV1-encoded protein mediates ER sterol export in yeast.  ARV1 mutants in this 
organism accumulate multiple lipids in the subcellular compartments and are sensitive to 
pharmacological modulators of both sterol and sphingolipid metabolism.  Fluorescence and 
electron microscopy studies demonstrate sterol accumulation, subcellular membrane expansion, 
elevated lipid droplet formation and vacuolar fragmentation in ARV1 mutants.  Motif-based 
regression analysis of ARV1 deletion transcription profiles indicates activation of Hac1p, an 
integral component of the UPR in yeast.  Accordingly, ARV1 mutants exhibit constitutive splicing 
of HAC1 transcripts, induction of a UPR reporter and elevated expression of UPR target genes.  
IRE1, encoding the unfolded protein sensor in the ER lumen, exhibits a lethal genetic interaction 
with ARV1, indicating a requirement for the UPR in cells lacking ARV1. Additionally, a screen of 
yeast mutants with defects in lipid metabolism demonstrates that UPR induction in ARV1 mutants 
does not reflect a generalized response to alterations in lipid homeostasis. Surprisingly, ARV1 
mutants expressing a variant of Ire1p defective in sensing unfolded proteins are viable.  
Moreover, these strains exhibit constitutive HAC1 splicing that is additive with DTT-mediated 
perturbation of protein folding.  These data suggest a component of UPR induction in arv1Δ 
strains is distinct from protein misfolding.  Decreased ARV1 expression in murine macrophages 
also results in UPR induction, particularly up-regulation of ATF4, CHOP and apoptosis.  
Cholesterol loading or inhibition of cholesterol esterification further elevates CHOP expression in 
ARV1 knockdown cells.  Thus, loss or down-regulation of ARV1 disturbs membrane and lipid 
homeostasis resulting in a disruption of ER integrity, one consequence of which is induction of the 









The organization of lipids within and between organelle membranes is essential for many 
cellular processes, including protein folding and trafficking, osmotic integrity and signal 
transduction.  Sterols, such as cholesterol, are often physically coupled with sphingolipids in the 
lipid bilayer of membranes, where they act as foci for many important processes [207].  By 
contrast, excess cholesterol is cytotoxic [148] and tightly regulated by the combined impact of 
biosynthesis, influx, efflux, and esterification [6].  Many of these events initiate at the ER.  
Consequently, the sterol content of the ER is maintained at a critical threshold of 5% (molar 
basis) of total ER lipids [16].  This is a minor fraction of cellular cholesterol relative to the other 
membranes, but its impact on the cell is significant.  
In mammals, cellular cholesterol and fatty acids are primarily sensed and controlled via the 
ER-associated sterol regulatory element binding protein and its co-factors.   Similarly, upon 
accumulation of unfolded proteins in the ER lumen, the membrane-associated stress transducer, 
IRE1, initiates a cytoprotective cascade called the unfolded protein response (UPR) [208]. Protein 
misfolding in the ER lumen initiates dimerization, trans-autophosphoryation and activation of the 
cytosolic endoribonuclease domain of Ire1p leading to removal of a 26-base pair intron from 
either the HAC1 (yeast) or XBP1 (higher eukaryotes) transcript.  The spliced transcript is 
translated into a transcription factor that activates expression of UPR target genes.  The IRE1-
mediated branch of the UPR is conserved in all eukaryotes.  However in mammalian cells, there 
are two additional ER membrane-bound stress transducers; ATF6 and PERK [117].  Prolonged 
ER stress triggers apoptosis, due to PERK-mediated activation of the cell death effector CHOP 
[209]. 
Although the UPR is considered a protective reaction to misfolded proteins, perturbations in 
lipid homeostasis also activate the UPR in both yeast and mammalian systems.  Cholesterol 
accumulation in murine macrophages induces IRE1- and PERK-mediated UPR induction, 
liberation of ER calcium stores and CHOP-mediated apoptosis, contributing to macrophage death 
and atherosclerosis [148].  The UPR is also induced by alterations in sphingolipid biosynthesis, 
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such as knockdown of ceramide synthases in mammalian cells [144] or loss of Orm1p and 
Orm2p in yeast [143].  Clearly, there is an intimate connection between the triad of lipid 
metabolism, protein folding and ER function, although the mechanism and hierarchies of these 
relationships are unresolved. 
The ARE2 required for viability (ARV1) gene encodes an ER-localized protein that is a key 
component of lipid homeostasis in yeast and mammals [194,201].  Deletion of yeast ARV1 results 
in accumulation of sterols and ceramide in the ER [194,197], consistent with a generalized role 
for this protein in anterograde lipid transport.  Yeast ARV1 is also required for the maturation of 
GPI-anchors in the ER [196].  The ARV1 gene is conserved throughout eukaryotic evolution.  The 
majority of conservation in this membrane-associated protein lies in a 61-residue sequence 
known as the ARV1 homology domain.  Importantly, expression of human ARV1 fully restores 
lipid transport and viability to yeast cells deleted for the endogenous gene [194,197].  In keeping 
with conservation, the antisense oligonucleotide (ASO)-mediated down-regulation of ARV1 in 
mice leads to elevated ER and serum cholesterol and mis-regulated bile acid metabolism [201]. 
In this study, we show that one consequence of loss of ARV1 in yeast and mammalian cells 
is induction of the UPR.  We also demonstrate that induction of the UPR in ARV1 mutants is 
unusual in its severity and is synergistic with protein misfolding.  This suggests a coordinated role 
for Arv1p in ER stress and lipid metabolism that is conserved throughout eukaryotic evolution.   
 
MATERIALS AND METHODS 
 
 
General.  Complete yeast media (YEPD) was prepared as described [210].  Selection medias 
were prepared with the appropriate drug(s), G418 (200 mg/L; Invitrogen) and clonNAT (100 mg/L; 
Werner BioAgents), as previously described [211].  Yeast molecular and genetic techniques were 
performed according to conventional protocols [210].  Dithiothreitol (DTT) and canavanine are 
from Sigma.  5-Fluorouracil (5-FOA) is from US Biological.  [α-32P]dCTP is from PerkinElmer Life 
Sciences.  All primers were purchased from Invitrogen.  Antibodies to CHOP/GADD153 (B-3) 
(catalog number sc-7351) and ATF6 (catalog number IMG-273) are from Santa Cruz 
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Biotechnology and Imgenex, respectively.  The HRP-conjugated goat anti–mouse and goat anti–
rabbit IgG secondary antibodies are from Biorad.  Tissue culture plastic is from Fisher Scientific.  
Tissue culture media and cell culture reagents were purchased from Invitrogen. The Vybrant 
Annexin V/Propidium Iodide Apoptosis Assay kit #2 is from Molecular Probes.  The Institutional 
Review Board at Columbia University Medical Center approved all animal protocols used in this 
paper 
Yeast Strains, Plasmids and Transformation.  Yeast strains (Appendix 1) are derived from 
W303-1A [212] or S288C [213] backgrounds.  Deletion mutants were purchased from Open 
Biosystems or generated using one-step PCR-mediated gene disruption [214].  PCR products 
containing 20 nucleotides of the selection cassette (Kluyveromyces lactis URA3 gene, Kanamycin 
(G418) resistance cassette or Nourseothricin resistance cassette) and 50 nucleotides of the 
gene-specific sequence were generated prior to transformation.  PCR products and plasmids 
were introduced into the host strain via lithium acetate transformation [215], followed by selection 
and confirmation by PCR.  Ire1p cLD plasmids [119] and the 4X unfolded protein response 
element (UPRE)-GFP reporter [216] were from Peter Walter and Randy Hampton, respectively.  
All yeast strains were grown at 30°C unless indicated. 
Growth Curves. Yeast cultures were inoculated at A600=0.1 and grown for 72 hours.  Growth 
curves were obtained using a Microbiology Workstation Bioscreen C (Thermo Electron Corp.) and 
analyzed using Microsoft Excel.  
 
Spot-Assay Random Spore Analysis and Pronging Assays. Random spore analysis was 
carried out as described [217].  Briefly, heterozygous diploid strains were sporulated for 7 days 
and MATa haploids were obtained by growth in haploid selection media (SD-His/Arg + 
canavanine) for 2 days. The MATa spore progeny were plated in serial dilutions on selection 
media (SD/MSG-His/Arg + canavanine) containing clonNAT, G418 or both and grown for 2 days 
to assess genotype viability.  For pronging assays, aliquots from 2 ml cultures were plated in 




Microarray and Bioinformatics.  Biotin-labeled and fragmented cRNA was hybridized to the 
Ye6100 or S98 Yeast GeneChip arrays (Affymetrix, [184]).  All data mining were performed as 
previously described [184].  The data discussed in this thesis have been deposited in NCBI’s 
Gene Expression Omnibus [218] and are accessible though GEO series accession number 
GSE26801.  For the motif-based regression analysis we used a modification of the procedure of 
Foat et al. [219] and a collection of 123 position weight matrices (PWMs) [220].  We used the 
convert2psam utility from the MatrixREDUCE v2.0 software package to convert each PWM to a 
position-specific affinity matrix (PSAM) [221,222,223].  For each TF, the resulting PSAM 
collection was used to predict the relative binding affinity profile across each promoter region.  
We defined the promoter region of each gene as 600bp upstream of the open reading frame, as 
obtained from the Saccharomyces Genome Database.  We used total promoter affinity as a 
predictor for differences in mRNA expression between the ARV1 deletion strain and the wild-type 
strain.  To obtain an estimate for the differential mRNA expression level between the ARV1 
deletion strain and the wild-type strain, we calculated log2-ratios of intensities of the ARV1 
deletion strain and the wild-type strain, and averaged over 3 biological replicates.  Then, we 
performed multivariate linear regression of the genomewide mRNA expression log-ratios on the 
total promoter affinities for all TFs.  To determine statistical significance, we performed 
multivariate linear regression after independent random permutation of expression log-ratios 
(1,000 samples), and then determine the mean and standard error of an empirical null 
distribution.  We used these values to compute a t-value and the corresponding p-value.  We also 
estimated false discovery rate (FDR) using random permutations; an FDR <5% based on 
empirical permutation test corresponded to a p-value < 3.15 10-4.   
 
Gene Ontology Analyses. We scored each Gene Ontology (GO) category for statistical 
association with the genome-wide pattern of differential mRNA expression between the ARV1 
deletion strain and control strain. The analysis was done using the R statistical programming 
language (www.r-project.org) and Bioconductor packages GO.db and org.Sc.sgd.db  
45 
 
(www.bioconductor.org). We tested for difference in distribution of the arv1Δ versus control 
mRNA expression log-ratio between the genes in a particular GO category and all other genes. 
This was done parametrically using the Welch t-test (T-profiler, [224]), and non-parametrically 
using the Wilcoxon-Mann-Whitney test. A Grubbs test (α = 10-8) was used to remove outliers 
before performing the t-test. For each GO category, we only considered genes that were also 
represented as probes on the DNA microarray, and we did not score any GO categories 
containing fewer than 10 such genes. We controlled for multiple testing by requiring a FDR less 
than 5%, corresponding to a p-value threshold equal to 8.39x10-5. 
 
Gene Expression Analyses. For northern blots, 10 µg of RNA was run on a 1.2% formaldehyde 
gel and transferred to a nylon membrane.  Membranes were hybridized with PCR-generated 
gene-specific probes and analyzed by audioradiography and phosphorimaging (GE Healthcare); 
n=3.  For real-time PCR, RNA was isolated from cells using the RNAeasy kit (Qiagen).  100 ng 
RNA was reverse transcribed using the SuperScript First-Strand System for RT-PCR (Invitrogen).  
Real-time PCR reactions were performed with the MyIQ Single-Color Real Time PCR Detection 
System (Biorad), SYBR Green 2X Supermix (Biorad) and the primers described (Appendix 2).  
Expression levels were calculated relative to a housekeeping gene as previously described [225].   
 
Isolation and Transfection of Mouse Peritoneal Macrophages.  Primary macrophages from 
adult female C57BL6J mice were harvested by peritoneal lavage after i.p. injection of methyl-BSA 
as previously described [153].  The ACAT inhibitor 58035 (3-[decyldimethylsilyl]-N-[2-(4-
methylphenyl)-1-phenylethyl]propanamide) and Acetylated-LDL (AcLDL) were prepared as 
previously described [153].  Macrophages were grown in media containing DMEM (high glucose), 
10% FBS, 1% Penicillin-Streptomycin and 20% L-cell conditioned media to 50-60% confluency.  
Media was replaced every 24 hours. On the day of the experiment, cells were treated with 250 
nM control or ARV1 ASO, complexed with Lipofectamine 2000 (Invitrogen).  At 6 hours, the 
transfection mixture was removed and replaced with full macrophage media.  Cells were then 
incubated 24-48 hours, with or without 10ug/ml 58035 for 5 hours.  Free-cholesterol loading 
46 
 
(positive control) contains no ASO but was treated with 100µg/ml AcLDL + 10µg/ml 58035 for 5-
18 hours. 
 
XBP1 Splicing Assay.  100 µg of RNA was reverse transcribed and PCR amplified (see 
Appendix 2 for primer sequence).  The XBP1 fragment was purified (Qiagen), resuspended in 35 
µl of sterile water and digested with PstI (NEB) according to the manufacturer’s instructions.  
Splicing was assessed by running digested fragments on a 1.5% agarose gel. 
 
Immunoblots.  Cells were washed 2X in cold PBS prior to lysis.  For CHOP (Santa Cruz 
Biotechnology) assays, whole cell lysates were isolated in Laemmli Sample Buffer (Biorad) 
containing 0.5% β-mercaptoethanol.  50µg of lysate was run on a 4-20% Tris-HCL gel (Biorad).  
For the ATF6 (Imgenex) assay, nuclear preps were isolated using the Nuclear Extraction Kit 
(Panomics) and 20 µg of nuclear prep was run on a 4-20% Tris-HCL gel (Biorad).  Protein was 
electro-transferred onto a 0.45 µm nitrocellulose membrane (Biorad) and incubated with the 
primary antibody overnight.  Protein bands were detected with HRP-conjugated secondary 
antibodies (Biorad) and either SuperSignal West Pico or SuperSignal West Fempto enhanced 
chemiluminescent solution (Pierce). 
 
Electron Microscopy.  Cells were grown to mid-log phase, prefixed in glutaraldehyde, postfixed 
in potassium permanganate, dehydrated by graded ethanol series and embedded in Spurr’s resin 
[226].  Cells were thin sectioned, stained with Reynold’s lead citrate [227] and visualized on a 
transmission electron microscope.   
 
Fluorescence Microscopy. Fluorescence imaging in yeast was carried out on a Zeiss Axiovert 
200M using a 63X oil immersion objective. All yeast images were taken using a Hamamatsu 
Orca-ER camera.  Nile Red (Sigma), FM4-64 (Invitrogen) and NBD-cholesterol (Invitrogen) were 
used at the indicated concentrations.  To examine sterol distribution, live cells were grown to 
saturation in YEPD, resuspended in YEPD containing 100 µg/ml Filipin (Polysciences, Inc.) and 
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imaged immediately.  Macrophages were assayed for apoptosis by staining with Alexa 488–
conjugated Annexin V and propidium iodide as previously described [153] Live cell images were 
obtained using an Olympus IX- 70 inverted fluorescent microscope equipped with filters 
appropriate for fluorescein and rhodamine, and a Cool Snap CCD camera (RS Photometrics) 
equipped with imaging software from Roper Scientific.  Four fields of cells were photographed for 
each condition and the number of annexin V/PI–positive cells in each field were counted and 






Loss of ARV1 in yeast is pleiotropic.  The independent identification of mutations in ARV1 from 
screens that perturbed sterol [194] or sphingolipid [197] metabolism suggests alterations in lipid 
distribution and membrane homeostasis in ARV1 deficient cells.  Indeed, an established 
biochemical feature of ARV1 mutants is accumulation of ER ceramide at the expense of complex 
sphingolipid formation [194].  Consistent with a growth inhibitory blockade in ER export of 
ceramide, we found that ARV1 mutants are sensitive to exogenous dihydrosphingosine, a 
substrate for ceramide synthases (Figure 2-1A).  Repression of the rate-limiting step in  
sphingolipid biosynthesis by treatment with the serine palmitoyltransferase inhibitor myriocin is 
also more toxic in ARV1 mutants than controls (Figure 2-1B), suggesting that formation of 
sphingolipids is especially critical in these strains. 
 Under standard growth conditions, loss of ARV1 results in subcellular accumulation 
[185,189] and esterification [194,197] of endogenously synthesized sterol.  To specifically assess 
the impact of ARV1 upon anterograde sterol transport from the ER, we inspected ARV1 mutants 
with lipid-specific fluorescent dyes under sterol-loading conditions.  Deletion of ARV1 results in 
anaerobic inviability, precluding the analysis of exogenous sterol uptake.  To overcome this, we 
assessed the role of ARV1 in the presence of a mutation in the UPC2 transcription factor that 
activates aerobic sterol uptake [184].  ARV1 mutants exhibited subcellular sterol accumulation as 
detected by filipin staining (Figure 2-2A). Interestingly, this staining pattern occurred in 43% of the 
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ARV1 mutant population and was completely absent from control cells.  Consistent with an 
accumulation of acyltransferase substrates at the ER, steryl ester lipid droplet formation was also 
increased in sterol-loaded arv1Δ strains stained with Nile Red (Figure 2-2B).  These strains were 
further profiled using the fluorescent sterol probe NBD-cholesterol, which also accumulated in 
arv1Δ strains as a marked proliferation of subcellular membranes (Figure 2-2C).   
We then investigated the ultrastructure of ARV1 mutants by transmission electron 
microscopy.  The ER in control S. cerevisiae strains (Figure 2-3A) is contiguous with the nuclear 
(perinuclear, pnER) and plasma membranes (cortical, cER).   By contrast, arv1Δ strains exhibit 
abundant cytoplasmic double membrane stretches (Figure 2-3B, C).  Consistent with the 
accumulation of neutral lipids described above, ARV1 mutants also exhibited more cytoplasmic 
lipid droplets than control cells.  These droplets were engulfed in a membranous structure that 
was absent from control strains.  In addition, we observed vacuolar fragmentation in arv1Δ strains 
(Figure 2-3C) that was confirmed by fluorescent imaging with the vacuole specific dye, FM4-64 
(Figure 2-3D and [189]).   
 
Transcriptional response to loss of ARV1.  Deletion of ARV1 has numerous consequences, 
including morphological changes in organelles and inviability in response to a variety of lipid-
related stresses.  These aberrancies are consistent with redistribution of sterols and sphingolipids 
within the cell. This pleiotropy led us to hypothesize that multiple homeostatic mechanisms are 
disturbed by loss of ARV1.  We therefore profiled the response to ARV1 deletion using 
transcription microarrays.  273 genes were mis-regulated greater than two-fold upon ARV1 
deletion (Appendix 3).  The gene with the greatest increase in expression was ULI1, with a 48-
fold change in expression.  ULI1 encodes a protein of unknown function that is upregulated 
during the UPR [228].  The scope of expression changes in arv1Δ strains is reflected in a GO 
analysis in which 57 GO categories were significantly enriched in the mutants (Appendix 4).  The 
GO categories describe cellular processes consistent with disrupted ER homeostasis in arv1Δ 
strains.  These include down-regulation of translation (e.g. ribosome biogenesis (GO:0042254) 
and translation (GO:0006412)) and up-regulation of ER stress responses (e.g. ER-associated 
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protein catabolism (GO:0030433) and ubiquitin-dependent protein catabolism (GO:0006511)).  
To identify the transcriptional programs altered in ARV1 mutants, we performed motif-based 
regression analysis of the microarray data [229].  This method infers changes in transcription 
factor activity by relating differential mRNA expression to the affinity with which the factor binds to 
the promoter region of each gene.  Three transcription factors are highly differentially activated in 
response to arv1Δ.  Transcriptional changes due to Thi2p [230] and Hap2p [231] activation were 
significant (Table 2-1) and confirmed by real-time PCR of representative targets (Figure 2-4).  
However, Hac1p, the transcriptional regulator of the UPR in yeast, exhibited the greatest change 
in differential activity in ARV1 deletion strains relative to controls, suggesting induction of the UPR 
in ARV1 mutants. 
 
Loss of ARV1 constitutively induces the UPR.  To confirm activation of the UPR in arv1Δ 
strains, we performed real-time expression analyses of canonical UPR target genes [126] and 
ULI1.  arv1Δ strains exhibit induction of the UPR target genes (Figure 2-5A), of similar magnitude 
to control cells treated with the reducing agent dithiothreitol (DTT), a established and marked 
inducer of the UPR.  
We then went on to assess the status of the UPR directly by an IRE1-mediated HAC1 
splicing assay.  ARV1 mutants exhibit constitutive HAC1 splicing, independent of DTT treatment 
(Figure 2-5B).  Furthermore, arv1Δ strains expressing a GFP reporter driven by an UPRE [173] 
exhibit constitutive UPR activation, as demonstrated by UPRE-GFP fluorescence (Figure 2-5C).   
The key role of UPR induction in the physiology of ARV1 deficient cells was further confirmed 
when we investigated the genetic interaction between ARV1 and IRE1, the major ER stress 
transducer in yeast [208].  Random spore analysis of a diploid strain heterozygous for deletions of 
ARV1 and IRE1 demonstrated that arv1Δ ire1Δ is a lethal combination (Figure 2-5D).  
Furthermore, in a tetrad manipulation analysis of 70 individual meiotic events of the same diploid, 
we could not recover arv1Δ ire1Δ double mutants (although single mutants were recovered at 




UPR induction and membrane lipid homeostasis.  Arv1p mediates lipid egress from the ER in 
yeast.  Furthermore, its loss results in induction of the UPR.  We questioned whether this was a 
general response to disruption of ER lipid homeostasis.  We screened 76 mutant strains known to 
be deficient in sterol, fatty acid and sphingolipid metabolism by a HAC1 splicing assay (Figure 2-6 
and 2-7).  Deletions in non-essential genes or hypomorphic (DAmP, [232]) alleles of essential 
genes were assessed for UPR induction by comparing the ratio of spliced HAC1 (HAC1i) to total 
HAC1 by densitometry of northern blots.  Strains exhibiting a HAC1i:total HAC1 ratio of 3 or 
greater (Appendix 5) were then subjected to real-time expression analyses of canonical UPR 
target genes (Figure 2-8).  The fold induction of PDI1 and KAR2 was expressed as a fraction of 
the control strain.  Of the strains examined, only the arv1Δ strain exhibited a PDI1 and KAR2 
induction of 2-fold or more (Table 2-2).  Thus, arv1Δ strains are unusual within the set of lipid 
mutants screened in terms of severity of UPR induction.   
ARV1 has also been implicated in GPI anchor maturation by a proposed GPI-flippase activity 
[196].  To determine if activation of the UPR in arv1Δ strains was distinct from other strains 
defective in GPI-anchor biosynthesis, we screened 22 mutations in the yeast GPI biosynthetic 
pathway [233] for UPR induction (Figure 2-9A).  Of the GPI mutants screened, only the ARV1 and 
PER1 deletions and the gaa1 hypomorph exhibited HAC1 splicing and a PDI1-KAR2 induction 
that was 2 times greater than control cells (Figure 2-9B; Table 2-3).  Gaa1p is a component of the 
GPI transamidase complex and similar to ARV1 mutants, the GAA1 mutant is defective in the 
synthesis of complex sphingolipids and sensitive to aureobasidin A [196].  Per1p is responsible 
for remodeling lipid moieties in the GPI anchor such that GPI-anchored proteins are unable to 
associate with detergent-resistant lipid rafts in PER1 mutants [234].  ARV1 deficiency is also 
unusual in its severity of UPR induction compared to the remainder of the genome.  Out of ~4500 
nonessential gene deletions investigated, the arv1Δ strain exhibits the second strongest induction 
of the UPR [203]. 
 
Interaction of protein misfolding and lipid dysregulation in arv1Δ  strains.  We hypothesize 
that the unusual severity of UPR induction in arv1Δ strains reflects the synergism of lipid 
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accumulation and protein misfolding in the ER.  Structural studies of Ire1p demonstrate that the 
Ire1p cLD aligns with other cLDs in a head-to-head (interface I, IFI) and tail-to-tail (interface II, 
IFII) fashion.  Ire1p cLD constructs in which the interfaces are mutated (IFIL and IFIIL), disrupt 
Ire1p oligomerization and the response to unfolded proteins [119].  We transformed arv1Δ ire1Δ 
heterozygous diploids with plasmids expressing the control and mutant cLDs and sporulated the 
strains.  Haploid arv1Δ ire1Δ progeny were not obtained from diploids containing the vector 
control.  By contrast, expression of control and mutant cLDs rescued arv1Δ ire1Δ lethality (Figure 
2-10A). Rescue was lost upon selection against the URA3-based cLD plasmid by growth on  5-
FOA, which is converted into a toxic substance in the presence of the URA3 gene product.  The 
mutant cLDs were sufficient to induce the UPR signaling cascade in an arv1Δ background (Figure 
2-10B, upper panel).  We then assayed UPR induction in ARV1 mutants treated with DTT to 
induce protein misfolding.  HAC1 splicing mediated by the Ire1p variants was further elevated in 
an arv1Δ strain under these conditions (Figure 2-10B, lower panel), indicative of an independent 
and additive interaction between ARV1 function and protein misfolding. 
 
Decreased ARV1 expression in mammalian cells induces ER stress and apoptosis. We 
questioned whether lipid accumulation in the ER due to decreased ARV1 expression could 
activate the UPR in mammalian cells.  Antisense oligonucleotides (ASOs) to ARV1 are effective 
in modulating ARV1 expression [201]. Since organs replete with macrophages (e.g. spleen) were 
not impacted in these studies, we used the ASOs in primary murine macrophages in vitro and 
observed a significant decrease in ARV1 expression (Figure 2-11).  In order to determine if the 
UPR is induced in ASO-treated macrophages, we probed for activation of the three major 
branches of the UPR.  Mammalian IRE1 splices XBP1 transcripts (analogous to HAC1 transcripts 
in yeast) to form an active transcription factor [125].  Surprisingly, ARV1 ASO-treated 
macrophages did not exhibit increased XBP1 splicing relative to controls (Figure 2-12A).  
Furthermore, induction of the UPR via processing of ATF6, another branch of the UPR in 
mammalian cells, was also unchanged (Figure 2-12B).  However, ATF4 levels were significantly 
increased upon ARV1 knockdown, reflecting activation of PERK-mediated UPR (Figure 2-13A).  
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Prolonged ER stress induces apoptosis mediated by CHOP [129], another target of PERK-
mediated UPR that is selectively activated by ATF4.  ARV1 knockdown significantly increased the 
levels of CHOP transcripts (Figure 2-13B).  To exacerbate cholesterol accumulation at the ER, 
we treated macrophages with the ACAT inhibitor 58035 in conjunction with the ASOs.  We 
observed a significant increase in ATF4 and CHOP expression in comparison to ARV1 ASO-
treatment alone (Figure 2-13B,C).  ARV1 ASO treatment also increased CHOP expression at the 
protein level, which was further elevated by addition of the ACAT inhibitor (Figure 2-13C). 
To determine if the effect of ARV1 knockdown was synergistic with exogenous cholesterol 
loading we treated ASO-transfected macrophages with increasing concentrations of acetylated 
low-density lipoprotein (AcLDL), and 10 µg/ml of the ACAT inhibitor 58035 [148].  Using CHOP 
transcript levels as a marker for UPR induction, we demonstrate that cholesterol loading 
increased the UPR in ARV1 knockdown cells in a statistically significant, dose-dependent manner 
(Figure 2-13D).   
Cholesterol loading of macrophages using AcLDL and an ACAT inhibitor triggers CHOP-
dependent apoptosis (Figure 2-14A and [148]).  We treated primary macrophages with ARV1 
ASOs for 24 hours in the absence of AcLDL and investigated annexin V/propidium iodide cellular 
fluorescence to assess apoptosis.  ARV1 ASO-treatment of macrophages increased the number 
of apoptotic cells relative to control ASO treatment (Figure 2-14B).  This was further exacerbated 
when combined with ACAT inhibition, suggesting a toxic accumulation of free cholesterol at the 
ER.  Furthermore, apoptosis in the ARV1 knockdown cells treated with the ACAT inhibitor 
exceeded that seen with exogenous cholesterol loading mediated by AcLDL treatment and ACAT 
inhibition (Figure 2-14C).  Thus, ARV1 knockdown results in apoptosis, likely due to elevated 







In this study, we show that one consequence of loss of ARV1 in yeast and mammalian cells 
is induction of the UPR.  We also demonstrate that induction of the UPR in ARV1 mutants in 
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unusual in its severity and is synergistic with protein misfolding.  This suggests a coordinated role 
for Arv1p in ER stress and lipid metabolism that is conserved throughout eukaryotic evolution. 
The endoplasmic reticulum represents a protected, sequestered environment for protein 
folding and lipid homeostasis.  ARV1 encodes a major, previously unsuspected, component in 
the repertoire of reactions that maintain the integrity of this compartment.  As might be 
anticipated for such a key process, loss of ARV1 activity has many sequelae.  It is growth 
limiting in yeast under a variety of conditions and embryonic lethal in nematodes [235]. Yeast 
cells and macrophages induce the UPR to survive loss of ARV1 and this induction is apparently 
independent of protein misfolding, although it certainly synergizes with this additional ER burden.  
Ablation of ARV1 in the murine liver results in cholestasis and hypercholesterolemia [201].  In 
addition to conservation of ARV1, the impact of its loss is also maintained throughout eukaryotic 
evolution.   
The range of phenotypes conferred by the ARV1 null allele in yeast suggest a wide-reaching 
role of the Arv1 protein in cell metabolism and the high impact of loss of lipid export from the ER. 
Our observations of sterol-loaded yeast cells (Figure 2-2) indicate that sterol transport to the ER 
from the periphery of ARV1 mutant cells is normal but that its egress from the ER is impaired.  
The lipid and ultra-structural changes of ARV1 mutants are likely upstream of the UPR, since 
constitutive induction of this cascade, for example in SCJ1 deletion mutants, does not phenocopy 
ARV1 deletion [236].   Unesterified sterols, ceramide and its derivatives optimize the fluidity and 
function of all eukaryotic cellular membranes.  Sterol transit from the ER to the plasma membrane 
is rapid, efficient, and energy requiring [237], and likely occurs via aqueous diffusion, vesicular 
transport and/or carrier proteins [238].  Similarly, ceramide egress from the ER to the Golgi is 
energy requiring and primarily accomplished by vesicular independent carrier proteins [239].  
Yeast Arv1p was isolated based on its role in sterol transport from the endoplasmic reticulum to 
the plasma membrane [194].  Subsequently, ARV1 deficient cells were found to possess lower 
levels of complex sphingolipids, and mislocalize GPI-intermediates, consistent with a general role 
for Arv1p in lipid mobilization at the ER [196].  However, the coordinated regulation of sterol 
levels with other lipids [207] makes it difficult to distinguish whether ER stress seen in ARV1 
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mutants is a consequence of aberrant sterol transport or reflects the ARV1-mediated transport of 
multiple lipid species. 
We also provide evidence that a component of the UPR is independent from protein 
misfolding.  Induction of the UPR in ARV1 deficient yeast cells is synergistic with the buildup of 
unfolded proteins in the ER lumen, plausibly due to changes in ER lipid homeostasis.  The 
mediators of the UPR in yeast (Ire1p) and mammals (IRE1, PERK and ATF6) are transmembrane 
proteins that require activation in, or release from, the ER membrane to be physiologically 
relevant.  It is not surprising that disrupting the membrane integrity of this organelle, by altering 
the sterol and/or sphingolipid content of the ER, impacts the UPR.  Thus, the UPR appears to be 
a downstream and essential response to the altered lipid homeostasis in ARV1 mutants.  This 
may be the case for many lipid-metabolic disorders in humans. 
It is interesting that not all UPR target genes [126] are activated upon deletion of ARV1 in 
yeast.  Membrane expansion during ER stress is one mechanism to alleviate the burden of 
accumulating proteins in the ER lumen.  Membrane biogenesis is regulated by the Ino2p-Ino4p 
heterodimer and suppressed by Opi1p [240].  Expression of these genes was not altered in the 
arv1Δ strain (Appendix 3), supporting the idea that the UPR and membrane expansion seen in 
ARV1 mutants is atypical, perhaps reflecting prolonged ER stress.  Furthermore, a comparison of 
the overlap between DTT-induced UPR targets [126] and genes upregulated in response to 
arv1Δ (Appendix 3) demonstrated that roughly 100 genes are co-upregulated (data not shown).  
Of those activated greater than 2-fold, only two are implicated in lipid metabolism (ARE1 and 
SCS3).  This supports the idea that the UPR seen in arv1Δ strains is distinct from DTT-mediated 
stress. Thus, constitutive UPR observed in arv1Δ strains may represent the impact of prolonged 
ER stress due to altered subcellular lipid homeostasis.   
In our ASO studies in macrophages, we saw a significant and consistent knockdown of ARV1 
transcripts (Figure 2-11).  Although we did not examine protein expression in these cells, the 
significant impact of decreased ARV1 expression on cell stress and apoptosis suggests a 
decrease in ARV1 protein expression and function. In macrophages treated with the ARV1 ASO 
for 48 hours, it is apparent that although PERK-mediated UPR is induced (Figure 2-13), not all 
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ER-stress transducers are activated (Figure 2-12).  In HEK293 cells, IRE1- and ATF6- mediated 
UPR induction diminishes with time while PERK-mediated UPR is sustained over a more 
prolonged period [241].  Selective activation of PERK signaling is pro-apoptotic, impairing cell 
proliferation and inducing apoptosis [242], while activation of IRE1 is anti-apoptotic.  We propose 
that PERK-mediated UPR and cell death in ARV1 deficient cells is a consequence of prolonged 
ER stress due to lipid overload. 
Selective activation of PERK-mediated UPR in the ARV1 ASO-treated macrophages may 
also reflect the more complex UPR cascade in mammalian cells.  In yeast HAC1 is the only 
known substrate of Ire1p [243], demonstrating that all UPR effector functions are controlled by 
this splicing event.  In contrast, the RNase activity of IRE1α in INS-1 cells controls both XBP1 
splicing and the degradation of roughly 200 mRNAs [244].  Thus, it would be interesting to 
examine known targets of IRE1α-mediated degradation (e.g. GALNT2, GYLTL1b, PDIA4 and 
RTN4) [244] in order to completely rule out IRE activation in ARV1 knockdown cells.  
Furthermore, calcium storage differs between mammalian cells and yeast.  Calcium is an 
important cofactor for many chaperones and changes in ER calcium status have been 
demonstrated to induce the UPR [148].  In yeast, the vacuole serves as the major calcium store 
[245], while the ER is the major calcium store in mammalian cells.  Glucose deprivation in MIN6 
cells causes selective activation of PERK-mediated UPR, a phenomenon attributed to calcium 
leak through SERCA inhibition [246]. Perhaps selective activation of PERK-ATF4-CHOP branch 
of the UPR in ARV1 knockdown macrophages is reflective ER calcium leakage, as it has been 
suggested that the threshold for IRE1 activation in response to decreases in ER calcium 
concentration is higher than that of PERK [246]. 
The link between disruption of cellular lipid homeostasis and ER stress is compelling.  The 
UPR and its consequences are frequently invoked upon lipid overload in many different cell 
types.  Moreover, genome-wide examination of UPR induction in yeast revealed that a low level 
UPR is induced in several mutants with defective lipid metabolism [203].  Some of these mutants 
were examined in our HAC1 splicing studies (e.g. sur4Δ, acb1Δ and lcb4Δ; Figure 2-6) and 
revealed little or no UPR induction.  This may reflect differences in assay sensitivity, in which we 
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would argue that assessment of HAC1 splicing is a more accurate reflection of UPR activation.  
However, we demonstrate that both within the lipid mutants examined and genome-wide [203], 
loss of ARV1 is one of the most potent inducers of the UPR.  Thus, we propose that the UPR is a 
generalized response to ER homeostasis, resulting from independent and often synergistic 
perturbations in membrane structure, lipid metabolism and protein folding.  The deterioration of 
any of these safeguards is likely to manifest as diseases in which lipids plays a role.  A disease 
association has yet to be reported for ARV1 although variation in this gene exists in human 
populations (http://www.ncbi.nlm.nih.gov/snp).  Thus, mutations in ARV1 may influence diseases 
such as obesity, atherosclerosis and type 2 diabetes. 
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Table 2-1. Motif-based regression analysis reveals UPR activation in arv1Δ  strains.  Three 
transcription factors (TFs) are highly differentially activated in response to arv1Δ.  The t-value 
metric represents the activity of each TF.  A significant p-value confirms that the activity of the TF 




Function t-value p-value 
HAC1 Transcription factor that regulates the unfolded 
protein response via UPRE binding; ER stress-








HAP2 Transcriptional activator and global regulator of 





Table 2-2. UPR induction in ARV1 mutants does not reflect a generalized response to 
alterations in lipid metabolism.  Lipid-metabolic mutants with a HAC1i/(HAC1i+HAC1u) score ≥ 
3 were rescreened by qRT-PCR analyses of canonical UPR target genes.  Mean fold induction 
(MFI) of PDI1 and KAR2 is expressed as a percent of the control strain.  Strains exhibiting a 




ORF Function PDI1 MFI KAR2 MFI 
ARV1 YLR242C Sterol and sphingolipid trafficking; 
GPI-anchor maturation 
219 376 
ERG11 YHR007C Ergosterol biosynthesis 132 121 
ERG2 YMR202W Ergosterol biosynthesis 136 114 
ERG24 YNL280C Ergosterol biosynthesis 106 103 
ERG28 YER044C Ergosterol biosynthesis 110 114 
ERG5 YMR015C Ergosterol biosynthesis 143 164 
ERG6 YML008C Ergosterol biosynthesis 120 122 
FAS2 YPL231W Long-chain fatty acid formation 84 146 
HMG1 YML075C Ergosterol biosynthesis 99 106 
LRO1 YNR008W Triglyceride formation 109 105 
PDR11 YIL013C Exogenous sterol uptake 121 124 






Table 2-3.  UPR induction in ARV1 mutants is distinct from majority of mutants exhibiting 
defects in GPI-anchor biosynthesis and attachment.  Mutants with a HAC1i/(HAC1i+HAC1u) 
score ≥ 2 were rescreened by qRT-PCR analyses of canonical UPR target genes.  Mean fold 
induction (MFI) of PDI1 and KAR2 is expressed as a percent of the control strain.  Strains 
exhibiting a PDI1-KAR2 MFI 2-fold or greater than the control strain are highlighted.   
 








GPI3 YPL175W DAmP Allele 2 127 216 
 GPI2 YPL076W DAmP Allele 1   
 GPI15 YNL038W DAmP Allele 0   
 GPI19 YDR437W DAmP Allele 1   
 GPI1 YGR216C Unavailable    
 ERI1 YPL096C-A Deletion Strain 0   
GlcNAc-PI de-N-
acetylation 
GPI12 YMR281W DAmP Allele 0   
GPI Flipping ARV1 YLR242C Deletion Strain 4 219 376 
Inositol acylation GWT1 YJL091C Unavailable    
α1,4 
mannosyltransfer  
GPI14 YJR013W DAmP Allele 1   
 PBN1 YCL052C DAmP Allele 1   
Etn-P transfer to 
Man-1 
MCD4 YKL165C Unavailable    
α1,6 
mannosyltransfer 
GPI18 YBR004C DAmP Allele 0   
α1,2 
mannosyltransfer 
GPI10 YGL142C DAmP Allele 0   
Etn-P transfer to 
Man-3 
GPI13 YLL031C DAmP Allele 0   
 GPI11 YDR302W DAmP Allele 0   
α1,2 
mannosyltransfer  
SMP3 YOR149C DAmP Allele 0   
Etn-P transfer to 
Man-2 
GPI7 YJL062W Deletion Strain 0   
 GPI11 YDR302W DAmP Allele 0   
GPI transamidase GPI8 YDR331W DAmP Allele 0   
 GAA1 YLR088W DAmP Allele 4 364 659 
 GPI17 YDR434W DAmP Allele 1   
 GPI16 YHR188C Unavailable    
 GAB1 YLR459W Unavailable    
Inositol 
deacylation  
BST1 YFL025C Deletion Strain 3 175 192 
sn-2 deacylation PER1 YCR044C Deletion Strain 3 213 232 
sn-2 C26acylation GUP1 YGL084C Deletion Strain 1   




   
 
Figure 2-1.  Loss of Arv1p disrupts sphingolipid homeostasis. (A) Growth of control and 
arv1Δ yeast strains in YPD with and without 1µM dihydrosphingosine (DHS); n=3 for each 




   
 
Figure 2-2.  Loss of Arv1p disrupts cholesterol distribution.  Control and arv1Δ strains (both 
upc2-1 background) grown for 24 hours in YPD + 5 µg/ml cholesterol, followed by staining with 
filipin (100 µg/ml) (A) or Nile Red (1 µg/ml) (B).  (C) Aerobic uptake of NBD-cholesterol (50 µg/ml) 







Figure 2-3. Loss of Arv1p disrupts organelle integrity.  Thin-section EM of control (A) and 
arv1Δ strains (B, C).  N, nucleus; V, vacuole; pnER and cER, perinuclear and cortical 
endoplasmic reticulum, respectively; PM, plasma membrane; LD, lipid droplet.  Arrows indicate 

















































Figure 2-4.  arv1Δ  activates Thi2p- and Hap2p-target genes.  (A) qRT-PCR expression 
measurements of Thi2p (A) and Hap2p (B) target genes as a consequence of arv1Δ.  Asterisks 
denote statistically significant (p<0.05) differences of the mean fold induction (ΔΔCt) ± s.d. in 












































Figure 2-5. The UPR is activated in arv1Δ  strains.  (A) Real-time PCR measurements of UPR 
target gene expression due to 2 mM DTT treatment for 45 minutes or arv1Δ.  Asterisks denote 
statistically significant (p<0.05) differences of the mean fold induction (ΔΔCt) ± s.d. in comparison 
to controls by unpaired t-test; n=3.  (B) Northern blot analysis of HAC1 mRNA in strains with the 
indicated mutation.  Unspliced HAC1u and spliced (induced) HAC1i are indicated; lower bands are 
splicing intermediates.  (C) Control and arv1Δ strains expressing GFP driven by an unfolded 
protein response element (UPRE).  (D) Random spore analysis of a diploid strain heterozygous 
for deletions of ARV1 and IRE1 on media selecting for the mutant genotypes (arv1Δ, (G418), 







Figure 2-6.  HAC1-splicing screen of yeast deletion mutants deficient in sterol, fatty acid 
and sphingolipid metabolism.  Northern blot analysis of HAC1 mRNA in strains with the 
indicated mutations.  Unspliced HAC1u and spliced (induced) HAC1i are indicated; lower bands 






Figure 2-7.  HAC1-splicing screen of hypomorphic yeast strains deficient in sterol, fatty 
acid and sphingolipid metabolism.  Northern blot analysis of HAC1 mRNA in hypomorphs 
(DAmP alleles) with the indicated defect.  Unspliced HAC1u and spliced (induced) HAC1i are 






Figure 2-8.  Expression of UPR targets in mutants exhibiting defects in lipid metabolism.  
Real-time PCR profiles of canonical UPR target genes in mutants or hypomorphs (DAmP alleles) 

















































Figure 2-9. UPR expression profile in the arv1Δ  strains is distinct from genes exhibiting 
defects in GPI anchor biosynthesis.  (A) northern blot analysis of HAC1 mRNA in strains 
defective in GPI anchor biosynthesis and attachment.  (B) qRT-PCR analyses of canonical UPR 





Figure 2-10.  UPR induction in arv1Δ  mutants is synergistic with the detection of unfolded 
proteins in the ER lumen.  (A) Plasmids mutated at interface 1 (IFIL) or interface 2 (IFIIL) of the 
Ire1p core luminal domain rescue arv1Δ ire1Δ synthetic lethality, as represented by growth on a 
URA-based selection media.  Counter selection for the plasmid by growth on 5-FOA restores the 
synthetic lethal phenotype.  The empty vector control (pRS416) in the arv1Δ ire1Δ strains was 
inviable.  Control genotype refers to yeast strains in the same genetic background as the double 
mutants. (B) Northern blot analysis of HAC1 mRNA in ire1Δ and arv1Δ ire1Δ strains expressing 
control Ire1p, IFIL Ire1p or IFIIL Ire1p with or without 2 mM DTT treatment.  EV denotes empty 
vector control.  Unspliced HAC1u and spliced (induced) HAC1i are indicated; lower bands are 




                    
 
Figure 2-11.  ASO-mediated knockdown of ARV1 expression in murine macrophages.  
ARV1 mRNA expression in macrophages treated with control (CON) or ARV1 ASO for 48 hours 
with or without the ACAT inhibitor, 58035.  Asterisks denote statistically significant (**p<0.005) 
differences of the mean fold induction (ΔΔCt) ± s.e. by unpaired t-test; n=6.   
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Figure 2-12.  IRE1- and ATF6-mediated UPR is not induced in ARV1 knockdown 
macrophages.  (A) XBP1 splicing assay (after PstI digestion) in macrophages treated with 
250nM control or ARV1 ASO for 48 hours.  NT is no treatment condition; AcLDL+58035 condition 










Figure 2-13.  ARV1 knockdown in murine macrophages induces PERK-Mediated UPR 
induction.  (A) ATF4 and (B) CHOP mRNA expression in macrophages treated with control 
(CON) or ARV1 ASO with or without the ACAT inhibitor, 58035.  Asterisks denote statistically 
significant (*p<0.05 and **p<0.005) differences of the mean fold induction (ΔΔCt) ± s.e. by 
unpaired t-test; n=6.  (C) CHOP protein levels in macrophages treated with control (CON) or 
ARV1 ASO with or without 58035.  CHOP expression was calculated by densitometry and 
normalized to a non-specific loading control.  (D) CHOP mRNA expression after treatment with 
control (CON) or ARV1 ASO for 48 hours with increasing concentrations of AcLDL (0 -100 µg/ml) 
and 58035 for 5 hours; n=5.  Asterisk denotes statistically significant (*p<0.05) difference of the 





Figure 2-14. ARV1 knockdown in murine macrophages induces apoptosis.  Annexin V and 
PI staining of macrophages treated with (A) AcLDL+58035 (24 hours) or (B) control or ARV1 ASO 
(24 hours) with or without 58035 for 18 hours.  (C) The percentage of total cells stained with 
annexin V and PI (mean ± s.e., 4 fields of cells; at least 100 cells/field).  Asterisks denote 
statistically significant differences (*p<0.05 and **p<0.005) by unpaired t-test. 
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CHAPTER 3: DECREASED EXPRESSION OF ARV1 RESULTS IN CHOLESTEROL 









This body of work was completed in collaboration with Daniel Radar’s group at the 
University of Pennsylvania and is published in the Journal of Biological Chemistry [201].  The 
data illustrated here have been adapted from the original publication for presentation in this 
thesis.  Contributions from co-authors are described.  Mark Graham and Rosann Crooke 
designed and synthesized antisense oligonucleotides.  Fumin Tong and Jeffery Billheimer 
performed the experiments described in Table 3-1 and Figures 3-3, 3-5, 3-9, 3-10 and 3-11.  Ying 
Liu performed the experiments described in Figure 3-1A and 3-1C.  Caryn Shechtman performed 
the experiments described in Figure 3-1(B,D-F), 3-2, 3-4, 3-6, 3-7, 3-8 and 3-12.  Stephen Sturley 
and Daniel Radar wrote the original manuscript.  Modifications to the original manuscript include 
additional introductory topics, methods, data and discussion points based on the work contributed 
by Caryn Shechtman that was not included in the published manuscript.  The model presented in 






Endoplasmic reticulum (ER) membrane cholesterol is maintained at an optimal 
concentration of approximately 5 mol % by the net impact of sterol synthesis, modification and 
export.  Arv1p was first identified in the yeast Saccharomyces cerevisiae as a key component of 
this homeostasis due to its probable role in intracellular sterol transport.  Mammalian ARV1, 
which can fully complement the yeast lesion, encodes a ubiquitously expressed, resident ER 
protein.  Repeated dosing of specific antisense oligonucleotides (ASOs) to ARV1 in mice 
produced a marked reduction of ARV1 transcripts in liver, adipose and, to a lesser extent, 
intestine.  This resulted in a transient activation of the hepatic farnesoid X receptor (FXR) 
regulatory pathway, elevated serum bile acids and hypercholesterolemia but had no effect on 
FXR targets in the intestine.  Prolonged ARV1 deficiency caused a reduced expression of the 
hepatic bile acid import pump NTCP and increased expression of the cholesterol export pump 
ABCG8.  Unlike yeast and macrophages, decreased ARV1 expression in the murine liver did not 
induce the unfolded protein response.  Knockdown of ARV1 in murine liver and HepG2 cells was 
associated with accumulation of cholesterol in the ER at the expense of the plasma membrane 
and suppression of sterol regulatory element binding proteins and their targets.   These studies 
indicate a critical role of mammalian ARV1 in sterol movement from the ER and in the ensuing 






The endoplasmic reticulum (ER) is the pivotal organelle with regard to cholesterol 
homeostasis.  It is here that cholesterol is synthesized via the mevalonate pathway, sensed by 
the sterol regulatory element binding protein (SREBP) cleavage activating protein system, and 
neutralized by esterification [27,247,248].  In certain cell types, ER cholesterol is secreted in 
lipoprotein particles or hydroxylated to form bile acids.  Consequently, sterol levels in the ER of all 
eukaryotic cells are strikingly low relative to the plasma membrane (PM) [249].  Movement of 
sterol between these organelles is rapid; the majority of endogenously synthesized cholesterol is 
transported from the ER to the PM within 10-20 minutes by an energy dependent process [250].  
Vesicular and non-vesicular cholesterol transport pathways have been described [50,205], 
however the molecular components of these events are surprisingly obscure.  The net impact of 
these processes is striking; any variation around the threshold concentration of approximately 5 
mol % results in activation or repression of key regulators of lipid homeostasis, including the 
master regulators, SREBP1 and 2 [16]. 
Bile formation is a critical component of dietary lipid absorption and cholesterol 
catabolism.  Due to their amphipathic nature, bile acids form mixed micelles in the gut, thereby 
solubilizing hydrophobic lipids and fat-soluble vitamins.  The biosynthesis and recycling of bile 
acids consists of a complex network of enzymes and transporters connected through 
enterohepatic circulation.  De novo bile acid biosynthesis is a hepatocyte-specific cascade of 17 
reactions that begins with the conversion of cholesterol to 7α-hydroxycholesterol.  This is the 
rate-limiting step in bile acid biosynthesis and is catalyzed by the microsomal cytochrome P-450, 
cholesterol 7α-hydroxylase (CYP7α1) [251].  Bile acid homeostasis is transcriptionally regulated 
by members of the nuclear hormone receptor superfamily, farnesoid X receptor (FXR) and liver X 
receptor (LXR).  FXR activation serves to restore bile acid homeostasis in the hepatocyte by 
decreasing uptake of bile acids and down-regulating biosynthesis.  In the enterocyte, FXR 
activation promotes intestinal bile acid transport [252].  Bile acids are the ligand for FXR, which 
indirectly regulates gene expression by repression via small heterodimer partner 1 (SHP) [253]; 
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thus, bile acids negatively regulate themselves.  In contrast, oxysterols-mediated LXR activation 
regulates expression of the ATP-binding cassette transporters G5/G8 (ABCG5, ABCG8) [254], 
which  function in cholesterol excretion from the hepatocyte into the bile [255]. 
 In the yeast Saccharomyces cerevisiae, ARV1 encodes a key component of sterol 
transport from the endoplasmic reticulum to the plasma membrane and was identified by 
complementation of yeast mutations that confer viability dependence upon sterol esterification 
[194].  This concept of synthetic lethality was based on the hypothesis that loss of one 
homeostatic pathway (e.g. sterol esterification) might be tolerated, however removal of multiple 
“detoxifying” events would be lethal.  Yeast with mutations in ARV1 have striking phenotypes, 
including an elevated ratio of subcellular sterols relative to the PM and abnormal phospholipid, 
sphingolipid and glycosylphosphatidylinositol metabolism [194,256,257].  The yeast ARV1 gene 
predicts a 321-residue protein with several transmembrane domains.  An ARV1 ortholog is 
present in every eukaryotic genome that has been sequenced.  Human ARV1 encodes a 271 
amino acid protein, the expression of which complements all known phenotypes associated with 
mutations in the yeast gene [194,256]. 
 Antisense oligonucleotides (ASOs) are short (13-25 nucleotide), single-stranded DNA 
molecules that completely hybridize to a target RNA [258].  ASOs are effective tools for disruption 
of gene expression in vitro and in vivo.  Recent advances in backbone modifications of ASOs 
(DNA and RNA), including 2’-O-(2-methoxy)-ethyl conjugation, have improved the specificity and 
stability of ASOs, resulting in increased knockdown efficiency [259].  To address the role of 
mammalian ARV1 in lipid homeostasis, we used antisense oligonucleotides (ASOs) to knock 
down the expression of the murine ARV1 gene in a subset of tissues.  We demonstrate a striking 
impact of loss of ARV1 on cholesterol and bile acid homeostasis, consistent with impaired 







MATERIALS AND METHODS 
 
Animal Procedures and Knockdown of ARV1 in Mice.  Weight-matched, 8- to 12-week 
C57BL/6 male mice were purchased from The Jackson Laboratory (Bar Harbor).  All mice were 
housed in specific pathogen-free animal facility in polycarbonate cages (up to 4 animals per cage) 
in a room with a daylight cycle from 6 am to 6 pm, temperature of 22ºC±1ºC, and humidity of 30-
50%.  For all experiments, animals were fed with a rodent chow diet prepared by Research Diets, 
Inc.  Mouse ARV1 ASOs were designed by ISIS Pharmaceuticals.  ASOs were prepared in 0.9% 
saline (200 µl) and intraperitoneally injected into mice twice a week for one or two weeks or as a 
single dose.  The ARV1 ASO sequences used in this study were CCTTCTCTTTTGAGGTAGCT 
and GCACAGTCACTGCTCACATC. 
Body weight and food intake were measured once every week.  After fasting the animals 
for 4 hours, blood was drawn from the retro-orbital sinus vein.  Plasma was obtained from 
heparinized blood and frozen at -20ºC for future analysis.  Samples for real-time PCR were cut 
and immersed into RNA later (Ambion) overnight and stored at -80ºC.  The left lobe and caudate 
lobes of mouse livers were snap frozen in liquid nitrogen and stored at -80ºC prior to the 
measurement of tissue lipids.  The University of Pennsylvania Institutional Animal Care and 
Usage Committee approved the experiments, and all procedures were performed as 
recommended by the NIH Guide for the CARE and USE of Laboratory Animals and the 
Laboratory Animal Welfare Act.   
 
Cell Culture and Cell Transfection.  Human HepG2 cells were grown in 35 mm culture dishes 
seeded at 6×105 cells per well in Eagle’s Minimum Essential Medium (ATCC), supplemented with 
10% fetal bovine serum, 100 µg/ml penicillin, and 100 µg/ml streptomycin.  Lipofectin transfection 
reagents, OptiMEM reduced serum medium, and all cell culture media were purchased from 
Invitrogen.  Cells were transfected by lipid-mediated Lipofectin transfection.  Cells were washed 
once with OptiMEM, then transfection mixes including 5 µM control ASO or human ARV1 ASO 
were incubated with the cells for 6 hours.  MEM and fetal bovine serum were added back to the 
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cell culture to make a 10% final serum concentration and incubated overnight.  After the 
treatment, the transfection mix was removed and the culture medium was replaced with complete 
growth medium and incubated an additional 16-20 hours.  To assess SREBP2 processing, cells 
were incubated in 10% (v/v) newborn calf lipoprotein-deficient serum, 50 µM compactin, 50 µM 
sodium mevalonate for 16 hours. 
 
Plasma Lipid and Lipoprotein Analysis.  Plasma total, free, and high density lipoprotein 
cholesterol; phospholipids, free fatty acids, and triglycerides (TG) and ALT levels were measured 
enzymatically on a Cobas Fara II (Roche Diagnostic Systems Inc.) using reagents from 
Diagnostic Chemicals Limited.  Pooled plasma samples (120 µl) from 4-6 mice were subjected to 
Fast Protein Liquid Chromatography (FPLC) gel filtration (Pharmacia LKB Biotechnology) on two 
superose 6 columns at a flow rate of 0.5 ml/min (1 run/sample), and fractions of 500 µl each were 
collected [260].  Individual fractions were assayed for cholesterol concentration using an 
enzymatic assay kit (Wako Chemicals USA, Inc.). 
 
Hepatic Cholesterol and Triglyceride Analysis.  PBS perfused livers were homogenized in 
PBS and incubated at 37ºC in the presence of deoxycholate for 5 min.  Cholesterol and 
triglycerides were measured enzymatically using Infinity triglyceride and Infinity Cholesterol 
reagents (Thermo Electron) [261].   
 
Measurement of Hepatic Triglyceride Secretion Rates in Mice.  The hepatic cholesterol and 
TG secretion rates were measured as previously described [262].  In brief, mice were 
intraperitoneally injected with 400 µl P-407 (1 mg/g) solution in sterile PBS.  Blood was collected 
via retro-orbital plexus prior to injection (0 h) and at 1 h, 2 h and 4 h after injection.  TG was 
measured enzymatically as described above.  The TG secretion rates were calculated as the 




Plasma, Hepatic and Biliary Bile Acids Measurement.  Bile acids in plasma and Bile (diluted 
1:1000) were measured using a Total Bile Acids kit (Wako Chemicals USA, Inc.).  For the liver 
bile acid measurement, total bile acids were extracted by 75% ethanol at 50ºC for 2 hours.  After 
clearance by centrifugation, the supernatant was transferred to a new tube and 20 µl of 
supernatant was used for measurement.  Bile salt compositions of the bile salt pool were 
determined by HPLC [263].  Briefly, mice were anesthetized, and ethanolic extracts of liver, 
gallbladder, common bile duct, and small intestine were prepared.  Prior to extraction, 
glycocholate was added as an internal standard. The bile salt hydrophobic index (HI), which 
provides a measure of the overall hydrophobicity of mixed bile salt solutions, was determined 
according to Heuman [264]. 
 
Subcellular Localization of ARV1.  CHO K1 cells were plated on glass cover slips in 6-well 
plates and transfected with either phARV1-EGFP (a PCR-generated fusion of GFP to the 5’ end 
of human ARV1 in pEGFP-N1 (Clontech, Inc.) or pEGFP-N1, using FuGene 6 reagent.  24 hours 
after transfection, cells were incubated with 200nM ER-Tracker at 37°C for 0.5 h, followed by 
incubation in growth medium for an additional 30 minutes.  Cells were fixed in 3.3% 
paraformaldehyde before mounting on slides.  Laser confocal images were captured using a 
Zeiss Laser Scanning Microscope LSM 510.  For co-localization of hARV1-EGFP and ER-
Tracker, samples were viewed using BP 500-550 IR (excitation wavelength at 480 nm, argon 
laser), and BP435-485 IR (excitation wavelength at 780 nm, multiphoton, Mira 900-F 
femtosecond-pulsed titanium-sapphire laser) filter sets, respectively.   
 
Subcellular Fractionation and Analysis.  The method for fractionation of cells and purification 
of nuclei is described by Sakai et al [265].  Briefly, the cells were washed with PBS and 1 µl/ml 
ALLN (N-acetyl-leucinal-leucinal-norleucinal) and swelled in hypotonic buffer A (10 mM HEPES at 
pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 25 µg/ml ALLN and a mixture of 
protease inhibitor) for 30 min at 4ºC, passed through a 22.5 gauge needle 30 times, and 
centrifuged at 1000 X g at 4 ºC.  The 1000 X g pellet was resuspended in 0.1 ml of buffer B (10 
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mM HEPES at pH 7.5, 0.42 M NaCl, 2.5% (v/v) glycerol, 1.5 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA, 25 µg/ml ALLN and protease inhibitors) and clarified by centrifugation (“nuclear extract”).  
The supernatant from the original 1000 X g spin was centrifuged at 10,000 X g for 30 min at 4ºC 
and pellet was dissolved in 0.1 ml of 10 mM Tris-HCl, pH 6.8, 100 mM NaCl, 1% (v/v) SDS, 1 mM 
EDTA, and 1 mM EGT (“membrane fraction”).  Nuclear and membrane fractions were resolved in 
10% NuPAGE gels (Invitrogen) and transferred to nitrocellulose membranes.  For SREBP-2 
detection, a rabbit anti-SREBP-2 polyclonal antibody  (Cayman 10007663).  The blots were also 
probed using a rabbit polyclonal antibody against HMG-CoA reductase (a gift of Dr. Ness) [266].  
A polyclonal anti-β-actin antibody (clone I-19) (Santa Cruz Biotechnology) was used to normalize 
sample loading.   
 Microsomal and plasma membrane preparations were prepared by subcellular 
fractionation using a sucrose gradient.  Tissues were homogenized on ice in homogenization 
buffer (10mM Tris, 0.25 sucrose, protease inhibitor cocktail tablets (Roche), pH 7.6) for 15 
strokes using a tight-fitting dounce homogenizer and centrifuged at 2000 rpm for 10 minutes at 
4°C to pellet nuclei and debris.  Supernatant was centrifuged at 10,000 x g for 20 minutes at 4°C 
to pellet microsomes.  The remaining supernatant containing plasma membranes was centrifuged 
at 24,000 rpm for 1 hour at 4°C to pellet membranes.  Pellets were resuspended in buffer (10mM 
HEPES pH 7.5, 0.25M sucrose) using a 23 gauge needle to ensure resuspension and stored at -
80°C.  20µg or 50µg of prep was boiled for 10 minutes and run on a SDS-PAGE gel (Biorad).  
Protein was electrotransferred onto a 0.45 µm nitrocellulose membrane (Biorad) and incubated 
with the NTCP (generously provided by Meenakshisundaram Ananthanarayanan), ABCG8 
(generously provided by Helen Hobbs) or Actin (Sigma) primary antibody overnight.  Protein 
bands were detected with HRP-conjugated secondary antibodies (Biorad) and SuperSignal West 
Pico (Pierce).  
 
Measurement of Endogenous Cholesterol and Cholesteryl Ester Synthesis.  To measure 
endogenous cholesterol synthesis, HepG2 cells were labeled with [3H]acetate.  After the 
transfection, cells were incubated with 1 ml MEM containing 5% fetal bovine serum and 25 µCi 
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[3H] acetate for 2 and 4 hours.  At the end of incubation, the cells were washed twice with ice cold 
PBS.  Lipids were extracted from the cells by adding 2 ml hexane:isopropanol (3:2) cholesterol 
and cholesteryl ester separated on TLC plates and quantified [267]. 
 
Filipin Staining.  Cells were grown on chamber slides and transfected with ASOs as described 
above.  Cells were fixed with 3% paraformaldehyde in PBS for 20 min, washed three times with 
PBS, and stained with filipin as described [268].  Coverslips were mounted with Prolong Antifade 
reagent (Molecular Probes), and filipin fluorescence was viewed and photographed using a Zeiss 
Axiovert inverted confocal microscope. 
 
RNA Isolation and Gene Expression Analysis.  Total RNA was isolated from indicated tissues 
using EZ1 RNA Mini or RNAeasy kit (Qiagen) according to the manufacturers’ instructions.  0.1 to 
1.0 µg of total RNA was reverse transcribed using iScript (BioRad) or SuperScript First-Strand 
(Invitrogen), according to the manufacturers instructions.  Primers were designed using Primer 
Express 2.0 software (Applied Biosystem) (Appendix 2).  For quantitative real-time PCR analysis, 
the reactions were performed using MicroAmp Optical 96-well plates with optical adhesive covers 
(Applied Biosystem, Foster City, CA).  The primers were added in appropriate concentrations to a 
2X Sybr Green master mix containing SYBR Green dye, AmpliTaq Gold DNA polymerase, and 
PCR buffer.  In certain cases, real-time PCR reactions were performed with the MyIQ Single-
Color Real Time PCR Detection System (Biorad), SYBR Green 2X Supermix (Biorad) and 
primers.  Expression levels were calculated using ΔΔCt analysis relative to GAPDH, as previously 
described [225].  To determine the mRNA expression of unknown samples, a relative 
quantification of the mRNA expression was performed using data from pooled hepatic cDNA 
samples, which were serially diluted.  Relative hepatic mRNA expression in the ARV1 ASO 
injected mice are reported as a percentage change from mRNA levels of the wild type mice.  
Human ARV1 specific primers and control GAPDH primers were used in 25-cycle standard PCR 
reactions with human multiple tissue cDNA (panel I and II from Clontech, Inc.) as templates.  15 
µl of each reaction were resolved on 2% agarose gels.  
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 For the XBP1 splicing assay 100 µg of RNA was reverse transcribed and PCR amplified 
(see Appendix 2 for primer sequence).  The XBP1 fragment was purified (Qiagen), resuspended 
in 35 µl of sterile water and digested with PstI (NEB) according to the manufacturer’s instructions.  
Splicing was assessed by running digested fragments on a 1.5% agarose gel. 
 
In Vitro Cholesterol Esterification. Cholesterol esterification under conditions where cholesterol 
is rate limiting is described by Billheimer and Tavani.  Briefly, livers were perfused in situ and 
homogenized in 0.1 M TRIS (pH 7.4) containing protease inhibitors.  Microsomes were isolated 
immediately by differential centrifugation, resuspended in TRIS buffer without protease inhibitors 
and frozen until use.  The assay contained 100 µg microsomal protein, 1 mg fatty acid free 
BSA, 1 mM glutathione and 40 µM [14C]oleoyl CoA (10,000 dpm/nmol).  The assay was initiated 
by the addition of oleoyl CoA and stopped after 20 min with chlorofom/methanol (2/1).  Lipids 
were extracted and cholesteryl ester separated by TLC and quantified. 
 
Uptake and Esterification of Exogenous Cholesterol.  HepG2 cells were transfected 
with ARV1 or control ASO as described above and incubated in MEM containing 5% LPDS and 
[3H]cholesterol (0.5 µCi).  Uptake by the cells and incorporation into esterified cholesterol was 





Expression and manipulation of ARV1.  The ARV1 protein is structurally and functionally 
conserved throughout evolution with representatives in every eukaryotic genome currently 
available [194].  In accordance with a very basic physiological function, the gene encoding this 
protein is expressed in most human tissues (Figure 3-1A).  Similarly in mice, ARV1 transcripts 
were detected in all tissues examined, with maximal expression in the lung (Figure 3-1B).  As 
might be anticipated for a protein with a key role in ER lipid homeostasis, an Arv1-GFP fusion 
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localized to the ER of transfected Chinese Hamster ovary (Figure 3-1C) and yeast cells [256].  To 
assess the role of ARV1 in mammalian physiology, C57BL/6 wild type mice were injected with a 
non-targeting control ASO and two different 2’-O-(2-methoxy)-ethyl modified ARV1 ASO’s 
corresponding to different regions of the ARV1 gene.  Quantitative real-time PCR analysis of total 
liver RNA from animals treated for two weeks indicated that the targeting ASO’s reduced hepatic 
ARV1 mRNA levels to 20 and 50% of control, respectively (data not shown).  Importantly, both 
ASOs produced qualitatively similar phenotypes with a severity that correlated with repression of 
the ARV1 gene that was absent from the non-targeting control.  Consequently, the more potent 
ARV1-ASO (045) was used for the remainder of the studies presented here.   
 Animals were i.p. injected twice weekly with the ARV1 or control ASO at 50 mg/kg body 
weight over 2 weeks and animals were sacrificed for analysis at 7 or 14 days.  Hepatic ARV1 
mRNA levels were decreased to approximately 20% of control ASO mice at both time points 
(Table 3-1, Figure 3-1D).  Similar decreases were observed in terms of repression of ARV1 in 
adipose and to a much lesser extent, intestine of the same animals (Figure 3-1E, F).  By contrast, 
we did not detect knockdown of ARV1 in the spleen, lung, heart or kidney of treated animals 
(Figure 3-2).   
Plasma ALT levels were similar in control ASO- and ARV1 ASO-treated mice at one 
week but elevated at 2 weeks in the ARV1 ASO-treated mice (Table 3-1).  Liver triglycerides were 
decreased and liver total cholesterol was unchanged in ARV1 knockdown mice after 2 weeks 
(Table 3-1).  Plasma cholesterol and phospholipid (Table 3-1) concentrations in ARV1 ASO-
treated mice were significantly elevated at one week and further increased after two weeks of 
administration with the ARV1 ASO.  Analysis of plasma lipoprotein distribution by FPLC at 1 and 
2 weeks (Figure 3-3A,B) showed that the increase was primarily in low density lipoproteins 
probably due to a decrease in LDL receptor (LDLR) (Figure 3-3D).  A decrease in HDL 
cholesterol was also observed at one week, which was further decreased at two weeks.   
To further assess whether the lipid changes were due to decreased clearance versus 
elevated synthesis we investigated the ASO-treated animals following i.p. injections with P-407 (1 
mg/g).  Blood was collected via retro-orbital plexus prior to injection (0 h) and at 1 h, 2 h and 4 h 
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after injection.  TG was measured enzymatically and secretion rates (mg/dL/h) were calculated as 
the slope of the plasma concentration vs. time after linear regression (Figure 3-3C).  There was 
no change in VLDL-TG production with knockdown of ARV1 at one week.   By contrast, we 
observed a ~50% reduction in LDL receptor mRNA abundance in the liver (Figure 3-3D), further 
suggesting that the increased LDL was due to delayed catabolism rather than elevated hepatic 
VLDL production. 
 
Decreased expression of ARV1 in vivo does not induce the unfolded protein response.  
Yeast and macrophages induce the unfolded protein response (UPR) in order to compensate for 
the loss of ARV1 [206].   We hypothesized that hepatic ARV1 deficiency may induce the UPR in 
vivo.  We probed for activation of IRE1- and PERK-mediated UPR in 2-week ASO-treated livers.  
ARV1 ASO-treated livers did not exhibit increased XBP1 splicing relative to controls (Figure 3-
4A).  This is consistent with findings in a macrophage model of ARV1-knockdown, as only PERK-
mediated UPR is induced upon decreased ARV1 expression in these cells [206].  We then 
probed for PERK-mediated UPR induction by quantitative PCR to assess ATF4 and CHOP 
expression.  We did not see a significant increase in ATF4 or CHOP expression in comparison to 
controls (Figure 3-4B,C).  These data indicate that reduction in hepatic ARV1 expression does 
not induce the UPR in vivo. 
 
Knockdown of ARV1 disrupts bile acid metabolism and results in FXR activation.  
Cholesterol homeostasis in the liver is a delicate balance between various input and output 
mechanisms.  Cholesterol input is regulated by de novo biosynthesis and receptor mediated 
endocytosis (LDL receptor and SR-BI), while cholesterol output is regulated by packaging steryl 
esters into lipoprotein particles for circulation and the formation and excretion of bile acids [251].  
Synthesis of bile salts in the heptaocytes constitutes the major pathway of cholesterol catabolism 
in the liver.   We hypothesized that the lack of UPR induction we see in ASO-treated livers 
reflects this phenomenon.  As such, we examined 1-, 2- and 4-week ASO-treated tissues for 
modulations in bile acid homeostasis and lipid metabolism.  A two-week administration of the 
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ARV1 ASO was associated with a 2-4 fold increase in plasma bile acids (Figure 3-5A) and 
hepatic bile acids (Figure 3-5B), without elevations in biliary bile acids (Figure 3-5C).  The bile 
acid pool was not significantly different between the treated (0.36 +/- 0.05 µmol/g) and the control 
group (0.43 +/- 0.10 µmol/g).  However, in ARV1-ASO treated animals, there was an increase in 
the hydrophobic index (HI) of the total biliary bile acid pool (-0.50 +/- 0.04 vs. -0.40 +/- 0.01 
µmol/g, p=0.001), primarily due to a significant decrease in tauromuricholic acid (66.1 to 53.4 
mol%; p<0.001) and corresponding increase in the more hydrophobic taurocholic acid (26.6 to 
40.9 mol%; p<0.001).  In multiple experiments, there was a significant increase in the 
concentration of cholesterol in gall bladder bile (2.1 +/- 0.32 vs 1.38 +/- 0.36 µg/µl, p=0.01) in the 
absence of changes in biliary PL concentrations in ARV1-ASO animals relative to controls.   
 Bile acids are the endogenous ligand for the nuclear receptor FXR.  In this manner, bile 
acids self-regulate their own biosynthesis, hepatic excretion and enterohepatic circulation, all of 
which are regulated by FXR activation [270].  We examined the expression of FXR targets in the 
liver, including CYP7α1, CYP8b1 and CYP27α1 by quantitative PCR, all of which function in de 
novo bile acid biosynthesis, in 1- and 2-week ASO-treated mice.  Surprisingly, we did not observe 
expression changes in any of the genes examined (Figure 3-6), suggesting that ARV1 
knockdown does not have an impact on downstream mediators of bile acid biosynthesis at these 
time points.  FXR activation also regulates intestinal bile acid metabolism by transcellular 
trafficking of bile salts, mediated by IBABP, and their subsequent secretion into portal circulation 
by OSTα and OSTβ [251,271].  We examined the expression of intestinal bile acid transporters 
IBABP, OSTα and OSTβ after 1- and 2-week ASO treatment.  We found no change in expression 
of IBABP, OSTα or OSTβ after 1-week ASO treatment (Figure 3-7).  This finding was anticipated, 
as we saw no change in intestinal expression of ARV1 at this time point (Figure 3-1F).  However, 
we also saw no change in gene expression after a 2-week ASO treatment, suggesting that 
expression of IBABP, OSTα and OSTβ are not impacted by decreased ARV1 expression in the 
intestine. 
The increased levels of bile acids in both the liver and plasma suggest that ARV1 
deficiency impacts bile acid homeostasis.  However, because we did not see significant changes 
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in FXR targets after 2-week ASO treatment, we examined the flux of bile salts and sterols to and 
from the liver, respectively, in 4-week ASO-treated mice.  Sinusoidal Na+-dependent taurocholate 
cotransport peptide (NTCP) is the major transporter responsible for bile salt uptake on the 
basolateral side of the hepatocyte membrane [272].  ARV1 knockdown mice exhibited decreased 
NTCP expression (Figure 3-8A).  Cholesterol secretion into the bile caniculus is carried out by the 
heterodimeric transporters ABCG5 and ABCG8 [254].  Thus, we examined ABCG8 expression in 
4-week ARV1 ASO-treated mice.  ARV1 knockdown mice exhibited increased expression of 
ABCG8 (Figure 3-8B), suggesting that cholesterol secretion into the bile is one route of sterol 
detoxification in these mice.  
We did not see activation of FXR-targets in ARV1 ASO treated mice at 1- and 2-weeks in 
the twice-weekly dosing experiments.  Therefore, we turned to experiments involving a single 
injection of the ARV1 ASO (Figure 3-9), in order to assess the acute impact of ARV1 deficiency.  
ARV1 gene expression was decreased to 18% of control ASO-treated mice on day 2 and was 
maintained at 32% of control by day 7 (Figure 3-9A).  ALT levels were not elevated after a single 
injection, indicating a lack of generalized hepatic injury in the ARV1 ASO treated animals over 
this time course (data not shown).  On day 2 after ARV1 ASO injection, plasma bile acid 
concentrations were already substantially elevated relative to the control treatment (33 µM 
compared with 8 µM, Figure 3-9B), with a reduction to baseline levels by day 7.  The 
concentrations of hepatic and biliary bile acids did not differ between groups (data not shown).   
To gain further insight into the mechanisms of the disruptions in bile acid and lipid 
metabolism caused by knockdown of ARV1, hepatic gene expression was analyzed at several 
time points within one week after a single injection of the ARV1 ASO.  CYP7α1, encoding the first 
and rate-limiting enzyme of the neutral bile acid synthetic pathway, was significantly decreased, 
two days after a single dose of ARV1 ASO (Figure 3-9C).  Conversely, the atypical nuclear 
receptor small heterodimer partner (SHP or NR0B2), a major target of FXR was significantly 
increased in ARV1 ASO-treated mice by two days after treatment (Figure 3-9D), and may explain 
the decrease in the mRNA levels of CYP7α1. Interestingly, this activation was transient; despite 
the prolonged knockdown of ARV1 over a two-week period, targets of the FXR transcriptional 
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regulatory pathway were not elevated at the two-week time point (Figures 3-6 and 3-7). By 
contrast, the mRNA level of NTCP was decreased and expression of the canalicular bile salt 
transporter (ABCB11/BSEP) was significantly increased after a two-week treatment of ARV1 ASO 
(Figure 3-9E,F).   
 
Knockdown of ARV1 results in ER cholesterol accumulation and dysregulation of lipid 
homeostasis in murine liver and human HepG2 cells.  We hypothesized that the knockdown 
of ARV1 in liver impaired transport of cholesterol from the ER to other cellular compartments such 
as the plasma membrane, resulting in cholesterol accumulation in the ER and down-regulation of 
the SREBP pathway.  Consequently, the FXR pathway may have become activated due to 
increases in bile acid synthesis in response to accumulation of unesterified cholesterol in the ER.  
To test this hypothesis at the cellular level, we treated human hepatoma (HepG2) cells with 5 µM 
human ARV1 ASO for 48 hours, thereby reducing mRNA levels of ARV1 to 12% of control cells 
(Figure 3-10A).  Consistent with ER cholesterol accumulation, mRNA levels of SREBP1c and 
HMG-CoA reductase were significantly decreased relative to the control ASO-treated cells 
(Figure 3-10B,C).  Moreover, consistent with transient FXR activation at 2 days post-injection 
observed in the animal studies, CYP7α1 mRNA was also significantly reduced in the HepG2 cells 
(Figure 3-10D).   
The prior observations may reflect regulatory events downstream of cholesterol 
accumulation at the ER in ARV1 knockdown cells.  To directly assess this we investigated the 
sterol status of HepG2 cells after ASO treatment, by staining with filipin which binds unesterified 
cholesterol, followed by confocal fluorescent microscopy (Figure 3-11A).  Control ASO-treated 
cells showed distinct plasma membrane fluorescence, while knockdown of ARV1 in HepG2 cells 
produced an intense intracellular fluorescence accumulation consistent with altered cholesterol 
trafficking in cells due to decreased ARV1 expression.  In order to corroborate decreased 
movement of cholesterol out of the ER in the whole animal, we took advantage of the fact that 
cholesterol availability is rate limiting in formation of CE.  Consequently, the ER substrate pool of 
cholesterol can be measured by in vitro microsomal ACAT assays performed in the absence of 
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exogenous sterol [273,274].  Mice were treated for two weeks with or without ARV1 ASO, 
sacrificed, livers perfused, microsomes isolated and ACAT activity determined.  Hepatic ACAT 
activity was increased almost 2-fold (123 ± 17 pmol/min/mg vs 66 ± 6 pmol/min/mg; p=0.01) in 
mice receiving the ARV1 ASO.  This is consistent with increased cholesterol in the ER.   The 
basal esterification of plasma membrane cholesterol can also be determined [275].  Equilibration 
of HepG2 cells with radiolabeled cholesterol in lipoprotein deficient serum (LPDS) provides an 
estimate of the amount of cholesterol in the plasma membrane (PM).  HepG2 cells were treated 
with or without ARV1 ASO and then grown in media containing lipoprotein deficient serum for 24 
hours.  Tritiated cholesterol was then added in ethanol and the amount of tracer taken up by the 
cell and esterified over a 6 hour period was determined.  There was a 3.08 ± 0.27 fold increase in 
the amount of [3H] cholesterol/mg protein taken up by the ARV1 ASO treated cells.  This is 
consistent with a depletion of cholesterol at the plasma membrane.  There was a similar 2.4 ± 
0.06 fold increase in the amount of exogenous cholesterol esterified such that the percent of 
tracer esterified did not change.  This would suggest that trafficking of cholesterol from the 
plasma membrane to the ER is not affected by reduced ARV1 expression. 
  SREBPs reside in the ER and are translocated to the Golgi for proteolytic activation in 
response to sterol concentration in the ER below a critical threshold of about 5 mol% [16].  If 
knockdown of ARV1 causes cholesterol accumulation in the ER, it should inhibit the proteolytic 
processing of the SREBPs.  HepG2 cells were grown in cholesterol-depleted conditions and 
assessed for SREBP by immunoblots after cell fractionation.  The amount of the mature form of 
SREBP-2 in the nuclear fraction was markedly decreased in the ARV1 ASO-treated cells 
compared with control ASO-treated cells (Figure 3-11B), indicating the inhibition of proteolytic 
processing of SREBP-2.  HMG-CoA reductase is regulated by SREBPs and by proteasomal 
degradation in response to ER cholesterol.  The levels of membrane associated HMG-CoA 
reductase protein were markedly reduced in HepG2 cells treated with ARV1 ASO relative to 
control ASO (Figure 3-11C), consistent with increased ER cholesterol.  Accordingly we observed 
a significant 40 % reduction in the rate of endogenously synthesized cholesterol in ARV1 
knockdown cells measured by [3H]acetate incorporation at 2h and 4h time points (Figure 3-11D).  
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Even though there was a decrease in endogenously synthesized cholesterol, the percent of the 
nascent cholesterol that was esterified increased by 1.5 fold (14.5 +/- 1.8% versus 9.6 +/- 0.8%, 
p<0.01). This is in agreement with a decreased export of nascent cholesterol out of the ER 




The molecular mechanisms that maintain mammalian ER cholesterol content, particularly 
the exit of cholesterol from the ER, remain elusive.  Since ARV1 encodes a significant component 
of subcellular sterol transport in yeast, we hypothesized that it also participates in intracellular 
transport of cholesterol in mammalian cells.  ARV1, a resident ER protein, is expressed 
ubiquitously in human and murine tissues.  Targeting expression of ARV1 by i.p injection of stable 
antisense oligonucleotides led to significant and persistent tissue specific knockdown in liver and 
adipose and to a lesser extent the intestine.  Knockdown of ARV1 in these locations in mice 
resulted in elevated plasma cholesterol, mainly LDL, and a decrease in HDL.  The decrease in 
HDL cholesterol likely due to the increase in plasma bile acids (Figure 3-5A), as increased 
plasma bile acids have been shown to inhibit LCAT activity and decrease HDL cholesterol 
[276,277].  ARV1 deficiency also led to increased hepatic bile acids, accompanied by a transient 
activation of FXR (summarized in Figure 3-12), a bile acid-sensing nuclear receptor that controls 
bile acid homeostasis.  In contrast to macrophages [278], ARV1 deficiency in the liver did not 
induce the UPR, a phenomenon that may be attributed, in part, to the incorporation of excess 
cholesterol into bile acids.  In support of this hypothesis, we showed that expression of the 
cholesterol transporter ABCG8 is increased upon prolonged ARV1 deficiency.  We confirmed that 
knockdown of ARV1 in both the murine liver and in HepG2 cells resulted in intracellular 
cholesterol accumulation due to impairment of cholesterol removal from the ER, as well as 
decreases in SREBP-2 processing.  We conclude that the ARV1 encoded protein plays a pivotal 
role in cholesterol metabolism in the hepatocyte as it does in yeast, by facilitating sterol 
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movement out of the ER.  Disruption of ARV1 thereby results in an ER accumulation of 
cholesterol and consequently misregulated cholesterol and bile acid homeostasis.   
In addition to transport to the PM, ER cholesterol has several possible fates in the liver 
including secretion in VLDL, esterification, and hydroxylation to form bile acids.  In the current 
study, knockdown of ARV1 significantly perturbed bile acid metabolism resulting in a substantial 
and acute increase in plasma bile acids.  ARV1 deficiency was associated with elevated 
hydrophobic bile acids and cholesterol in bile.  Hydrophobic bile acids are better ligands for FXR 
than their hydrophilic counterparts [102,279], perhaps accounting for activation of FXR.  
Consistent with FXR’s role in protecting the hepatocyte from bile acid toxicity, we observed rapid 
but transient induction of SHP (a key FXR target gene and mediator of many of FXR’s 
transcriptional effects), transient repression of CYP7α1 (a key enzyme in endogenous bile acid 
synthesis), upregulation of ABCB11 (a bile salt export pump involved in transporting bile acids 
through the hepatocyte canalicular membrane into bile), and repression of NTCP (a bile acid 
transporter required for hepatic re-absorption of bile acids from plasma).  The effects of ARV1 
repression on FXR-regulated gene expression and plasma bile acids occurred within two days 
after a single dose of ARV1 ASO and in the absence of any markers of hepatocellular injury.  
FXR activation, which normally protects the hepatocyte from bile acid toxicity, is thus the most 
sensitive early marker of acute hepatic ARV1 depletion.  However, even though CYP7α1 is down-
regulated the synthesis of bile acids is also dependent upon the availability of cholesterol 
substrate [280,281].  Because ARV1 depletion increased the supply of substrate, it is feasible that 
continued bile acid synthesis takes place though CYP7α1 is decreased. Our data are consistent 
with a model (Figure 3-13) whereby the ARV1 protein plays a pivotal role in lipid metabolism by 
facilitating cholesterol movement out of the ER.  In the setting of reduced hepatic ARV1, elevated 
ER cholesterol suppresses SREBP processing and down-regulates LDL receptor expression, 
leading to elevated plasma LDL cholesterol levels.  The primary mechanism that results in 
aberrant bile acid metabolism is less clear.  However, accumulation of cholesterol in the ER likely 
drives bile acid biosynthesis, even while inducing the FXR pathways, by providing more substrate 
while at the same time affecting the hydrophobic index of newly synthesized bile acids.  
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Moreover, the deprivation of cholesterol at the plasma membrane due to ARV1 knockdown, along 
with the greater solubilization of PM cholesterol by the more hydrophobic bile acids, significantly 
alters the properties of this organelle.  The increase in hydrophobic bile acids may account for the 
observed increase of cholesterol in the bile.   Of note, the activity of transporters such as 
ABCB11, ABCC2 and possibly ATP8B1 [282] is reduced when canalicular membrane cholesterol 
is low.  ABCB11 is the major bile salt transporter, thus its inactivation would create a cholestatic 
situation whereby bile salts are retained in cells.  Our studies identify ARV1 as encoding an 





Table 3-1.  Physiological characteristics of C57BL/6 wild type mice treated with ARV1 or 
control ASO biweekly for either one week or two weeks.  Values are expressed as means ± 
s.e.  HDL, high-density lipoprotein; ALT, alanine aminotransferase.  Representative data of three 
separate identical experiments was performed with 4-6 male mice per group per treatment in all 
experimental groups.   aSignificant difference (P<0.05) between ARV1 ASO-treated mice and 
control ASO-treated mice.  bSignificant difference (P<0.001) between ARV1 ASO-treated mice or 




 1 Week-Treatment 2 Week-Treatment 
 Control ASO ARV1 ASO Control ASO ARV1 ASO 
Weight (g) 28.0±0.5 27.9±1.3 26.5±1.3 23.9±2.5 
Liver/body weight 4.1±0.4% 5.5±0.18%a 4.3±0.47% 6.6±0.37%a 
Plasma ALT (IU/L) 25.0±12.2 28.0±4.3 20.8±1.5 583.5±65.8b 
Plasma Cholesterol 
(mg/dL) 
75.0±1.4 121.5±22.4a 76.8±4.3 167.5±40.9b 
Plasma Phospholipids 
(mg/dL) 
170.5±2.4 246.5±37.0a 204.8±11.4 346.0±67.6a 
Plasma Triglyceride 
(mg/dL) 
47.0±5.0 63.0±18.9 41.8±7.4 23.8±7.5a 
Plasma Free Fatty Acids 
(meq/L) 
1.1±0.1 1.1±0.2 1.4±0.1 1.2±0.1 
Hepatic Triglyceride (mg/g 
liver) 
3.7±1.1 4.8±0.5 5.1±0.8 2.7±0.9a 
Hepatic Cholesterol (mg/g 
liver) 
3.5±0.7 3.1±0.4 2.5±0.2 2.4±0.3 






Figure 3-1.  ARV1 expression, localization and knockdown. (A) ARV1 is expressed prolifically 
in human tissues. PCRs were used to determine ARV1 expression levels in RNA derived from 
heart, brain, placenta, lung, liver, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small 
intestine, and colon. Lanes 1–14, respectively, were derived from multiple tissue cDNA panels I 
and II (Clontech). Reaction products were resolved by agarose gel electrophoresis and ethidium 
bromide staining. (B) ARV1 is expressed in murine tissues. RNA derived from the indicated 
murine tissues was analyzed by quantitative RT-PCR. (C) ARV1 is a resident protein of the 
endoplasmic reticulum. CHO K1 cells transfected with either phARV1-EGFP (human ARV1 fused 
at its N terminus with GFP in EGFP-N1 (Clontech)) or pEGFP-N1 were incubated with 200 nm 
ER-Tracker and visualized by confocal microscopy. (D-F) ARV1 mRNA levels in mice injected 
with control or ARV1 ASOs are shown. Results indicate statistically significant differences 
(*p<0.05,**p< 0.01) of the mean fold induction (ΔΔCt) ± s.e. in comparison to control ASO 

















Figure 3-2.  ASO treatment does not alter ARV1 expression in the spleen, lung, heart and 
kidney.  Real-time PCR of RNA derived from the (A) spleen, (B) lung, (C) heart and (D) kidney 
after 1- and 2-week treatment with the control or ARV1 ASO.  Results indicate no statistically 
significant differences (p<0.05) of the mean fold induction (ΔΔCt) ± s.e. in comparison to control 







Figure 3-3.  Knockdown of hepatic ARV1 affects plasma lipid homeostasis. FPLC analysis of 
the plasma lipoproteins of pooled plasma samples derived from four to six mice injected with 
ASOs biweekly for 1 week (A) or 2 weeks (B). (C) Measurement of TG secretion rates in mice 
treated with control ASO or ARV1 ASO. Wild-type mice treated with control ASO or ARV1 ASO 
for a week and mice were injected intraperitoneally with 400 µl of P-407 (1 mg/g) solution at zero 
time point. Rate of TG production was measured over varying time periods in P-407-treated mice. 
Two to three separate identical experiments were performed with four to six mice/group per 
treatment in all experimental groups. Values are expressed as means ± s.e. of the mice in the 
representative experiment. Asterisks denote statistically significant differences from control for 
ASO-treated animals with p<0.05 (*) and p < 0.001 (**) by unpaired t-test. (D) Hepatic LDLR 



























































Figure 3-4. Knockdown of ARV1 expression in the liver does not induce the UPR.  (A) XBP1 
splicing assay in livers treated with the control or ARV1 ASO for 2 weeks.  RNA was amplified by 
RT-PCR followed by digestion with PstI.  Undigested (Un) and PstI-digested (Pd) cDNAs are 
indicated.  Tunicamycin condition is the positive control. ATF4 (B) and CHOP (C) mRNA 
expression in livers treated with the control or ARV1 ASO for 2 weeks.  No statistically significant 
differences (p<0.05) of the mean fold induction (ΔΔCt) ± s.e. were observed; n=5.   
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Figure 3-5.  Bile acid quantification in ASO-treated mice.  Values are expressed as means ± 
s.e. of the mice in the representative experiment. Values shown are for plasma (A), liver (B), and 
bile (C). Asterisks denote a statistical significance difference compared to control; p<0.05 by 
unpaired t-test. Representative data of at least two separate identical experiments performed with 








































Figure 3-6.  1- and 2-week knockdown of ARV1 expression in the liver does not alter genes 
involved in bile acid synthesis.  Expression of (A) CYP7α1, (B) CYP8b1 and (C) CYP27α1 
mRNA derived from the liver after 1- and 2-week treatment with the control or ARV1 ASO.  
Results indicate no statistically significant differences (p<0.05) of the mean fold induction (ΔΔCt) 







































Figure 3-7.  ARV1 deficiency does not alter the expression of intestinal bile acid 
transporters.  Expression of (A) IBABP, (B) OSTα and (C) OSTβ mRNA derived from the 
intestine after 1- and 2-week treatment with the control or ARV1 ASO.  Results indicate no 
statistically significant differences (p<0.05) of the mean fold induction (ΔΔCt) ± s.e. in comparison 
























Figure 3-8.  Prolonged ARV1 deficiency alters expression of hepatic bile acid and 
cholesterol transporters.  (A) Western blots of NTCP (runs as a doublet as shown in [283]) and 
β-actin expression in total microsomal liver protein (20 µg) treated with the control or ARV1 ASO 
for 4 weeks. (B) Western blots of ABCG8 and β-actin expression in plasma membrane protein 






Figure 3-9.  Knockdown of hepatic ARV1 induces changes in plasma bile acids and 
activation of FXR regulatory pathways. Wild-type mice were injected with a single dose of 
either control ASO or ARV1 ASO and subgroups of animals were killed at day 2, day 4, and day 7 
post-injection. Liver total RNA was isolated, and real-time RT-PCR was performed to assess 
hepatic gene expression. (A) Hepatic expression of ARV1 gene, (B) plasma bile acids 
concentrations and selected genes involved in FXR regulatory pathways including CYP7α1 (C) 
and SHP (D). In a separate experiment, mice were injected with either control ASO or ARV1 ASO 
over the time course of 2 weeks and real-time RT-PCR was performed to assess the hepatic 
mRNA levels of genes involved in bile acid metabolism including NTCP (E) and ABCB11 (F). 
Asterisks indicate significant differences in ARV1 ASO-treated groups compared with that of the 






Figure 3-10.  Regulation of genes involved in lipid and bile acid metabolism in HepG2 cells 
treated with ARV1 ASO. Total RNA was isolated from HepG2 cells treated with 5 µm control 
ASO or ARV1 ASO. Real-time RT-PCR was performed to assess the mRNA levels of selected 
genes involved in lipid and bile acid related pathways including ARV1 (A), SREBP (B), HMG-CoA 
reductase (C) and CYP7α1 (D). Asterisks indicate significant differences of mRNA levels in ARV1 
ASO-treated group compared with that of the control ASO-treated group with p<0.05 (*) and 































Figure 3-11.  Impairment of cholesterol trafficking in HepG2 Cells with knockdown of ARV1. 
HepG2 cells were plated on collagen-coated plate and then treated with 5 µm control ASO or 
ARV1 ASO. Two days after the transfection, the cells were subjected to the studies. (A) Free 
cholesterol accumulation was detected by filipin staining. Cells were stained with 0.05 mg/ml 
filipin (fluorescence) and examined by confocal microscopy. (B) Knockdown of ARV1 suppresses 
the processing of endogenous SREBP-2 in HepG2 cells. Western blot analysis was performed 
with antibody against SREBP-2 on nuclear fraction of control ASO and ARV1 ASO-treated 
HepG2 cell. P and M indicate the precursor (125 kDa) and mature (68 kDa) forms of SREBP-2, 
respectively. Each lane contains 60 µg of nuclear extract and the arbitrary unit of SREBP-2 
mature form was normalized to β-actin. Although the precursor form does not change, the mature 
form was decreased dramatically in ARV1 ASO-treated cell samples. (C) Knockdown of ARV1 
decreases HMG-CoA reductase protein levels in HepG2 cells. Western blot analysis was 
performed with antibody against human HMG-CoA reductase on membrane fraction of control 
ASO and ARV1 ASO-treated HepG2 cell. Each lane contains 60 µg of membrane fraction. (D) 
Endogenous cholesterol synthesis in HepG2 cells was measured by [3H]acetate incorporation. 
Cells were incubated and labeled with [3H]acetate for 2 h and 4 h. Cellular lipids were extracted 
and determined by TLC. Data values represent mean ± s.e. of triplicate cultures at each time 
point. Asterisks denote statistical significance of ARV1 ASO treatment from control cells with 







































Figure 3-12.  Summary of FXR activation in ARV1 deficient livers.  (A) Twice-weekly ASO 
injection studies demonstrate that expression of ARV1 is significantly decreased at 1- and 2- 
week time points.  In contrast, FXR targets were not significantly upregulated at these time points. 
This may reflect a transient activation of FXR that was missed by examining targets ~3.5 days 
post-injection.  (B) Single-dose ASO injection studies demonstrate that decreases in ARV1 
expression at 2-days post-injection significantly upregulate FXR targets.  However, slight 
increases in ARV1 expression (though still significantly below control levels) at 4 days, no longer 







Figure 3-13. Model of the role of ARV1 in subcellular cholesterol trafficking in mammalian 
cells. We propose that the ARV1-encoded protein facilitates vesicular and/or nonvesicular 
cholesterol movement from the ER to the PM. When ARV1 expression is disrupted, cholesterol is 
cycled inefficiently to the PM and therefore accumulates inside the cells, probably at the ER. 
Accumulation of intracellular cholesterol causes the following outcomes: down-regulation of 
SREBP; a concomitant decrease in endogenous cholesterol synthesis and uptake via HMG-CoA 
reductase and the LDL receptor (LDLR), respectively; an increase in bile acid biosynthesis and 
elevated cholesterol secretion into bile. ACAT2, acyl-CoA:cholesterol acyltransferase 2; SCAP, 
SREBP cleavage-activating protein, CYP7α1, cholesterol 7α-hydroxylase; ABCB11 and 
ABCG5/8, members of the ATP-binding cassette superfamily of membrane transporters. 
Cholesterol is denoted by the open circles. 
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The aim of this thesis was to examine the consequences of ARV1 deficiency in S. 
cerevisiae and mammalian systems.  Experiments in yeast demonstrated that loss of Arv1p 
impacts many facets of subcellular homeostasis.  arv1Δ strains were sensitive to modulations in 
sphingolipid homeostasis and accumulated exogenous sterols, consistent with previous findings 
demonstrating that Arv1p impacts subcellular lipid distribution [194,197].  Loss of Arv1p caused 
morphological changes in cell structure, including vacuolar fragmentation and subcellular 
membrane expansion.  ARV1 mutants also exhibited constitutive UPR induction.  Furthermore, 
genetic interaction studies demonstrated that a functional UPR is necessary for viability in the 
absence of Arv1p.  
We hypothesized that changes in ER lipid homeostasis may be a contributing factor to 
UPR induction in arv1Δ strains.  To explore this hypothesis, mutant forms of Ire1p that are 
hindered in their ability to sense unfolded proteins were expressed in arv1Δ strains in the 
presence of DTT to induce protein misfolding.  arv1Δ strains expressing the mutant forms of Ire1p 
exhibited an arv1Δ-induced component of HAC1 splicing that is independent from DTT-induced 
protein misfolding.  These data suggest that a component of UPR induction in arv1Δ strains is 
independent and synergistic with protein misfolding in the ER lumen, presumably due to altered 
lipid homeostasis. 
Consistent with functional conservation of ARV1 [194], decreased expression of ARV1 in 
murine macrophages activated PERK-mediated UPR induction and eventual apoptosis.  
Furthermore, this phenomenon was exacerbated by inhibition of cholesterol esterification.  Taken 
together, the yeast and macrophage studies implicate loss or down-regulation of ARV1 as a 
causal factor for UPR induction.  In the context of UPR activation, these data suggest that 
subcellular lipid accumulation may function independently of protein misfolding.       
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 ARV1 also impacts intracellular cholesterol trafficking and bile acid homeostasis in 
mammalian cells.  Intraperitoneal injections of ASOs to ARV1 significantly decreased ARV1 
expression in the liver and adipose tissue.  As a result, mice became hypercholesterolemic and 
exhibited increased plasma and hepatic bile acids. Furthermore, examination of the UPR in ASO-
treated livers revealed that ARV1 knockdown does not activate the UPR, perhaps because 
excess cholesterol can be incorporated into bile acids (in contrast to yeast and macrophages, 
which cannot do so).  In order to establish the acute cause for the changes seen in ARV1 ASO-
treated animals, mice were injected with a single dose of the ARV1 ASO and examined at 
sequential time points post-injection.  This resulted in increased plasma bile acids and transient 
activation of FXR regulatory pathways.   
Decreased ARV1 expression in HepG2 cells caused accumulation of intracellular free 
cholesterol and decreases in SREBP and its targets.  Altogether, the in vitro and in vivo ARV1 
knockdown studies present an attractive model for hepatic ARV1 function in which intracellular 
cholesterol accumulation caused by ARV1 deficiency results in decreased cholesterol 
biosynthesis and incorporation of excess ER cholesterol into bile acids.  This alters bile acid 





How ARV1 mediates the trafficking of lipids out of the ER is not understood.  Loss of 
Arv1p alters subcellular sterol distribution [194].  These observations suggest that Arv1p may 
promote the translocation of sterols across or between membranes, but the primary substrate of 
the Arv1p has not been directly determined.  In vitro sterol transport assays are needed to 
determine if Arv1p facilitates sterol transport.  As such, there are several possible mechanisms by 
which Arv1p could mediate lipid export from the ER.  It is possible that ARV1 may function as the 
transport vehicle.  ARV1 lacks any known lipid-recognition domains, though the presence of a 
novel, previously unidentified domain cannot be excluded.  Furthermore, while ARV1 is localized 
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to the ER in plants and humans [200,201], studies in yeast demonstrate that Arv1p localizes to 
both the ER and the Golgi [197], suggesting it may be able to translocate within organelles.  
However, a caveat of the yeast localization studies is that Arv1p is overexpressed, so it is 
possible that Golgi localization reflects the abberant accumulation of Arv1p in other organelles.  
ARV1 could also function as a membrane lipid transporter, passing off the lipid moiety to a 
cytosolic carrier.  Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) labeling studies by 
Kajiwara, et al. support this hypothesis, suggesting that yeast Arv1p may function as a flippase 
for GPI-anchor precursors at the ER membrane [196].  However, pulse-chase studies with energy 
poisons demonstrate that sterol transport in yeast is an energy-dependent process [237] and 
Arv1p does not possess a known ATP-binding domain [284].  It is also possible that Arv1p 
functions as a receptor to facilitate lipid transport.  Arv1p contains a putative zinc-binding motif 
[194], which may facilitate protein-protein or protein-lipid interactions.  In support of this, zinc-
binding regions of membrane-associated proteins have been implicated in charged lipid binding 
and recruitment of proteins to membranes [285], suggesting it may play a role in lipid transport.  
Finally, another possible scenario is that ARV1 inhibits the movement of a lipid transport protein.  
Perhaps ARV1-binding retains another protein in the ER, in a similar fashion to Insig.  Like Insig 
[12], ARV1 is a putative six transmembrane domain protein and has been implicated in the 
regulation of subcellular sterol homeostasis [194,201].  Protein-protein interaction studies will help 
to identify any potential binding partners of Arv1p.   
It is also possible that Arv1p may not function in lipid transport.  Rather, it may alter lipid 
distribution within cells by priming the ER for acceptance of the sterol moiety.  Lipid labeling 
studies demonstrate that ARV1 mutants accumulate saturated fatty acids [197].  In accordance 
with the “umbrella model”, a model for cholesterol solubility in membranes, saturated fatty acyl 
chains of membrane phospholipids effectively shield the hydrophobic sterol moiety from the 
surrounding polar environment [286].  Thus, it is possible that increased saturation of the ER 
membrane in ARV1 mutants may facilitate sterol accumulation in this compartment. 
Based on what is known about Arv1p, I favor a model where Arv1p sits at the ER 
membrane and passes off the sterol moiety to a lipid transfer protein.  As discussed above, there 
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are several ways Arv1p could facilitate lipid transport, and further experiments are necessary 
(discussed below) in order to elucidate the exact mechanism by which Arv1p contributes to the 
movement of sterols and other lipids species.  The most likely candidates for the carrier protein 
are the yeast oxysterol binding protein homologues (OSHs).   OSHs have been implicated in 
nonvesicular sterol transport [287].  Furthermore, in vitro liposome assays demonstrate that OSH 
proteins can bind two membranes simultaneously [70], suggesting they may facilitate sterol 
movement in areas of the cell where membranes are juxtaposed.  Thus, it is compelling to think 
that Arv1p passes off the sterol moiety to an OSH protein to facilitate ER-to-PM transport of 
sterols.  
Since yeast Arv1p impacts many facets of subcellular homeostasis (see Table 4-1), we 
cannot exclude the possibility that the intracellular sterol trafficking defects seen in arv1Δ cells 
[194] are secondary to either the sphingolipid trafficking [197] or GPI-anchor biosynthetic [196] 
defects.  Indeed, these processes are intimately connected.  GPI-anchored proteins associate 
with detergent-resistant membrane fractions in mammalian cells [288].  In yeast, lcb-100 cells, 
which exhibit a temperature sensitive mutation in serine palmitotransferase (SPT), the first step of 
sphingolipid synthesis, exhibit increased subcellular sterol accumulation and decreased sterols in 
the plasma membrane [45].  Moreover, pulse-chase experiments demonstrate that ceramide 
synthesis is necessary for the efficient ER-to-Golgi transport of the GPI-anchored protein Gas1p 
[289] and that myriocin, an inhibitor of SPT, delays Gas1p transport [290].  In contrast, ergosterol 
biosynthetic mutants do not impact the transport of Gas1p [291], suggesting the connection 
between sterol distribution and GPI-protein maturation may be influenced by sphingolipid, in 
particular ceramide, homeostasis.  Thus, future studies (discussed below) are necessary to 




In order to further characterize ARV1 function, we can utilize both yeast and mammalian 
model systems.  The studies in S. cerevisiae (experiments 1-5) primarily focus on understanding 
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the biochemical properties and molecular mechanisms of Arv1p function, while studies in a 
murine model (experiments 6 and 7) attempt to elucidate the role of ARV1 in lipid homeostasis 
and physiology. 
 
1. To determine if Arv1p binds lipids.  It is evident from published work [194,197] as well as the 
data presented in this thesis that loss of Arv1p impacts lipid movement from the ER.  However, it 
remains to be determined if Arv1p binds lipids.  The most plausible lipid-binding partners of Arv1p 
are sterols, sphingolipids and/or GPI-anchor precursors.  We propose to use yeast as a model 
system for Arv1p lipid-binding experiments both in vitro and in vivo.   
Yeast strains bearing a galactose-inducible plasmid encoding a NH2-terminal GST-
tagged Arv1p are commercially available from Open Biosystems (Figure 4-1A).  As such, we can 
examine lipid-binding in vitro by purifying Arv1p and incubating it with either a photoactivatable 
cholesterol [292], sphingosine [293] or GPI-anchor precursor [294] analog in the presence of UV 
light.  These analogs contain diazarine rings that covalently crosslink to any binding partners 
upon UV irradiation.  Interactions can then be identified by SDS-PAGE and fluorography.   
Success of the in vitro lipid-binding experiments is dependent on the ability to purify large 
quantities of a functional membrane protein.  Thus, we also propose in vivo experiments to 
examine native lipid-binding interactions.  Anaerobic growth will facilitate the uptake of 
photocholesterol; anaerobiosis is not necessary for the uptake of photosphingosine or the 
photoactivatable GPI-anchor precursor analog.  Following uptake, cells will be subjected to UV 
irradiation, immunoprecipitation, SDS-PAGE and fluorography in order to identify lipid 
interactions.  Preliminary findings demonstrate that GST-Arv1p is functional (Figure 4-1B) and 
expressed aerobically and during anaerobiosis (Figure 4-2).  In vivo lipid-binding studies are in 
progress.   
 
2. To determine if Arv1p interacts with other proteins.  Whether Arv1p functions as a lipid-
transporter or mediates the transport function of another protein is unknown.  Protein-protein 
interaction studies will help to elucidate if Arv1p functions in a complex to facilitate lipid export.  
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Iyer, et al. have developed a yeast two-hybrid system specially designed to identify interactions 
with membrane proteins [295].  This system is based on the reconstitution of the ubiquitin moiety 
through protein-protein interactions, thereby releasing transcription factors that activate reporter 
genes.  By using Arv1p as the bait for the membrane yeast two-hybrid, we will be able to identify 
any proteins acting in concert with Arv1p to mediate lipid export from the ER.  We hypothesize 
that Arv1p will interact with OSH proteins. 
 
3. To identify domains critical for Arv1p function.  Mutagenesis and NH2-terminal truncation 
studies of the A. thaliana orthologue of Arv1p (AtArv2p) demonstrate that the zinc-binding motif is 
dispensable while the C-terminal portion of the AHD is functionally important [200].  However, 
these studies overexpressed AtArv2p in S. cerevisiae, obscuring the native protein environment.  
We propose site-directed mutagenesis of S. cerevisiae Arv1p expressed on a yeast centromere 
plasmid; thus, expression of the mutagenized protein will be closer to physiological levels.  The A. 
thaliana truncation studies suggest that functionality corresponds to amino acids 41-63 of the S. 
cerevisiae ARV1 homology domain (AHD).  Thus, we propose to mutate highly conserved 
residues in this area of the protein and access functionality by examining arv1Δ phenotypes 
(temperature sensitivity, anaerobic inviability and nystatin sensitivity).  Mutants will also be 
assessed for lipid binding and any protein-protein interactions that were identified in experiments 
1 and 2.  These experiments with elucidate domains that are important for both lipid and protein 
interactions.  
 The initial publication on Arv1p by Tinkelenberg, et al. identified seven ARV1 mutant 
alleles (arv1-1 through arv1-7) [194].  These mutants provide insight on the functionality of Arv1p.  
For example, two mutants, arv1-2 and arv1-4 exhibit intragenic complementation, which suggests 
Arv1p may function as a multimer [194].  Preliminary studies, in which some of the mutant alleles 
were sequenced, demonstrate that arv1-2 is a truncation at amino acid 267 and arv1-4 is a 
frameshift mutation at amino acid 148.  Moreover, arv1-1 exhibits a stop codon at amino acid 65.  
None of these strains exhibit mutations in the AHD, suggesting a role for C-terminal portion of the 
protein in function, perhaps by mediating protein-protein interactions.  Thus, we also propose to 
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generate specific mutations and truncations based on the mutants obtained from the screen in 
order to identify regions of the protein important for Arv1p function.  These mutants primarily 
encompass the C-terminal portion of the protein, including predicted transmembrane domains 
(arv1-2), which may serve to alter membrane orientation.  These mutants will also be assessed 
for Arv1p function, ability to bind lipids and protein-protein interactions. 
 
4.  To characterize genetic interactions with ARV1.  S. cerevisiae is a powerful model system 
for the study of genetic interactions.  The synthetic genetic array (SGA) is a method to study 
genetic interactions on a large-scale.  A mutant query strain (i.e., arv1Δ) is crossed to all 
nonessential gene deletion mutants.  The relationship between double mutants is assessed by 
growth in comparison to the respective single mutant strains [296].  Synthetic lethal interactions 
are those in which both of the single mutants are viable but the double mutant is inviable.  These 
interactions serve to identify genes functioning in either a parallel or compensatory fashion.  In 
contrast, suppressor interactions are those in which the double mutant strain grows better than 
either of the single mutants.  In this context, the loss of one gene alleviates the lesion of the other.  
Examining both the synthetic lethal and suppressor interactions with ARV1 will help to identify 
pathways altered in response to arv1Δ in yeast.  Preliminary analysis of the arv1Δ SGA supports 
previous findings that the UPR (Ire1p and Hac1p) is necessary in the absence of Arv1p [202,206], 
suggesting that these and other genetic interactions are biologically relevant.    
 
5. To characterize Arv1p-mediated lipid movement.  It is unclear if Arv1p-mediated lipid 
egress from the ER is mediated by vesicular or non-vesicular trafficking.  Methyl-β-cyclodextrin 
studies in the vesicular trafficking mutants (temperature sensitive sec mutants) demonstrate that 
transport of newly synthesized ergosterol to the PM is not dependent on a functional secretory 
pathway [45].  In contrast, DHS labeling studies in sec mutants show that complex sphingolipid 
(IPC) formation, which requires ceramide to be trafficked from the ER to the Golgi, occurs by 
vesicular and non-vesicular (40-50%) routes [297].  We can explore the role of Arv1p in vesicular 
trafficking by the use of brefeldin A, a compound that inhibits trafficking through the secretory 
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pathway [298].  Brefeldin A is unable to penetrate the plasma membrane in yeast unless the 
permeability of plasma membrane is altered by erg6 deletion [299].  Lipid labeling studies show a 
drastic decrease in the formation of complex sphingolipids (a process that occurs in the Golgi) in 
the presence of brefeldin A.  Since arv1Δ strains exhibit ceramide accumulation in the ER at the 
expense of complex sphingolipid formation [197], overexpression of Arv1p in an erg6Δ 
background in the presence of brefeldin A will provide valuable insight into the lipid-trafficking 
mechanism of Arv1p.  If overexpression of Arv1p can rescue the sphingolipid defects caused by 
brefeldin A treatment, then Arv1p-mediated sphingolipid trafficking likely functions in a non-
vesicular fashion.  
 
6. To assess the role of ARV1-mediated sphingolipid transport in mammalian cells.  To 
date, studies of ARV1-mediated lipid movement in mammalian cells have primarily focused on 
cholesterol transport [201].  However, yeast Arv1p has also been implicated in ceramide 
trafficking [197], so it is possible that ARV1 may mediate sphingolipid trafficking in mammalian 
cells.  Ceramide transfer protein (CERT) accounts for the majority of ER-to-Golgi trafficking of 
ceramide in mammalian cells.  However, analyses of LY-A cells, which possess a defective 
CERT protein, suggest that CERT does not account for all ceramide trafficking, as CERT-
independent ceramide transport accounts for 5-10% of sphingomyelin formation [300,301].  Thus, 
it is possible that ARV1 may mediate ER-to-Golgi ceramide transport either independently or in 
concert with CERT.  We can utilize LY-A cells or HPA-12, a potent inhibitor of CERT [302,303], to 
access CERT-independent ceramide transport in vitro.  ASO-mediated knockdown of ARV1 
expression followed by lipid composition analysis will elucidate the role of ARV1-mediated 
ceramide trafficking in mammalian cells.  Moreover, ARV1 knockdown in LY-A cells or in 
combination with HPA-12 treatment will provide insight into the potential ARV1-CERT interaction.  
If ARV1 knockdown in LY-A or HPA-12-treated cells further decreases sphingomyelin formation in 
the Golgi, then ARV1 may mediate CERT-independent transport of ceramide out of the ER.  In 
contrast, if ARV1 knockdown in LY-A or HPA-12-treated cells does not alter sphingomyelin 




7. Construct a conditional knockout of ARV1 in a murine model.    Examination of ARV1 
function in a mouse model is important for understanding the associated molecular mechanisms 
and pathologies inherent to humans.  RNAi studies in C. elegans demonstrate that loss of ARV1 
is embryonic lethal in nematodes [235].  As such, it is unlikely that mice containing a germ-line 
mutation in ARV1 will be viable.  Based on this hypothesis, we propose to use the Cre/LoxP 
system [304] to generate tissue-specific knockout models of ARV1 in vivo.  These studies are 
currently in progress in collaboration with Daniel Radar’s group at University of Pennsylvania.  
Exon 1 of murine ARV1 contains the translation start codon as well as the majority of the 
predicted AHD.  A mouse encoding exon 1 flanked with LoxP sites (ARV1flox/flox) has been 
generated through DNA-targeting in embryonic stem cells, blastocyst implantation and 
subsequent breeding.  The ARV1flox/flox mouse will be crossed with transgenic mice expressing 
Cre recombinase under the control of either a ubiquitous promoter (to generate a complete 
knockout, if viable) or a tissue-specific promoter (to generate tissue-specific ARV1-deficient mice) 
[305].  Tissues of particular interest include the pancreas and brain in order to study the impact of 
ARV1 on the development of type 2 diabetes and neurodegeneration, respectively. 
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Table 4-1.  Updated overview of arv1Δ phenotypes in S. cerevisiae.  The data in this table 




Sterol Homeostasis and Trafficking  
• Inviability in the absence of sterol esterification proteins [194] 
• Increased free sterols in subcellular membranes [194]§ 
• Increased sterol esterification [194] 
• Accumulation on sterol intermediates [197] 
• Exogenous cholesterol accumulation This thesis 
• Nystatin sensitivity [194,195] 
• Lovastatin sensitivity [195] 
• Anaerobic inviability [194] 
• Vacuolar fragmentation [187]* 
Sphingolipid Biosynthesis and Trafficking  
Defects in complex sphingolipid formation [196,197] 
Ceramide accumulation [197] 
Sensitivity to exogenous dihydrosphingosine This thesis 
Myriosin sensitivity This thesis 
Aureobasidin A sensitivity [196] 
Fatty Acid and Phospholipid Homeostasis  
Lipid droplet accumulation [195]* 
Decreased fatty acid biosynthesis [197] 
Altered phospholipid composition [197] 
GPI-Anchor Biosynthesis and Trafficking  
Accumulation of early GPI-anchor precursors [196] 
Delayed maturation of GPI-anchored proteins [196,202] 
Weakened membrane association of GPI-anchored proteins [196] 
Defective GPI-anchoring [196] 
Sensitivity to calcofluor white [196] 
Other  
Temperature sensitivity (37°C) [194] 
Defective fluid-phase endocytosis [187] 
Kar2p secretion [202] 
UPR induction [203]* 
Defective mating [199] 
 
*This finding was reproduced in this thesis. 




















Figure 4-1.  GST-Arv1p is a functional protein.  (A) Schematic of the promoter-tag-ORF region 
of the yeast GST-ARV1 fusion plasmid (not to scale). (B) Serial dilutions of wild-type and arv1Δ 
strains expressing either an empty vector (EV) or a plasmid encoding GST-Arv1p.  Strains were 
grown for three days on plasmid selection media in the presence of galactose under the indicated 
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Figure 4-2.  Expression of GST-Arv1p.  Immunoprecipitation of GST-tagged Arv1p (64 kDa) 
after (A) five hours of aerobic induction or (B) three days of anaerobic induction with galactose.  
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Background Reference Figure(s) 
SCY 328  W303 
MATa leu2-3,112 trp1-1 








(K. lactis)  
 
W303 
MATa leu2-3,112 trp1-1 





SCY 955 upc2-1 hi  W303 
MATα leu2-3,112 trp1-1 
can1-100 ura3-1 ade2-1 his3-
11,15 
[306] 2-2 




MATα leu2-3,112 trp1-1 
can1-100 ura3-1 ade2-1 his3-
11,15 
[306] 2-2 
SCY 2110  S288C 
can1::MFA1pr-HIS3-MFαpr-
LEU2 
MATα ura3Δ0 leu2Δ0 his3Δ1 
lys2Δ0 met15Δ0 




arv1::NATR  S288C 
can1::MFA1pr-HIS3-MFαpr-
LEU2 
MATα ura3Δ0 leu2Δ0 his3Δ1 
lys2Δ0 met15Δ0 
[296] 2-1A; 2-6; 2-
7; 2-8 
SCY 2504 arv1::NATR/AR






MATa ura3Δ0 leu2Δ0 his3Δ1 
lys2Δ0 met15Δ0 
[296] 2-5D; 2-9 
 
 
Strain Collection Reference Figure(s) 
MATa Deletion Library Open Biosystems;. [213] 2-6; 2-7; 2-8 




Appendix 2. Primers used in this study. 
Gene Forward Primer Reverse Primer 
yHAC1 (probe) GTCAAACATAACAACCTCCTC GATCAATTGAATTGTCAAAG 
yULI1 ACGCCCTATGCAGTAGCAAT GACTCAGGAGGTCCATTCCA 
yERO1 CAATGAAGGAAGCGGATGAT ACCAAATTTGACCAGCTTGC 
yEUG1 TGTTCCCACACCACGTTAGA ACAATTGGCTTGGCAGTACC 
yLHS1 ATTTCCACCAGGTGAACAGC GGGATTAGCGTGCAATTCAT 
yPDI1 TACTCCATGGCCAACAAACA TCAAAAACATCAGCGTCAGC 
yKAR2 TCGAAGTCCAAGCCACTTCT GCACGTTTAGCCTTTTCAGC 
yTHI21 TTTTGCACGAAAAACTGCTG GCAAGGTCTTTTGCGACTTC 
yTHI20 TTGGTTGCATCCCTTACTCC ACCTTCATCCATGGCTTCAC 
yTHI4 ATGCCGCTTTGTTCATCTCT CCATGCAACATTGAGTACCG 
yYCR100c TATAGCCGGAGGAGAAACCA TCCGATCGAATTCATTGTCA 
yARH1 CGGAACAAAAGGGGTGTTTA ACAGGTGCCCTTCTTAGCAA 
ySDC25 TCATGCTCGTCAGAAACGTC TGGCCCTTACAAGGCTTAGA 
yACT1 AGACTCCTACGTTGGTGATGA ATCGACATCACACTTCATG 
mARV1 TCAGGAGCTGTACCGGGACTA GGTTTCTGGCAGGATTTGCA 
mATF4 TCGATGCTCTGTTTCGAATG GGCAACCTGGTCGACTTTTA 
mCHOP GTCCCTAGCTTGGCTGACAGA TGGAGAGCGAGGGCTTTG 
mXBP1 AACTCCAGCTAGAAAATCAGC GAGGTCCCCACTGACAGAGA 
mCYP7α1 CTTGAGCCAGAGTCCAATGCT GGCAACCTCCTGCAATTCA 
mCYP8b1 GAACTCAACCAGGCCATGCT GGCACCCAGACTCGAACCT 
mCYP27α1 GGTCCAGGAACAGGTCAAGA CCAAAGGAGGTTGTCCACAT 
mIBABP TCATCACAGAGGTCCAGCAG AACTTGTCACCCACGACCTC 
mOSTα GGCATCTATGACCCAGGAGA TGGATCCCATGTTCTGTTCA 
mOSTβ ATCCTGGCAAACAGAAATCG GGGTCTGGCAGAAAGACAAG 
mGAPDH CATGGCCTTCCGTGTTCCTA CGCGCACGTCAGATCCA 
141 
 
Appendix 3.  Transcriptional changes in response to arv1Δ  in yeast. 




YFR026C ULI1 Putative protein of unknown function 
involved in and induced by the endoplasmic 
reticulum unfolded protein response 
5.60 48.503 
YOL037C  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; partially overlaps the uncharacterized 
ORF YOL036W 
4.73 26.600 
YNR065C  Protein of unknown function; protein-protein 
interactions suggest a possible role in actin 
patch formation; YNR065C is not an 
essential gene 
3.00 8.000 
YNL335W DDI3 Protein of unknown function; expression is 
induced over 100-fold by DNA damage; 
induction decreased in rad6 and rad18 
mutants 
2.97 7.817 
YPR077C  Dubious open reading frame unlikely to 
encode a functional protein, based on 
available experimental and comparative 
sequence data; expression increased by 
deletion of NAP1 
2.97 7.817 
YGR032W GSC2 Catalytic subunit of 1,3-beta-glucan 
synthase, involved in formation of the inner 
layer of the spore wall; activity positively 
regulated by Rho1p and negatively by 
Smk1p; has similarity to an alternate 
catalytic subunit, Fks1p (Gsc1p) 
2.93 7.639 
YGR259C  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; overlaps almost completely with the 
verified ORF TNA1/YGR260W 
2.93 7.639 
YBR136W MEC1 Genome integrity checkpoint protein and PI 
kinase superfamily member; signal 
transducer required for cell cycle arrest and 
transcriptional responses prompted by 
damaged or unreplicated DNA; monitors and 
participates in meiotic recombination 
2.93 7.639 
YIL037C PRM2 Pheromone-regulated protein, predicted to 
have 4 transmembrane segments and a 
coiled coil domain; regulated by Ste12p; 
required for efficient nuclear fusion 
2.83 7.127 
YIL072W HOP1 Meiosis-specific DNA binding protein that 
displays Red1p dependent localization to the 
unsynapsed axial-lateral elements of the 
synaptonemal complex; required for 
homologous chromosome synapsis and 
chiasma formation 
2.83 7.127 
YKR061W KTR2 Mannosyltransferase involved in N-linked 
protein glycosylation; member of the 




YMR118C  Protein of unknown function with similarity to 
succinate dehydrogenase cytochrome b 
subunit; YMR118C is not an essential gene 
2.70 6.498 
YGR213C RTA1 Protein involved in 7-aminocholesterol 
resistance; has seven potential membrane-
spanning regions; expression is induced 
under both low-heme and low-oxygen 
conditions; member of the fungal lipid-
translocating exporter (LTE) family of protein 
2.63 6.205 
YLR247C IRC20 Putative helicase; localizes to the 
mitochondrion and the nucleus; YLR247C is 
not an essential gene; null mutant displays 
increased levels of spontaneous Rad52p foci 
2.40 5.278 
YPL258C THI21 Hydroxymethylpyrimidine phosphate kinase, 
involved in the last steps in thiamine 
biosynthesis; member of a gene family with 
THI20 and THI22; Thi20p also has this 
activity 
2.30 4.925 
YIR028W DAL4 Allantoin permease; expression sensitive to 
nitrogen catabolite repression and induced 
by allophanate, an intermediate in allantoin 
degradation 
2.27 4.812 
YDR351W SBE2 Protein involved in the transport of cell wall 
components from the Golgi to the cell 
surface; required for bud growth 
2.27 4.812 
YIL108W  Putative metalloprotease 2.20 4.595 
YCR048W ARE1 Acyl-CoA:sterol acyltransferase, isozyme of 
Are2p; endoplasmic reticulum enzyme that 
contributes the major sterol esterification 
activity in the absence of oxygen 
2.20 4.595 
YBR117C TKL2 Transketolase, similar to Tkl1p; catalyzes 
conversion of xylulose-5-phosphate and 
ribose-5-phosphate to sedoheptulose-7-
phosphate and glyceraldehyde-3-phosphate 
in the pentose phosphate pathway; needed 
for synthesis of aromatic amino acids 
2.17 4.490 
YKL165C MCD4 Protein involved in 
glycosylphosphatidylinositol (GPI) anchor 
synthesis; multimembrane-spanning protein 
that localizes to the endoplasmic reticulum; 
highly conserved among eukaryotes 
2.17 4.490 
YCR100C  Putative protein of unknown function 2.10 4.287 
YOL031C SIL1 Nucleotide exchange factor for the 
endoplasmic reticulum (ER) lumenal Hsp70 
chaperone Kar2p, required for protein 
translocation into the ER; homolog of 
Yarrowia lipolytica SLS1; GrpE-like protein 
2.10 4.287 
YHR209W CRG1 Putative S-adenosylmethionine-dependent 
methyltransferase; mediates cantharidin 
resistance 
2.07 4.189 
YKL161C  Protein kinase implicated in the Slt2p 
mitogen-activated (MAP) kinase signaling 
pathway; associates with Rlm1p 
2.07 4.189 
YBL048W RRT1 Identified in a screen for mutants with 




dubious open reading frame unlikely to 
encode a protein, based on experimental 
and comparative sequence data 
YKR091W SRL3 Cytoplasmic protein that, when 
overexpressed, suppresses the lethality of a 
rad53 null mutation; potential Cdc28p 
substrate 
2.00 4.000 
YIL023C YKE4 Zinc transporter; localizes to the ER; null 
mutant is sensitive to calcofluor white, leads 
to zinc accumulation in cytosol; ortholog of 
the mouse KE4 and member of the ZIP 
(ZRT, IRT-like Protein) family 
1.97 3.909 
YKL107W  Putative protein of unknown function; 
proposed to be a palmitoylated membrane 
protein 
1.97 3.909 
YGR039W  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; partially overlaps the Autonomously 
Replicating Sequence ARS722 
1.93 3.819 
YMR184W ADD37 Protein of unknown function involved in ER-
associated protein degradation; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm and is induced in 
response to the DNA-damaging agent MMS; 
YMR184W is not an essential gene 
1.90 3.732 
YDL057W  Putative protein of unknown function; 
YDL057W is not an essential gene 
1.90 3.732 
YIL073C SPO22 Meiosis-specific protein essential for 
chromosome synapsis, involved in 
completion of nuclear divisions during 
meiosis; induced early in meiosis 
1.90 3.732 
YIL099W SGA1 Intracellular sporulation-specific 
glucoamylase involved in glycogen 
degradation; induced during starvation of a/a 
diploids late in sporulation, but dispensable 
for sporulation 
1.87 3.647 
YEL041W YEF1 ATP-NADH kinase; phosphorylates both 
NAD and NADH; homooctameric structure 
consisting of 60-kDa subunits; sequence 
similarity to Utr1p and Pos5p; 
overexpression complements certain pos5 
phenotypes 
1.83 3.564 
YNL249C MPA43 Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-
throughput studies 
1.83 3.564 
YOR176W HEM15 Ferrochelatase, a mitochondrial inner 
membrane protein, catalyzes the insertion of 
ferrous iron into protoporphyrin IX, the eighth 
and final step in the heme biosynthetic 
pathway 
1.83 3.564 
YKL104C GFA1 Glutamine-fructose-6-phosphate 
amidotransferase, catalyzes the formation of 




fructose-6-P and glutamine in the first step of 
chitin biosynthesis 
YLR024C UBR2 Cytoplasmic ubiquitin-protein ligase (E3); 
required for ubiquitylation of Rpn4p; 
mediates formation of a Mub1p-Ubr2p-
Rad6p complex 
1.80 3.482 
YOR306C MCH5 Plasma membrane riboflavin transporter; 
facilitates the uptake of vitamin B2; required 
for FAD-dependent processes; sequence 
similarity to mammalian monocarboxylate 
permeases, however mutants are not 
deficient in monocarboxylate transport 
1.80 3.482 
YOR289W  Putative protein of unknown function; 
transcription induced by the unfolded protein 
response; green fluorescent protein (GFP)-
fusion protein localizes to both the cytoplasm 
and the nucleus 
1.77 3.403 
YFL033C RIM15 Glucose-repressible protein kinase involved 
in signal transduction during cell proliferation 
in response to nutrients, specifically the 
establishment of stationary phase; identified 
as a regulator of IME2; substrate of Pho80p-
Pho85p kinase 
1.73 3.325 
YHR043C DOG2 2-deoxyglucose-6-phosphate phosphatase, 
member of a family of low molecular weight 
phosphatases, similar to Dog1p, induced by 
oxidative and osmotic stress, confers 2-
deoxyglucose resistance when 
overexpressed 
1.73 3.325 
YHL048W COS8 Nuclear membrane protein, member of the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins; 
regulation suggests a potential role in the 
unfolded protein response 
1.73 3.325 
YFR042W KEG1 Integral membrane protein of the ER; 
physically interacts with Kre6p; has a role in 
the synthesis of beta-1,6-glucan in the cell 
wall; required for cell viability 
1.70 3.249 
YDL215C GDH2 NAD(+)-dependent glutamate 
dehydrogenase, degrades glutamate to 
ammonia and alpha-ketoglutarate; 
expression sensitive to nitrogen catabolite 
repression and intracellular ammonia levels 
1.70 3.249 
YGL121C GPG1 Proposed gamma subunit of the 
heterotrimeric G protein that interacts with 
the receptor Gpr1p; involved in regulation of 
pseudohyphal growth; requires Gpb1p or 
Gpb2p to interact with Gpa2p; 
overproduction causes prion curing 
1.70 3.249 
YIL117C PRM5 Pheromone-regulated protein, predicted to 
have 1 transmembrane segment; induced 
during cell integrity signaling 
1.70 3.249 
YMR040W YET2 Protein of unknown function that may 
interact with ribosomes, based on co-





YGL156W AMS1 Vacuolar alpha mannosidase, involved in 
free oligosaccharide (fOS) degradation; 
delivered to the vacuole in a novel pathway 
separate from the secretory pathway 
1.67 3.175 
YML130C ERO1 Thiol oxidase required for oxidative protein 
folding in the endoplasmic reticulum 
1.67 3.175 
YOL159C  Soluble protein of unknown function; deletion 
mutants are viable and have elevated levels 
of Ty1 retrotransposition and Ty1 cDNA 
1.67 3.175 
YPL067C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm; YPL067C is not 
an essential gene 
1.67 3.175 
YPL088W  Putative aryl alcohol dehydrogenase; 
transcription is activated by paralogous 
transcription factors Yrm1p and Yrr1p along 
with genes involved in multidrug resistance 
1.67 3.175 
YLR104W  Putative protein of unknown function; mutant 
is deficient in amounts of cell wall 
mannosylphosphate; genetic interactions 
suggest a role in ER-associated protein 
degradation (ERAD) 
1.67 3.175 
YBR033W EDS1 Putative zinc cluster protein; YBR033W is 
not an essential gene 
1.63 3.102 
YJR054W  Vacuolar protein of unknown function; 
potential Cdc28p substrate 
1.63 3.102 
YBR201W DER1 Endoplasmic reticulum membrane protein, 
required for ER-associated protein 
degradation of misfolded or unassembled 
proteins; N- and C- termini protrude into the 
cytoplasm, has similarity to Dfm1p 
1.60 3.031 
YMR191W SPG5 Protein required for survival at high 
temperature during stationary phase; not 
required for growth on nonfermentable 
carbon sources 
1.60 3.031 
YOR338W  Putative protein of unknown function; 
YOR338W transcription is regulated by 
Azf1p and its transcript is a specific target of 
the G protein effector Scp160p; identified as 
being required for sporulation in a high-
throughput mutant screen 
1.60 3.031 
YBR302C COS2 Protein of unknown function, member of the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins 
1.57 2.962 
YER132C PMD1 Protein with an N-terminal kelch-like domain, 
putative negative regulator of early meiotic 
gene expression; required, with Mds3p, for 
growth under alkaline conditions 
1.57 2.962 
YJR079W  Putative protein of unknown function; 
mutation results in impaired mitochondrial 
respiration 
1.57 2.962 
YMR103C  Dubious open reading frame unlikely to 
encode a protein, based on available 





YBR295W PCA1 Cadmium transporting P-type ATPase; may 
also have a role in copper and iron 
homeostasis; stabilized by Cd binding, which 
prevents ubiquitination; S288C and other lab 
strains contain a G970R mutation which 
eliminates Cd transport function 
1.57 2.962 
YPL052W OAZ1 Regulator of ornithine decarboxylase 
(Spe1p), antizyme that binds to Spe1p to 
regulate ubiquitin-independent degradation; 
ribosomal frameshifting during synthesis of 
Oaz1p and its ubiquitin-mediated 
degradation are both polyamine-regulated 
1.53 2.895 
YDR503C LPP1 Lipid phosphate phosphatase, catalyzes 
Mg(2+)-independent dephosphorylation of 
phosphatidic acid (PA), lysophosphatidic 
acid, and diacylglycerol pyrophosphate; 
involved in control of the cellular levels of 
phosphatidylinositol and PA 
1.53 2.895 
YDR518W EUG1 Protein disulfide isomerase of the 
endoplasmic reticulum lumen, function 
overlaps with that of Pdi1p; may interact with 
nascent polypeptides in the ER 
1.53 2.895 
YJR030C  Putative protein of unknown function; 
expression repressed in carbon limited vs 
carbon replete chemostat cultures; YJR030C 
is a non-essential gene 
1.53 2.895 
YPR079W MRL1 Membrane protein with similarity to 
mammalian mannose-6-phosphate 
receptors, possibly functions as a sorting 
receptor in the delivery of vacuolar 
hydrolases 
1.53 2.895 
YPR193C HPA2 Tetrameric histone acetyltransferase with 
similarity to Gcn5p, Hat1p, Elp3p, and 
Hpa3p; acetylates histones H3 and H4 in 
vitro and exhibits autoacetylation activity 
1.53 2.895 
YFL030W AGX1 Alanine:glyoxylate aminotransferase (AGT), 
catalyzes the synthesis of glycine from 
glyoxylate, which is one of three pathways 
for glycine biosynthesis in yeast; has 
similarity to mammalian and plant 
alanine:glyoxylate aminotransferases 
1.50 2.828 
YKL071W  Putative protein of unknown function; 
expression induced in cells treated with the 
mycotoxin patulin, and also the quinone 
methide triterpene celastrol; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm 
1.50 2.828 
YBR045C GIP1 Meiosis-specific regulatory subunit of the 
Glc7p protein phosphatase, regulates spore 
wall formation and septin organization, 
required for expression of some late meiotic 
genes and for normal localization of Glc7p 
1.47 2.764 
YER060W FCY21 Putative purine-cytosine permease, very 





YIR043C  member of the COS family of 
subtelomerically-encoded proteins 
1.47 2.764 
YMR187C  Putative protein of unknown function; 
YMR187C is not an essential gene 
1.47 2.764 
YPL006W NCR1 Vacuolar membrane protein that transits 
through the biosynthetic vacuolar protein 
sorting pathway, involved in sphingolipid 
metabolism; glycoprotein and functional 
orthologue of human Niemann Pick C1 
(NPC1) protein 
1.47 2.764 
YNL336W COS1 Protein of unknown function, member of the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins 
1.47 2.764 
YOL113W SKM1 Member of the PAK family of 
serine/threonine protein kinases with 
similarity to Ste20p and Cla4p; proposed to 
be a downstream effector of Cdc42p during 
polarized growth 
1.47 2.764 
YIR041W PAU15 Protein of unknown function, member of the 
seripauperin multigene family encoded 
mainly in subtelomeric regions 
1.43 2.701 
YPL170W DAP1 Heme-binding protein involved in regulation 
of cytochrome P450 protein Erg11p; damage 
response protein, related to mammalian 
membrane progesterone receptors; 
mutations lead to defects in telomeres, 
mitochondria, and sterol synthesis 
1.43 2.701 
YBR137W  Protein of unknown function; localized to the 
cytoplasm; binds to Replication Protein A 
(RPA); YBR137W is not an essential gene 
1.43 2.701 
YJR151C DAN4 Cell wall mannoprotein with similarity to 
Tir1p, Tir2p, Tir3p, and Tir4p; expressed 
under anaerobic conditions, completely 
repressed during aerobic growth 
1.43 2.701 
YOR288C MPD1 Member of the protein disulfide isomerase 
(PDI) family; interacts with and inhibits the 
chaperone activity of Cne1p; MPD1 
overexpression in a pdi1 null mutant 
suppresses defects in Pdi1p functions such 
as carboxypeptidase Y maturation 
1.43 2.701 
YPL221W FLC1 Putative FAD transporter; required for uptake 
of FAD into endoplasmic reticulum; involved 
in cell wall maintenance 
1.43 2.701 
YEL049W PAU2 Member of the seripauperin multigene family 
encoded mainly in subtelomeric regions, 
active during alcoholic fermentation, 
regulated by anaerobiosis, negatively 
regulated by oxygen, repressed by heme 
1.40 2.639 
YGR092W DBF2 Ser/Thr kinase involved in transcription and 
stress response; functions as part of a 
network of genes in exit from mitosis; 
localization is cell cycle regulated; activated 
by Cdc15p during the exit from mitosis 
1.40 2.639 
YGR166W KRE11 Protein involved in biosynthesis of cell wall 1.40 2.639 
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beta-glucans; subunit of the TRAPP 
(transport protein particle) complex, which is 
involved in the late steps of endoplasmic 
reticulum to Golgi transport 
YJR156C THI11 Protein involved in synthesis of the thiamine 
precursor hydroxymethylpyrimidine (HMP); 
member of a subtelomeric gene family 
including THI5, THI11, THI12, and THI13 
1.40 2.639 
YPR195C  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data 
1.40 2.639 
YKL073W LHS1 Molecular chaperone of the endoplasmic 
reticulum lumen, involved in polypeptide 
translocation and folding; nucleotide 
exchange factor for the ER lumenal Hsp70 
chaperone Kar2p; regulated by the unfolded 
protein response pathway 
1.37 2.579 
YBL033C RIB1 GTP cyclohydrolase II; catalyzes the first 
step of the riboflavin biosynthesis pathway 
1.37 2.579 
YFL062W COS4 Protein of unknown function, member of the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins 
1.37 2.579 
YGL261C PAU11 Putative protein of unknown function and 
member of the seripauperin multigene family 
encoded mainly in subtelomeric regions; 
mRNA expression appears to be regulated 
by SUT1 and UPC2 
1.37 2.579 
YML016C PPZ1 Serine/threonine protein phosphatase Z, 
isoform of Ppz2p; involved in regulation of 
potassium transport, which affects osmotic 
stability, cell cycle progression, and 
halotolerance 
1.37 2.579 
YOR193W PEX27 Peripheral peroxisomal membrane protein 
involved in controlling peroxisome size and 
number, interacts with homologous protein 
Pex25p 
1.37 2.579 
YOR250C CLP1 Subunit of cleavage factor I (CFI), involved in 
both the endonucleolyitc cleavage and 
polyadenylation steps of mRNA 3'-end 
maturation 
1.37 2.579 
YBL008W HIR1 Subunit of the HIR complex, a nucleosome 
assembly complex involved in regulation of 
histone gene transcription; contributes to 
nucleosome formation, heterochromatic 
gene silencing, and formation of functional 
kinetochores 
1.33 2.520 
YCL038C ATG22 Vacuolar integral membrane protein required 
for efflux of amino acids during autophagic 
body breakdown in the vacuole; null 
mutation causes a gradual loss of viability 
during starvation 
1.33 2.520 
YDL020C RPN4 Transcription factor that stimulates 
expression of proteasome genes; Rpn4p 




proteasome in a negative feedback control 
mechanism; RPN4 is transcriptionally 
regulated by various stress responses 
YDR242W AMD2 Putative amidase 1.33 2.520 
YDR540C IRC4 Putative protein of unknown function; null 
mutant displays increased levels of 
spontaneous Rad52p foci; green fluorescent 
protein (GFP)-fusion protein localizes to the 
cytoplasm and nucleus 
1.33 2.520 
YHR157W REC104 Protein involved in early stages of meiotic 
recombination; required for meiotic crossing 
over; forms a complex with Rec102p and 
Spo11p necessary during the initiation of 
recombination 
1.33 2.520 
YJR149W  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm 
1.33 2.520 
YLR241W  Putative protein of unknown function, may be 
involved in detoxification 
1.33 2.520 
YML132W COS3 Protein involved in salt resistance; interacts 
with sodium:hydrogen antiporter Nha1p; 
member of the DUP380 subfamily of 
conserved, often subtelomerically-encoded 
proteins 
1.33 2.520 
YOR208W PTP2 Phosphotyrosine-specific protein 
phosphatase involved in the inactivation of 
mitogen-activated protein kinase (MAPK) 
during osmolarity sensing; dephosporylates 
Hog1p MAPK and regulates its localization; 
localized to the nucleus 
1.33 2.520 
YBR007C DSF2 Deletion suppressor of mpt5 mutation 1.30 2.462 
YDR026C  Protein of unknown function that may 
interact with ribosomes, based on co-
purification experiments; Myb-like DNA-
binding protein that may bind to the Ter 
region of rDNA; interacts physically with 
Fob1p 
1.30 2.462 
YGL126W SCS3 Protein required for inositol prototrophy, 
identified as an ortholog of the FIT family of 
proteins involved in triglyceride droplet 
biosynthesis; disputed role in the synthesis 
of inositol phospholipids from inositol 
1.30 2.462 
YJR107W  Putative protein of unknown function; has 
sequence or structural similarity to lipases 
1.30 2.462 
YLR126C  Putative protein of unknown function with 
similarity to glutamine amidotransferase 
proteins; has Aft1p-binding motif in the 
promoter; may be involved in copper and 
iron homeostasis; YLR126C is not an 
essential protein 
1.30 2.462 
YNL333W SNZ2 Member of a stationary phase-induced gene 
family; transcription of SNZ2 is induced prior 
to diauxic shift, and also in the absence of 
thiamin in a Thi2p-dependent manner; forms 





YLR080W EMP46 Integral membrane component of 
endoplasmic reticulum-derived COPII-coated 
vesicles, which function in ER to Golgi 
transport 
1.30 2.462 
YPR006C ICL2 2-methylisocitrate lyase of the mitochondrial 
matrix, functions in the methylcitrate cycle to 
catalyze the conversion of 2-methylisocitrate 
to succinate and pyruvate; ICL2 transcription 
is repressed by glucose and induced by 
ethanol 
1.30 2.462 
YAL053W FLC2 Putative FAD transporter; required for uptake 
of FAD into endoplasmic reticulum; involved 
in cell wall maintenance 
1.27 2.406 
YGR168C  Putative protein of unknown function; 
YGR168C is not an essential gene 
1.27 2.406 
YGR243W FMP43 Putative protein of unknown function; 
expression regulated by osmotic and alkaline 
stresses; the authentic, non-tagged protein is 
detected in highly purified mitochondria in 
high-throughput studies 
1.27 2.406 
YJL223C PAU1 Member of the seripauperin multigene family 
encoded mainly in subtelomeric regions, 
active during alcoholic fermentation, 
regulated by anaerobiosis, negatively 
regulated by oxygen, repressed by heme; 
identical to Pau14p 
1.27 2.406 
YMR090W  Putative protein of unknown function with 
similarity to DTDP-glucose 4,6-
dehydratases; GFP-fusion protein localizes 
to the cytoplasm; up-regulated in response 
to the fungicide mancozeb; not essential for 
viability 
1.27 2.406 
YKR067W GPT2 Glycerol-3-phosphate/dihydroxyacetone 
phosphate dual substrate-specific sn-1 
acyltransferase located in lipid particles and 
the ER; involved in the stepwise acylation of 
glycerol-3-phosphate and dihydroxyacetone 
in lipid biosynthesis 
1.27 2.406 
YLR032W RAD5 DNA helicase proposed to promote 
replication fork regression during 
postreplication repair by template switching; 
RING finger containing ubiquitin ligase; 
stimulates the synthesis of free and PCNA-
bound polyubiquitin chains by Ubc13p-
Mms2p 
1.27 2.406 
YMR013C SEC59 Dolichol kinase, catalyzes the terminal step 
in dolichyl monophosphate (Dol-P) 
biosynthesis; required for viability and for 
normal rates of lipid intermediate synthesis 
and protein N-glycosylation 
1.27 2.406 
YOL011W PLB3 Phospholipase B (lysophospholipase) 
involved in phospholipid metabolism; 
hydrolyzes phosphatidylinositol and 




transacylase activity in vitro 
YDL193W NUS1 Putative prenyltransferase, required for cell 
viability; proposed to be involved in protein 
trafficking because tet-repressible mutant 
shows accumulation of hypoglycosylated 
forms of CPY 
1.23 2.351 
YGL250W RMR1 Protein required for meiotic recombination 
and gene conversion; null mutant displays 
reduced PIS1 expression and growth defects 
on non-fermentable carbon sources and 
minimal media; GFP-fusion protein localizes 
to both cytoplasm and nucleus 
1.23 2.351 
YHL046C PAU13 Protein of unknown function, member of the 
seripauperin multigene family encoded 
mainly in subtelomeric regions; expression is 
induced after ethanol shock 
1.23 2.351 
YHR142W CHS7 Protein of unknown function, involved in 
chitin biosynthesis by regulating Chs3p 
export from the ER 
1.23 2.351 
YNR058W BIO3 7,8-diamino-pelargonic acid 
aminotransferase (DAPA), catalyzes the 
second step in the biotin biosynthesis 
pathway; BIO3 is in a cluster of 3 genes 
(BIO3, BIO4, and BIO5) that mediate biotin 
synthesis 
1.23 2.351 
YOR236W DFR1 Dihydrofolate reductase, part of the dTTP 
biosynthetic pathway, involved in folate 
metabolism, possibly required for 
mitochondrial function 
1.23 2.351 
YPL162C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the membrane of vacuole with 
cell cycle-correlated morphology 
1.23 2.351 
YGR110W CLD1 Mitochondrial cardiolipin-specific 
phospholipase; functions upstream of Taz1p 
to generate monolyso-cardiolipin; 
transcription increases upon genotoxic 
stress; involved in restricting Ty1 
transposition; has homology to mammalian 
CGI-58 
1.23 2.351 
YJL161W FMP33 Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-
throughput studies 
1.23 2.351 
YDR055W PST1 Cell wall protein that contains a putative GPI-
attachment site; secreted by regenerating 
protoplasts; up-regulated by activation of the 
cell integrity pathway, as mediated by 
Rlm1p; upregulated by cell wall damage via 
disruption of FKS1 
1.20 2.297 
YFR041C ERJ5 Type I membrane protein with a J domain is 
required to preserve the folding capacity of 
the endoplasmic reticulum; loss of the non-
essential ERJ5 gene leads to a constitutively 




YGR144W THI4 Thiazole synthase, catalyzes formation of a 
thiazole intermediate during thiamine 
biosynthesis; required for mitochondrial 
genome stability in response to DNA 
damaging agents 
1.20 2.297 
YIL024C  Putative protein of unknown function; non-
essential gene; expression directly regulated 
by the metabolic and meiotic transcriptional 
regulator Ume6p 
1.20 2.297 
YIL109C SEC24 Component of the Sec23p-Sec24p 
heterodimeric complex of the COPII vesicle 
coat; involved in ER to Golgi transport, cargo 
selection and autophagy; required for the 
binding of the Sec13 complex to ER 
membranes; homologous to Lst1p and 
Lss1p 
1.20 2.297 
YIL176C PAU14 Protein of unknown function, member of the 
seripauperin multigene family encoded 
mainly in subtelomeric regions; identical to 
Pau1p 
1.20 2.297 
YJL042W MHP1 Microtubule-associated protein involved in 
assembly and stabilization of microtubules; 
overproduction results in cell cycle arrest at 
G2 phase; similar to Drosophila protein MAP 
and to mammalian MAP4 proteins 
1.20 2.297 
YKL206C ADD66 Protein involved in 20S proteasome 
assembly; forms a heterodimer with Pba1p 
that binds to proteasome precursors; similar 
to human PAC2 constituent of the PAC1-
PAC2 complex involved in proteasome 
assembly 
1.20 2.297 
YLR225C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm; YLR225C is not 
an essential gene 
1.20 2.297 
YNL294C RIM21 Component of the RIM101 pathway, has a 
role in cell wall construction and alkaline pH 
response; has similarity to A. nidulans PalH 
1.20 2.297 
YNR075W COS10 Protein of unknown function, member of the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins 
1.20 2.297 
YOL055C THI20 Multifunctional protein with 
hydroxymethylpyrimidine phosphate (HMP-
P) kinase and thiaminase activities; involved 
in thiamine biosynthesis and degradation; in 
a gene family with THI21 and THI22; HMP-P 
kinase activity redundant with Thi21p 
1.20 2.297 
YBR258C SHG1 Subunit of the COMPASS (Set1C) complex, 
which methylates histone H3 on lysine 4 and 
is required in transcriptional silencing near 
telomeres 
1.17 2.245 
YDR141C DOP1 Protein of unknown function, essential for 
viability, involved in establishing cellular 
polarity and morphogenesis; the authentic, 




purified mitochondria in high-throughput 
studies 
YDR407C TRS120 One of 10 subunits of the transport protein 
particle (TRAPP) complex of the cis-Golgi 
which mediates vesicle docking and fusion; 
involved in endoplasmic reticulum (ER) to 
Golgi membrane traffic 
1.17 2.245 
YIL063C YRB2 Protein of unknown function involved in 
nuclear processes of the Ran-GTPase cycle; 
involved in nuclear protein export; contains 
Ran Binding Domain and FxFG repeats; 
interacts with Srm1p, GTP-Gsp1p, Rna1p 
and Crm1p; is not essential 
1.17 2.245 
YKL074C MUD2 Protein involved in early pre-mRNA splicing; 
component of the pre-mRNA-U1 snRNP 
complex, the commitment complex; interacts 
with Msl5p/BBP splicing factor and Sub2p; 
similar to metazoan splicing factor U2AF65 
1.17 2.245 
YLL016W SDC25 GDP/GTP exchange factor for Ras, has an 
SH3 domain 
1.17 2.245 
YLR252W  Dubious open reading frame unlikely to 
encode a protein, based on experimental 
and comparative sequence data; partially 
overlaps the verified gene SYM1, a 
mitochondrial protein involved in ethanol 
metabolism 
1.17 2.245 
YMR180C CTL1 RNA 5'-triphosphatase, localizes to both the 
nucleus and cytoplasm 
1.17 2.245 
YNR076W PAU6 Member of the seripauperin multigene family 
encoded mainly in subtelomeric regions, 
active during alcoholic fermentation, 
regulated by anaerobiosis, negatively 
regulated by oxygen, repressed by heme; 
identical to Pau18p 
1.17 2.245 
YPL175W SPT14 UDP-GlcNAc-binding and catalytic subunit of 
the enzyme that mediates the first step in 
glycosylphosphatidylinositol (GPI) 
biosynthesis, mutations cause defects in 
transcription and in biogenesis of cell wall 
proteins 
1.17 2.245 
YBR208C DUR1,2 Urea amidolyase, contains both urea 
carboxylase and allophanate hydrolase 
activities, degrades urea to CO2 and NH3; 
expression sensitive to nitrogen catabolite 
repression and induced by allophanate, an 
intermediate in allantoin degradation 
1.13 2.194 
YCR036W RBK1 Putative ribokinase 1.13 2.194 
YGR256W GND2 6-phosphogluconate dehydrogenase 
(decarboxylating), catalyzes an NADPH 
regenerating reaction in the pentose 
phosphate pathway; required for growth on 
D-glucono-delta-lactone 
1.13 2.194 
YGR284C ERV29 Protein localized to COPII-coated vesicles, 
involved in vesicle formation and 




YLR414C  Putative protein of unknown function; 
localizes to bud and cytoplasm; co-localizes 
with Sur7p in punctate patches in the plasma 
membrane; null mutant displays decreased 
thermotolerance; transcription induced on 
cell wall damage 
1.13 2.194 
YNL053W MSG5 Dual-specificity protein phosphatase; exists 
in 2 isoforms; required for maintenance of a 
low level of signaling through the cell 
integrity pathway, adaptive response to 
pheromone; regulates and is regulated by 
Slt2p; dephosphorylates Fus3p 
1.13 2.194 
YDL146W LDB17 Protein involved in the regulation of 
endocytosis; transiently recruited to actin 
cortical patches in a SLA1-dependent 
manner after late coat component assembly; 
GFP-fusion protein localizes to the 
periphery, cytoplasm, bud, and bud neck 
1.13 2.194 
YDR306C  F-box protein of unknown function; interacts 
with Sgt1p via a Leucine-Rich Repeat (LRR) 
domain 
1.13 2.194 
YGL127C SOH1 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; involved in telomere 
maintenance; conserved with other 
metazoan MED31 subunits 
1.13 2.194 
YLL058W  Putative protein of unknown function with 
similarity to Str2p, which is a cystathionine 
gamma-synthase important in sulfur 
metabolism; YLL058W is not an essential 
gene 
1.13 2.194 
YOR062C  Protein of unknown function; similar to 
YKR075Cp and Reg1p; expression 
regulated by glucose and Rgt1p; GFP-fusion 
protein is induced in response to the DNA-
damaging agent MMS 
1.13 2.194 
YOR318C  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; transcript is predicted to be spliced but 
there is no evidence that it is spliced in vivo 
1.13 2.194 
YPL244C HUT1 Protein with a role in UDP-galactose 
transport to the Golgi lumen, has similarity to 
human UDP-galactose transporter UGTrel1, 
exhibits a genetic interaction with S. 
cerevisiae ERO1 
1.13 2.194 
YGL062W PYC1 Pyruvate carboxylase isoform, cytoplasmic 
enzyme that converts pyruvate to 
oxaloacetate; highly similar to isoform Pyc2p 
but differentially regulated; mutations in the 
human homolog are associated with lactic 
acidosis 
1.10 2.144 
YGL248W PDE1 Low-affinity cyclic AMP phosphodiesterase, 




acidification-induced cAMP signaling, target 
of the cAMP-protein kinase A (PKA) 
pathway; glucose induces transcription and 
inhibits translation 
YJR052W RAD7 Protein that recognizes and binds damaged 
DNA in an ATP-dependent manner (with 
Rad16p) during nucleotide excision repair; 
subunit of Nucleotide Excision Repair Factor 
4 (NEF4) and the Elongin-Cullin-Socs (ECS) 
ligase complex 
1.10 2.144 
YAR023C  Putative integral membrane protein, member 
of DUP240 gene family 
1.10 2.144 
YBL078C ATG8 Component of autophagosomes and Cvt 
vesicles; undergoes conjugation to 
phosphatidylethanolamine (PE); Atg8p-PE is 
anchored to membranes, is involved in 
phagophore expansion, and may mediate 
membrane fusion during autophagosome 
formation 
1.10 2.144 
YDR376W ARH1 Oxidoreductase of the mitochondrial inner 
membrane, involved in cytoplasmic and 
mitochondrial iron homeostasis and required 
for activity of Fe-S cluster-containing 
enzymes; one of the few mitochondrial 
proteins essential for viability 
1.10 2.144 
YGR294W PAU12 Protein of unknown function, member of the 
seripauperin multigene family encoded 
mainly in subtelomeric regions 
1.10 2.144 
YKL123W  Dubious open reading frame, unlikely to 
encode a protein; partially overlaps the 
verified gene SSH4 
1.10 2.144 
YKL174C TPO5 Protein involved in excretion of putrescine 
and spermidine; putative polyamine 
transporter in the Golgi or post-Golgi 
vesicles 
1.10 2.144 
YNL058C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the vacuole; YNL058C is not an 
essential gene 
1.10 2.144 
YOL048C RRT8 Putative protein of unknown function; 
identified in a screen for mutants with 
increased levels of rDNA transcription; green 
fluorescent protein (GFP)-fusion protein 
localizes to lipid particles 
1.10 2.144 
YOR099W KTR1 Alpha-1,2-mannosyltransferase involved in 
O- and N-linked protein glycosylation; type II 
membrane protein; member of the 
KRE2/MNT1 mannosyltransferase family 
1.10 2.144 
YCL043C PDI1 Protein disulfide isomerase, multifunctional 
protein resident in the endoplasmic reticulum 
lumen, essential for the formation of disulfide 
bonds in secretory and cell-surface proteins, 
unscrambles non-native disulfide bonds 
1.07 2.095 
YDL045C FAD1 Flavin adenine dinucleotide (FAD) 




synthesis of FAD from riboflavin 
YDR070C FMP16 Putative protein of unknown function; 
proposed to be involved in responding to 
conditions of stress; the authentic, non-
tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
1.07 2.095 
YEL031W SPF1 P-type ATPase, ion transporter of the ER 
membrane involved in ER function and Ca2+ 
homeostasis; required for regulating Hmg2p 
degradation; confers sensitivity to a killer 
toxin (SMKT) produced by Pichia farinosa 
KK1 
1.07 2.095 
YEL058W PCM1 Essential N-acetylglucosamine-phosphate 
mutase; converts GlcNAc-6-P to GlcNAc-1-
P, which is a precursor for the biosynthesis 
of chitin and for the formation of N-
glycosylated mannoproteins and 
glycosylphosphatidylinositol anchors 
1.07 2.095 
YGL104C VPS73 Mitochondrial protein; mutation affects 
vacuolar protein sorting; putative transporter; 
member of the sugar porter family 
1.07 2.095 
YGR028W MSP1 Mitochondrial protein involved in sorting of 
proteins in the mitochondria; putative 
membrane-spanning ATPase 
1.07 2.095 
YJR161C COS5 Protein of unknown function, member the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins 
1.07 2.095 
YKL065C YET1 Endoplasmic reticulum transmembrane 
protein; may interact with ribosomes, based 
on co-purification experiments; homolog of 
human BAP31 protein 
1.07 2.095 
YLR378C SEC61 Essential subunit of Sec61 complex 
(Sec61p, Sbh1p, and Sss1p); forms a 
channel for SRP-dependent protein import 
and retrograde transport of misfolded 
proteins out of the ER; with Sec63 complex 
allows SRP-independent protein import into 
ER 
1.07 2.095 
YLR461W PAU4 Member of the seripauperin multigene family 
encoded mainly in subtelomeric regions; 
active during alcoholic fermentation, 
regulated by anaerobiosis, negatively 
regulated by oxygen, repressed by heme 
1.07 2.095 
YML033W SRC1 spliced mRNA and cell cycle regulated gene 1.07 2.095 
YPL150W  Putative protein kinase of unknown cellular 
role 
1.07 2.095 
YBR023C CHS3 Chitin synthase III, catalyzes the transfer of 
N-acetylglucosamine (GlcNAc) to chitin; 
required for synthesis of the majority of cell 
wall chitin, the chitin ring during bud 
emergence, and spore wall chitosan 
1.03 2.047 
YDL110C TMA17 Protein of unknown function that associates 
with ribosomes; heterozygous deletion 
demonstrated increases in chromosome 




protein abundance is decreased upon 
intracellular iron depletion 
YLL012W YEH1 Steryl ester hydrolase, one of three gene 
products (Yeh1p, Yeh2p, Tgl1p) responsible 
for steryl ester hydrolase activity and 
involved in sterol homeostasis; localized to 
lipid particle membranes 
1.03 2.047 
YOR138C RUP1 Protein involved in regulation of Rsp5p, 
which is an essential HECT ubiquitin ligase; 
has a WW domain consensus motif of 
PPPSY (residues 131-135) that mediates 
binding of Rsp5p to Ubp2p; contains an UBA 
domain 
1.03 2.047 
YDR001C NTH1 Neutral trehalase, degrades trehalose; 
required for thermotolerance and may 
mediate resistance to other cellular stresses; 
may be phosphorylated by Cdc28p 
1.03 2.047 
YLR070C XYL2 Xylitol dehydrogenase, converts xylitol to D-
xylulose; expression induced by xylose, even 
though this pentose sugar is not well utilized 
by S. cerevisiae; null mutant has cell wall 
defect 
1.03 2.047 
YPR135W CTF4 Chromatin-associated protein, required for 
sister chromatid cohesion; interacts with 
DNA polymerase alpha (Pol1p) and may link 
DNA synthesis to sister chromatid cohesion 
1.03 2.047 
YBR149W ARA1 NADP+ dependent arabinose 
dehydrogenase, involved in carbohydrate 
metabolism; purified as homodimer; naturally 
occurs with a N-terminus degradation 
product 
1.00 2.000 
YBR188C NTC20 Member of a complex, including Prp19p, that 
binds to the spliceosome; required for pre-
mRNA splicing 
1.00 2.000 
YCL047C  Putative protein of unknown function 1.00 2.000 
YCR073C SSK22 MAP kinase kinase kinase of the HOG1 
mitogen-activated signaling pathway; 
functionally redundant with, and homologous 
to, Ssk2p; interacts with and is activated by 
Ssk1p; phosphorylates Pbs2p 
1.00 2.000 
YDR400W URH1 Uridine nucleosidase (uridine-cytidine N-
ribohydrolase), cleaves N-glycosidic bonds 
in nucleosides; involved in the pyrimidine 
salvage and nicotinamide riboside salvage 
pathways 
1.00 2.000 
YGL179C TOS3 Protein kinase, related to and functionally 
redundant with Elm1p and Sak1p for the 
phosphorylation and activation of Snf1p; 
functionally orthologous to LKB1, a 
mammalian kinase associated with Peutz-
Jeghers cancer-susceptibility syndrome 
1.00 2.000 
YHR151C MTC6 Protein of unknown function; mtc6 is 
synthetically sick with cdc13-1 
1.00 2.000 
YIL059C  Dubious open reading frame unlikely to 




experimental and comparative sequence 
data; partially overlaps the uncharacterized 
ORF YIL060W 
YJR022W LSM8 Lsm (Like Sm) protein; forms 
heteroheptameric complex (with Lsm2p, 
Lsm3p, Lsm4p, Lsm5p, Lsm6p, and Lsm7p) 
that is part of spliceosomal U6 snRNP and is 
also implicated in processing of pre-tRNA, 
pre-snoRNA, and pre-rRNA 
1.00 2.000 
YLR078C BOS1 v-SNARE (vesicle specific SNAP receptor), 
localized to the endoplasmic reticulum 
membrane and necessary for vesicular 
transport from the ER to the Golgi 
1.00 2.000 
YLR251W SYM1 Protein required for ethanol metabolism; 
induced by heat shock and localized to the 
inner mitochondrial membrane; homologous 
to mammalian peroxisomal membrane 
protein Mpv17 
1.00 2.000 
YOR003W YSP3 Putative precursor to the subtilisin-like 
protease III 
1.00 2.000 
YOR353C SOG2 Key component of the RAM signaling 
network, required for proper cell 
morphogenesis and cell separation after 
mitosis 
1.00 2.000 
YPR146C  Dubious open reading frame unlikely to 
encode a functional protein, based on 





FCY22 Putative purine-cytosine permease, very 
similar to Fcy2p but cannot substitute for its 
function 
1.00 2.000 
YOR052C  Nuclear protein of unknown function; 
expression induced by nitrogen limitation in a 
GLN3, GAT1-independent manner and by 
weak acid 
1.00 2.000 
YCR083W TRX3 Mitochondrial thioredoxin, highly conserved 
oxidoreductase required to maintain the 
redox homeostasis of the cell, forms the 
mitochondrial thioredoxin system with Trr2p, 
redox state is maintained by both Trr2p and 
Glr1p 
0.97 1.954 
YER077C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the mitochondrion; null mutation 
results in a decrease in plasma membrane 
electron transport 
0.97 1.954 
YGR011W  Dubious open reading frame unlikely to 
encode a functional protein, based on 
available experimental and comparative 
sequence data 
0.97 1.954 
YGR295C COS6 Protein of unknown function, member of the 
DUP380 subfamily of conserved, often 
subtelomerically-encoded proteins 
0.97 1.954 
YJL031C BET4 Alpha subunit of Type II 




vesicular transport between the endoplasmic 
reticulum and the Golgi; provides a 
membrane attachment moiety to Rab-like 
proteins Ypt1p and Sec4p 
YLR107W REX3 RNA exonuclease; required for maturation of 
the RNA component of RNase MRP; 
functions redundantly with Rnh70p and 
Rex2p in processing of U5 snRNA and 
RNase P RNA; member of RNase D family 
of exonucleases 
0.97 1.954 
YAL051W OAF1 Oleate-activated transcription factor, acts 
alone and as a heterodimer with Pip2p; 
activates genes involved in beta-oxidation of 
fatty acids and peroxisome organization and 
biogenesis 
0.97 1.954 
YBR160W CDC28 Catalytic subunit of the main cell cycle 
cyclin-dependent kinase (CDK); alternately 
associates with G1 cyclins (CLNs) and G2/M 
cyclins (CLBs) which direct the CDK to 
specific substrates 
0.97 1.954 
YDR142C PEX7 Peroxisomal signal receptor for the N-
terminal nonapeptide signal (PTS2) of 
peroxisomal matrix proteins; WD repeat 
protein; defects in human homolog cause 
lethal rhizomelic chondrodysplasia punctata 
(RCDP) 
0.97 1.954 
YGR153W  Putative protein of unknown function 0.97 1.954 
YJL016W  Putative protein of unknown function; GFP-
fusion protein localizes to the cytoplasm; 
conserved in closely related Saccharomyces 
species 
0.97 1.954 
YLR199C PBA1 Protein involved in 20S proteasome 
assembly; forms a heterodimer with Add66p 
that binds to proteasome precursors; similar 
to human PAC1 constituent of the PAC1-
PAC2 complex involved in proteasome 
assembly 
0.97 1.954 
YOL112W MSB4 GTPase-activating protein of the Ras 
superfamily that acts primarily on Sec4p, 
localizes to the bud site and bud tip, has 
similarity to Msb3p; msb3 msb4 double 
mutation causes defects in secretion and 
actin organization 
0.97 1.954 
YBR269C FMP21 Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-
throughput studies 
0.97 1.954 
YER008C SEC3 Non-essential subunit of the exocyst 
complex (Sec3p, Sec5p, Sec6p, Sec8p, 
Sec10p, Sec15p, Exo70p, Exo84p) which 
mediates targeting of post-Golgi vesicles to 
sites of active exocytosis; Sec3p specifically 
is a spatial landmark for secretion 
0.97 1.954 
YLR144C ACF2 Intracellular beta-1,3-endoglucanase, 




may have a role in cortical actin cytoskeleton 
assembly 
YLR443W ECM7 Non-essential putative integral membrane 
protein; mutant has cell wall defects; 
transcription is induced under conditions of 
zinc deficiency 
0.93 1.910 
YAL054C ACS1 Acetyl-coA synthetase isoform which, along 
with Acs2p, is the nuclear source of acetyl-
coA for histone acetlyation; expressed during 
growth on nonfermentable carbon sources 
and under aerobic conditions 
0.93 1.910 
YDR117C TMA64 Protein of unknown function that associates 
with ribosomes; has a putative RNA binding 
domain 
0.93 1.910 
YDR411C DFM1 ER localized derlin-like family member 
involved in ER stress and homeostasis; not 
involved in ERAD or substrate 
retrotranslocation; interacts with CDC48; 
contains four transmembrane domains and 
two SHP boxes 
0.93 1.910 
YIL040W APQ12 Protein involved in nucleocytoplasmic 
transport of mRNA 
0.93 1.910 
YKR088C TVP38 Integral membrane protein localized to late 
Golgi vesicles along with the v-SNARE 
Tlg2p; required for asymmetric localization of 
Kar9p during mitosis; GFP-fusion protein 
localizes to the cytoplasm in a punctate 
pattern 
0.93 1.910 
YML109W ZDS2 Protein that interacts with silencing proteins 
at the telomere, involved in transcriptional 
silencing; implicated in the mitotic exit 
network through regulation of Cdc14p 
localization; paralog of Zds1p 
0.93 1.910 
YPR107C YTH1 Essential RNA-binding component of 
cleavage and polyadenylation factor, 
contains five zinc fingers; required for pre-
mRNA 3'-end processing and 
polyadenylation 
0.93 1.910 
YBL088C TEL1 Protein kinase primarily involved in telomere 
length regulation; contributes to cell cycle 
checkpoint control in response to DNA 
damage; functionally redundant with Mec1p; 
homolog of human ataxia telangiectasia 
(ATM) gene 
0.90 1.866 
YDL235C YPD1 Phosphorelay intermediate protein, 
phosphorylated by the plasma membrane 
sensor Sln1p in response to osmotic stress 
and then in turn phosphorylates the 
response regulators Ssk1p in the cytosol and 
Skn7p in the nucleus 
0.90 1.866 
YDR166C SEC5 Essential 107kDa subunit of the exocyst 
complex (Sec3p, Sec5p, Sec6p, Sec8p, 
Sec10p, Sec15p, Exo70p, and Exo84p), 
which has the essential function of mediating 




active sites of exocytosis 
YDR391C  Putative protein of unknown function, 
possibly involved in zinc homeostasis; 
Bdf1p-dependent transcription induced by 
salt stress; green fluorescent protein (GFP)-
fusion protein localizes to both the cytoplasm 
and the nucleus 
0.90 1.866 
YDR476C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the endoplasmic reticulum; 
YDR476C is not an essential gene 
0.90 1.866 
YHR030C SLT2 Serine/threonine MAP kinase involved in 
regulating the maintenance of cell wall 
integrity and progression through the cell 
cycle; regulated by the PKC1-mediated 
signaling pathway 
0.90 1.866 
YJL074C SMC3 Subunit of the multiprotein cohesin complex 
required for sister chromatid cohesion in 
mitotic cells; also required, with Rec8p, for 
cohesion and recombination during meiosis; 
phylogenetically conserved SMC 
chromosomal ATPase family member 
0.90 1.866 
YOR080W DIA2 Origin-binding F-box protein that forms an 
SCF ubiquitin ligase complex with Skp1p 
and Cdc53p; plays a role in DNA replication, 
involved in invasive and pseudohyphal 
growth 
0.90 1.866 
YOR174W MED4 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; essential for transcriptional 
regulation 
0.90 1.866 
YPL001W HAT1 Catalytic subunit of the Hat1p-Hat2p histone 
acetyltransferase complex that uses the 
cofactor acetyl coenzyme A, to acetylate free 
nuclear and cytoplasmic histone H4; 
involved in telomeric silencing and DNA 
double-strand break repair 
0.90 1.866 
YPR198W SGE1 Plasma membrane multidrug transporter of 
the major facilitator superfamily, acts as an 
extrusion permease; partial multicopy 
suppressor of gal11 mutations 
0.90 1.866 
YLR205C HMX1 ER localized, heme-binding peroxidase 
involved in the degradation of heme; does 
not exhibit heme oxygenase activity despite 
similarity to heme oxygenases; expression 
regulated by AFT1 
0.90 1.866 
YPR167C MET16 3'-phosphoadenylsulfate reductase, reduces 
3'-phosphoadenylyl sulfate to adenosine-
3',5'-bisphosphate and free sulfite using 
reduced thioredoxin as cosubstrate, involved 
in sulfate assimilation and methionine 
metabolism 
0.90 1.866 
YBR053C  Putative protein of unknown function; 




YCR032W BPH1 Protein homologous to human Chediak-
Higashi syndrome and murine Beige 
proteins, which are implicated in disease 
syndromes due to defective lysosomal 
trafficking; mutant phenotype and genetic 
interactions suggest a role in protein sorting 
0.87 1.823 
YDL093W PMT5 Protein O-mannosyltransferase, transfers 
mannose residues from dolichyl phosphate-
D-mannose to protein serine/threonine 
residues; acts in a complex with Pmt3p, can 
instead interact with Pmt2p in some 
conditions; target for new antifungals 
0.87 1.823 
YER121W  Putative protein of unknown function; may be 
involved in phosphatase regulation and/or 
generation of precursor metabolites and 
energy 
0.87 1.823 
YFR039C  Putative protein of unknown function; may be 
involved in response to high salt and 
changes in carbon source; deletion mutant 
has decreased spore survival in Drosophila 
feces 
0.87 1.823 
YGR137W  Dubious open reading frame unlikely to 
encode a functional protein, based on 
available experimental and comparative 
sequence data 
0.87 1.823 
YML029W USA1 Protein involved in ER-associated protein 
degradation (ERAD); component of the 
Hrd1p complex; interacts with the U1 
snRNP-specific protein, Snp1p 
0.87 1.823 
YOL044W PEX15 Phosphorylated tail-anchored type II integral 
peroxisomal membrane protein required for 
peroxisome biogenesis, cells lacking Pex15p 
mislocalize peroxisomal matrix proteins to 
cytosol, overexpression results in impaired 
peroxisome assembly 
0.87 1.823 
YOR034C AKR2 Ankyrin repeat-containing protein similar to 
Akr1p; member of a family of putative 
palmitoyltransferases containing an Asp-His-
His-Cys-cysteine rich (DHHC-CRD) domain; 
possibly involved in constitutive endocytosis 
of Ste3p 
0.87 1.823 
YOR311C DGK1 Diacylglycerol kinase, localized to the 
endoplasmic reticulum (ER); overproduction 
induces enlargement of ER-like membrane 
structures and suppresses a temperature-
sensitive sly1 mutation; contains a CTP 
transferase domain 
0.87 1.823 
YPL094C SEC62 Essential subunit of Sec63 complex 
(Sec63p, Sec62p, Sec66p and Sec72p); with 
Sec61 complex, Kar2p/BiP and Lhs1p forms 
a channel competent for SRP-dependent 
and post-translational SRP-independent 
protein targeting and import into the ER 
0.87 1.823 
YPR085C ASA1 Putative protein of unknown function; subunit 




Tra1p, Tti1p, Tti2, Asa1p and Tra1p) which 
is part of the chromatin remodeling 
machinery 
YEL020C  Hypothetical protein with low sequence 
identity to Pdc1p 
0.87 1.823 
YIR044C  probable pseudogene; putative product has 
similarity to N-terminal region of Cos2p, 
Ycr007p, and Ykl291p 
0.87 1.823 
YKL057C NUP120 Subunit of the Nup84p subcomplex of the 
nuclear pore complex (NPC), required for 
even distribution of NPCs around the nuclear 
envelope, involved in establishment of a 
normal nucleocytoplasmic concentration 
gradient of the GTPase Gsp1p 
0.87 1.823 
YPL039W  Putative protein of unknown function; 
YPL039W is not an essential gene 
0.87 1.823 
YPR127W  Protein of unknown function, differentially 
expressed during alcoholic fermentation; 
expression activated by transcription factor 
YRM1/YOR172W; green fluorescent protein 
(GFP)-fusion protein localizes to both the 
cytoplasm and the nucleus 
0.87 1.823 
YBR119W MUD1 U1 snRNP A protein, homolog of human U1-
A; involved in nuclear mRNA splicing 
0.83 1.782 
YGL157W  NADPH-dependent aldehyde reductase, 
utilizes aromatic and alophatic aldehyde 
substrates; member of the short-chain 
dehydrogenase/reductase superfamily 
0.83 1.782 
YHR191C CTF8 Subunit of a complex with Ctf18p that shares 
some subunits with Replication Factor C and 
is required for sister chromatid cohesion 
0.83 1.782 
YJL085W EXO70 Subunit of the exocyst complex (Sec3p, 
Sec5p, Sec6p, Sec8p, Sec10p, Sec15p, 
Exo70p, and Exo84p), which directs 
secretory vesicles to active sites of 
exocytosis; acts with Sec3p in membrane 
targeting of the exocyst via PI(4,5)P2 binding 
0.83 1.782 
YKL133C  Putative protein of unknown function; has 
similarity to Mgr3p, but unlike MGR3, is not 
required for growth of cells lacking the 
mitochondrial genome (null mutation does 
not confer a petite-negative phenotype) 
0.83 1.782 
YKR049C FMP46 Putative redox protein containing a 
thioredoxin fold; the authentic, non-tagged 
protein is detected in highly purified 
mitochondria in high-throughput studies 
0.83 1.782 
YLL064C PAU18 Protein of unknown function, member of the 
seripauperin multigene family encoded 
mainly in subtelomeric regions; identical to 
Pau6p 
0.83 1.782 
YLR001C  Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-





YLR046C  Putative membrane protein; member of the 
fungal lipid-translocating exporter (LTE) 
family of proteins; transcription is activated 
by paralogous transcription factors Yrm1p 
and Yrr1p along with genes involved in 
multidrug resistance 
0.83 1.782 
YLR105C SEN2 Subunit of the tRNA splicing endonuclease, 
which is composed of Sen2p, Sen15p, 
Sen34p, and Sen54p; Sen2p contains the 
active site for tRNA 5' splice site cleavage 
and has similarity to Sen34p and to Archaeal 
tRNA splicing endonuclease 
0.83 1.782 
YLR349W  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; overlaps the verified ORF 
DIC1/YLR348C 
0.83 1.782 
YMR238W DFG5 Putative mannosidase, essential 
glycosylphosphatidylinositol (GPI)-anchored 
membrane protein required for cell wall 
biogenesis in bud formation, involved in 
filamentous growth, homologous to Dcw1p 
0.83 1.782 
YPR159W KRE6 Protein required for beta-1,6 glucan 
biosynthesis; putative beta-glucan synthase; 
appears functionally redundant with Skn1p 
0.83 1.782 
YDL095W PMT1 Protein O-mannosyltransferase, transfers 
mannose residues from dolichyl phosphate-
D-mannose to protein serine/threonine 
residues; one of seven related proteins 
involved in O-glycosylation which is essential 
for cell wall rigidity 
0.80 1.741 
YDL124W  NADPH-dependent alpha-keto amide 
reductase; reduces aromatic alpha-keto 
amides, aliphatic alpha-keto esters, and 
aromatic alpha-keto esters; member of the 
aldo-keto reductase (AKR) family 
0.80 1.741 
YIL001W  Putative protein of unknown function; 
contains a BTB/POZ domain which generally 
function in protein interactions; deletion 
slightly improved competitive fitness in rich 
media; GFP-tagged protein is localized to 
the cytoplasm 
0.80 1.741 
YKL022C CDC16 Subunit of the anaphase-promoting 
complex/cyclosome (APC/C), which is a 
ubiquitin-protein ligase required for 
degradation of anaphase inhibitors, including 
mitotic cyclins, during the 
metaphase/anaphase transition; required for 
sporulation 
0.80 1.741 
YOR059C  Hypothetical protein 0.80 1.741 
YOR380W RDR1 Transcriptional repressor involved in the 
control of multidrug resistance; negatively 
regulates expression of the PDR5 gene; 





YPR101W SNT309 Component of NineTeen complex (NTC) 
containing Prp19p involved in mRNA 
splicing, interacts physically and genetically 
with Prp19p 
0.80 1.741 
YFL017C GNA1 Evolutionarily conserved glucosamine-6-
phosphate acetyltransferase required for 
multiple cell cycle events including passage 
through START, DNA synthesis, and mitosis; 
involved in UDP-N-acetylglucosamine 
synthesis, forms GlcNAc6P from AcCoA 
0.80 1.741 
YGR047C TFC4 One of six subunits of the RNA polymerase 
III transcription initiation factor complex 
(TFIIIC); part of the TauA domain of TFIIIC 
that binds BoxA DNA promoter sites of tRNA 
and similar genes; has TPR motifs; human 
homolog is TFIIIC-102 
0.80 1.741 
YGR263C SAY1 Sterol deacetylase; component of the sterol 
acetylation/deacetylation cycle along with 
Atf2p; integral membrane protein with active 
site in the ER lumen; green fluorescent 
protein (GFP)-fusion protein localizes to the 
endoplasmic reticulum 
0.80 1.741 
YKR097W PCK1 Phosphoenolpyruvate carboxykinase, key 
enzyme in gluconeogenesis, catalyzes early 
reaction in carbohydrate biosynthesis, 
glucose represses transcription and 
accelerates mRNA degradation, regulated by 
Mcm1p and Cat8p, located in the cytosol 
0.80 1.741 
YMR041C ARA2 NAD-dependent arabinose dehydrogenase, 
involved in biosynthesis of dehydro-D-
arabinono-1,4-lactone; similar to plant L-
galactose dehydrogenase 
0.80 1.741 
YOR036W PEP12 Target membrane receptor (t-SNARE) for 
vesicular intermediates traveling between 
the Golgi apparatus and the vacuole; 
controls entry of biosynthetic, endocytic, and 
retrograde traffic into the prevacuolar 
compartment; syntaxin 
0.80 1.741 
YOR079C ATX2 Golgi membrane protein involved in 
manganese homeostasis; overproduction 
suppresses the sod1 (copper, zinc 
superoxide dismutase) null mutation 
0.80 1.741 
YPR046W MCM16 Protein involved in kinetochore-microtubule 
mediated chromosome segregation; binds to 
centromere DNA 
0.80 1.741 
YPR109W  Predicted membrane protein; dipoid deletion 
strain has high budding index 
0.77 1.701 
YAL014C SYN8 Endosomal SNARE related to mammalian 
syntaxin 8 
0.77 1.701 
YAR031W PRM9 Pheromone-regulated protein with 3 
predicted transmembrane segments and an 
FF sequence, a motif involved in COPII 
binding; member of DUP240 gene family 
0.77 1.701 
YBL095W  Putative protein of unknown function; the 




highly purified mitochondria in high-
throughput studies 
YBL107C  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm; YBL107C is not 
an essential gene 
0.77 1.701 
YBR002C RER2 Cis-prenyltransferase involved in dolichol 
synthesis; participates in endoplasmic 
reticulum (ER) protein sorting 
0.77 1.701 
YBR004C GPI18 Functional ortholog of human PIG-V, which 
is a mannosyltransferase that transfers the 
second mannose in 
glycosylphosphatidylinositol biosynthesis; 
the authentic, non-tagged protein was 
localized to mitochondria 
0.77 1.701 
YDR027C VPS54 Component of the GARP (Golgi-associated 
retrograde protein) complex, Vps51p-
Vps52p-Vps53p-Vps54p, which is required 
for the recycling of proteins from endosomes 
to the late Golgi; potentially phosphorylated 
by Cdc28p 
0.77 1.701 
YDR325W YCG1 Subunit of the condensin complex; required 
for establishment and maintenance of 
chromosome condensation, chromosome 
segregation and chromatin binding of the 
condensin complex; required for clustering of 
tRNA genes at the nucleolus 
0.77 1.701 
YGL142C GPI10 Integral membrane protein involved in 
glycosylphosphatidylinositol (GPI) anchor 
synthesis; putative alpha 1,2 
mannosyltransferase required for addition of 
the third mannose onto the GPI core 
structure; human PIG-Bp is a functional 
homolog 
0.77 1.701 
YGR125W  Putative protein of unknown function; 
deletion mutant has decreased rapamycin 
resistance but normal wormannin resistance; 
green fluorescent protein (GFP)-fusion 
protein localizes to the vacuole 
0.77 1.701 
YKL046C DCW1 Putative mannosidase, GPI-anchored 
membrane protein required for cell wall 
biosynthesis in bud formation;homologous to 
Dfg5p 
0.77 1.701 
YKL224C PAU16 Protein of unknown function, member of the 
seripauperin multigene family encoded 
mainly in subtelomeric regions 
0.77 1.701 
YLR200W YKE2 Subunit of the heterohexameric 
Gim/prefoldin protein complex involved in the 
folding of alpha-tubulin, beta-tubulin, and 
actin 
0.77 1.701 
YLR280C  Dubious open reading frame unlikely to 
encode a functional protein, based on 
available experimental and comparative 
sequence data 
0.77 1.701 
YAL062W GDH3 NADP(+)-dependent glutamate 0.73 1.662 
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dehydrogenase, synthesizes glutamate from 
ammonia and alpha-ketoglutarate; rate of 
alpha-ketoglutarate utilization differs from 
Gdh1p; expression regulated by nitrogen 
and carbon sources 
YCL049C  Protein of unknown function; localizes to 
membrane fraction; YCL049C is not an 
essential gene; 
0.73 1.662 
YCR086W CSM1 Nucleolar protein that forms a complex with 
Lrs4p and then Mam1p at kinetochores 
during meiosis I to mediate accurate 
homolog segregation; required for condensin 
recruitment to the replication fork barrier site 
and rDNA repeat segregation 
0.73 1.662 
YDR338C  Putative protein of unknown function 0.73 1.662 
YDR420W HKR1 Mucin family member that functions as an 
osmosensor in the Sho1p-mediated HOG 
pathway with Msb2p; proposed to be a 
negative regulator of filamentous growth; 
mutant displays defects in beta-1,3 glucan 
synthesis and bud site selection 
0.73 1.662 
YDR434W GPI17 Transmembrane protein subunit of the 
glycosylphosphatidylinositol transamidase 
complex that adds GPIs to newly 
synthesized proteins; human PIG-Sp 
homolog 
0.73 1.662 
YER013W PRP22 DEAH-box RNA-dependent ATPase/ATP-
dependent RNA helicase, associates with 
lariat intermediates before the second 
catalytic step of splicing; mediates ATP-
dependent mRNA release from the 
spliceosome and unwinds RNA duplexes 
0.73 1.662 
YFL031W HAC1 Basic leucine zipper (bZIP) transcription 
factor (ATF/CREB1 homolog) that regulates 
the unfolded protein response, via UPRE 
binding, and membrane biogenesis; ER 
stress-induced splicing pathway facilitates 
efficient Hac1p synthesis 
0.73 1.662 
YHL030W ECM29 Major component of the proteasome; tethers 
the proteasome core particle to the 
regulatory particle, and enhances the 
stability of the proteasome 
0.73 1.662 
YHR006W STP2 Transcription factor, activated by proteolytic 
processing in response to signals from the 
SPS sensor system for external amino acids; 
activates transcription of amino acid 
permease genes 
0.73 1.662 
YKL185W ASH1 Zinc-finger inhibitor of HO transcription; 
mRNA is localized and translated in the 
distal tip of anaphase cells, resulting in 
accumulation of Ash1p in daughter cell 
nuclei and inhibition of HO expression; 
potential Cdc28p substrate 
0.73 1.662 
YLR292C SEC72 Non-essential subunit of Sec63 complex 




Sec61 complex, Kar2p/BiP and Lhs1p forms 
a channel competent for SRP-dependent 
and post-translational SRP-independent 
protein targeting and import into the ER 
YMR054W STV1 Subunit a of the vacuolar-ATPase V0 
domain, one of two isoforms (Stv1p and 
Vph1p); Stv1p is located in V-ATPase 
complexes of the Golgi and endosomes 
while Vph1p is located in V-ATPase 
complexes of the vacuole 
0.73 1.662 
YOR336W KRE5 Protein required for beta-1,6 glucan 
biosynthesis; mutations result in aberrant 
morphology and severe growth defects 
0.73 1.662 
YPR121W THI22 Protein with similarity to 
hydroxymethylpyrimidine phosphate kinases; 
member of a gene family with THI20 and 
THI21; not required for thiamine biosynthesis 
0.73 1.662 
YJR047C ANB1 Translation elongation factor eIF-5A, 
previously thought to function in translation 
initiation; similar to and functionally 
redundant with Hyp2p; undergoes an 
essential hypusination modification; 
expressed under anaerobic conditions 
0.73 1.662 
YOR153W PDR5 Plasma membrane ATP-binding cassette 
(ABC) transporter, multidrug transporter 
actively regulated by Pdr1p; also involved in 
steroid transport, cation resistance, and 
cellular detoxification during exponential 
growth 
0.73 1.662 
YDR058C TGL2 Protein with lipolytic activity towards 
triacylglycerols and diacylglycerols when 
expressed in E. coli; role in yeast lipid 
degradation is unclear 
0.70 1.625 
YER092W IES5 Protein that associates with the INO80 
chromatin remodeling complex under low-
salt conditions 
0.70 1.625 
YER093C TSC11 Subunit of TORC2 (Tor2p-Lst8p-Avo1-Avo2-
Tsc11p-Bit61p), a membrane-associated 
complex that regulates actin cytoskeletal 
dynamics during polarized growth and cell 
wall integrity; involved in sphingolipid 
metabolism; contains a RasGEFN domain 
0.70 1.625 
YFR046C CNN1 Kinetochore protein of unknown function; 
associated with the essential kinetochore 
proteins Nnf1p and Spc24p; phosphorylated 
by both Clb5-Cdk1 and, to a lesser extent, 
Clb2-Cdk1. 
0.70 1.625 
YLR450W HMG2 One of two isozymes of HMG-CoA reductase 
that convert HMG-CoA to mevalonate, a 
rate-limiting step in sterol biosynthesis; 
overproduction induces assembly of 
peripheral ER membrane arrays and short 
nuclear-associated membrane stacks 
0.70 1.625 
YML011C RAD33 Protein involved in nucleotide excision 




fusion protein localizes to the nucleus 
YNL271C BNI1 Formin, nucleates the formation of linear 
actin filaments, involved in cell processes 
such as budding and mitotic spindle 
orientation which require the formation of 
polarized actin cables, functionally redundant 
with BNR1 
0.70 1.625 
YOL165C AAD15 Putative aryl-alcohol dehydrogenase with 
similarity to P. chrysosporium aryl-alcohol 
dehydrogenase; mutational analysis has not 
yet revealed a physiological role 
0.70 1.625 
YPL154C PEP4 Vacuolar aspartyl protease (proteinase A), 
required for the posttranslational precursor 
maturation of vacuolar proteinases; 
important for protein turnover after oxidative 
damage; synthesized as a zymogen, self-
activates 
0.70 1.625 
YPR138C MEP3 Ammonium permease of high capacity and 
low affinity; belongs to a ubiquitous family of 
cytoplasmic membrane proteins that 
transport only ammonium (NH4+); 
expression is under the nitrogen catabolite 
repression regulation ammonia permease 
0.70 1.625 
YAR027W UIP3 Putative integral membrane protein of 
unknown function; interacts with Ulp1p at the 
nuclear periphery; member of DUP240 gene 
family 
0.70 1.625 
YJR141W  Essential protein of unknown function 0.70 1.625 
YMR010W  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm; YMR010W is not 
an essential gene; YMR010W mRNA is 
transcribed with ADI1 
0.70 1.625 
YBR166C TYR1 Prephenate dehydrogenase involved in 
tyrosine biosynthesis, expression is 
dependent on phenylalanine levels 
0.67 1.587 
YBR297W MAL33 MAL-activator protein, part of complex locus 
MAL3; nonfunctional in genomic reference 
strain S288C 
0.67 1.587 
YCR082W AHC2 Protein of unknown function, putative 
transcriptional regulator; proposed to be a 
Ada Histone acetyltransferase complex 
component; GFP tagged protein is localized 
to the cytoplasm and nucleus 
0.67 1.587 
YDL072C YET3 Protein of unknown function; YET3 null 
mutant decreases the level of secreted 
invertase; homolog of human BAP31 protein 
0.67 1.587 
YDR539W  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm; YDR539W is not 
an essential gene; homolog of E. coli UbiD 
0.67 1.587 
YER144C UBP5 Putative ubiquitin-specific protease, closest 
paralog of Doa4p but has no functional 
overlap; concentrates at the bud neck 
0.67 1.587 
YFR047C BNA6 Quinolinate phosphoribosyl transferase, 0.67 1.587 
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required for the de novo biosynthesis of NAD 
from tryptophan via kynurenine; expression 
regulated by Hst1p 
YFR052W RPN12 Subunit of the 19S regulatory particle of the 
26S proteasome lid; synthetically lethal with 
RPT1, which is an ATPase component of the 
19S regulatory particle; physically interacts 
with Nob1p and Rpn3p 
0.67 1.587 
YGR010W NMA2 Nicotinic acid mononucleotide 
adenylyltransferase, involved in de novo and 
salvage synthesis of NAD(+) 
0.67 1.587 
YHR045W  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the endoplasmic reticulum 
0.67 1.587 
YIL076W SEC28 Epsilon-COP subunit of the coatomer; 
regulates retrograde Golgi-to-ER protein 
traffic; stabilizes Cop1p, the alpha-COP and 
the coatomer complex; non-essential for cell 
growth 
0.67 1.587 
YJL178C ATG27 Type I membrane protein involved in 
autophagy and the cytoplasm-to-vacuole 
targeting (Cvt) pathway; may be involved in 
membrane delivery to the phagophore 
assembly site 
0.67 1.587 
YKR068C BET3 Hydrophilic protein that acts in conjunction 
with SNARE proteins in targeting and fusion 
of ER to Golgi transport vesicles; component 
of the TRAPP (transport protein particle) 
complex 
0.67 1.587 
YLR194C  Structural constituent of the cell wall 
attached to the plasma membrane by a GPI-
anchor; expression is upregulated in 
response to cell wall stress 
0.67 1.587 
YLR326W  Putative protein of unknown function, 
predicted to be palmitoylated 
0.67 1.587 
YMR112C MED11 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; essential protein 
0.67 1.587 
YMR174C PAI3 Cytoplasmic proteinase A (Pep4p) inhibitor, 
dependent on Pbs2p and Hog1p protein 
kinases for osmotic induction; intrinsically 
unstructured, N-terminal half becomes 
ordered in the active site of proteinase A 
upon contact 
0.67 1.587 
YPL152W RRD2 Activator of the phosphotyrosyl phosphatase 
activity of PP2A,peptidyl-prolyl cis/trans-
isomerase; regulates G1 phase progression, 
the osmoresponse, microtubule dynamics; 
subunit of the Tap42p-Pph21p-Rrd2p 
complex 
0.67 1.587 
YBL055C  3'-->5' exonuclease and endonuclease with a 
possible role in apoptosis; has similarity to 





YER018C SPC25 Component of the evolutionarily conserved 
kinetochore-associated Ndc80 complex 
(Ndc80p-Nuf2p-Spc24p-Spc25p); involved in 
chromosome segregation, spindle 
checkpoint activity and kinetochore 
clustering 
0.63 1.551 
YFL029C CAK1 Cyclin-dependent kinase-activating kinase 
required for passage through the cell cycle, 
phosphorylates and activates Cdc28p; 
nucleotide-binding pocket differs significantly 
from those of most other protein kinases 
0.63 1.551 
YGR235C  Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-
throughput studies 
0.63 1.551 
YIL156W UBP7 Ubiquitin-specific protease that cleaves 
ubiquitin-protein fusions 
0.63 1.551 
YJL030W MAD2 Component of the spindle-assembly 
checkpoint complex, which delays the onset 
of anaphase in cells with defects in mitotic 
spindle assembly; forms a complex with 
Mad1p 
0.63 1.551 
YPL053C KTR6 Probable mannosylphosphate transferase 
involved in the synthesis of core 
oligosaccharides in protein glycosylation 
pathway; member of the KRE2/MNT1 
mannosyltransferase family 
0.63 1.551 
YAR003W SWD1 Subunit of the COMPASS (Set1C) complex, 
which methylates histone H3 on lysine 4 and 
is required in transcriptional silencing near 
telomeres; WD40 beta propeller superfamily 
member with similarity to mammalian Rbbp7 
0.63 1.551 
YAR028W  Putative integral membrane protein, member 
of DUP240 gene family; GFP-fusion protein 
is induced in response to the DNA-damaging 
agent MMS 
0.63 1.551 
YFL006W  unknown function, similar to C.elegans 
C14C10.5 (32%) 
0.63 1.551 
YGR048W UFD1 Protein that interacts with Cdc48p and 
Npl4p, involved in recognition of 
polyubiquitinated proteins and their 
presentation to the 26S proteasome for 
degradation; involved in transporting proteins 
from the ER to the cytosol 
0.63 1.551 
YHR175W CTR2 Putative low-affinity copper transporter of the 
vacuolar membrane; mutation confers 
resistance to toxic copper concentrations, 
while overexpression confers resistance to 
copper starvation 
0.63 1.551 
YJL005W CYR1 Adenylate cyclase, required for cAMP 
production and cAMP-dependent protein 
kinase signaling; the cAMP pathway controls 
a variety of cellular processes, including 
metabolism, cell cycle, stress response, 




YOR097C  Putative protein of unknown function; 
identified as interacting with Hsp82p in a 
high-throughput two-hybrid screen; 
YOR097C is not an essential gene 
0.63 1.551 
YAL023C PMT2 Protein O-mannosyltransferase, transfers 
mannose residues from dolichyl phosphate-
D-mannose to protein serine/threonine 
residues; acts in a complex with Pmt1p, can 
instead interact with Pmt5p in some 
conditions; target for new antifungals 
0.60 1.516 
YDR059C UBC5 Ubiquitin-conjugating enzyme that mediates 
selective degradation of short-lived, 
abnormal, or excess proteins, including 
histone H3; central component of the cellular 
stress response; expression is heat inducible 
0.60 1.516 
YDR231C COX20 Mitochondrial inner membrane protein, 
required for proteolytic processing of Cox2p 
and its assembly into cytochrome c oxidase 
0.60 1.516 
YDR284C DPP1 Diacylglycerol pyrophosphate (DGPP) 
phosphatase, zinc-regulated vacuolar 
membrane-associated lipid phosphatase, 
dephosphorylates DGPP to phosphatidate 
(PA) and Pi, then PA to diacylglycerol; 
involved in lipid signaling and cell 
metabolism 
0.60 1.516 
YFL043C  due to a sequence change (deletion of G at 
46151), YFL043C is now part of YFL042C 
0.60 1.516 
YGL185C  Putative protein with sequence similarity to 
hydroxyacid dehydrogenases; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm 
0.60 1.516 
YHR028C DAP2 Dipeptidyl aminopeptidase, synthesized as a 
glycosylated precursor; localizes to the 
vacuolar membrane; similar to Ste13p 
0.60 1.516 
YIL165C  Putative protein of unknown function; in 
closely related species and other S. 
cerevisiae strain backgrounds YIL165C and 
adjacent ORF, YIL164C, likely constitute a 
single ORF encoding a nitrilase gene 
0.60 1.516 
YJR024C MDE1 5'-methylthioribulose-1-phosphate 
dehydratase; acts in the methionine salvage 
pathway; potential Smt3p sumoylation 
substrate; expression downregulated by 
caspofungin and deletion mutant is 
caspofungin resistant 
0.60 1.516 
YKR100C SKG1 Transmembrane protein with a role in cell 
wall polymer composition; localizes on the 
inner surface of the plasma membrane at the 
bud and in the daughter cell 
0.60 1.516 
YLR011W LOT6 FMN-dependent NAD(P)H:quinone 
reductase, may be involved in quinone 
detoxification; expression elevated at low 
temperature; sequesters the Cin5p 
transcription factor in the cytoplasm in 





YLR224W  F-box protein and component of SCF 
ubiquitin ligase complexes involved in 
ubiquitin-dependent protein catabolism; 
readily monoubiquitinated in vitro by SCF-
Ubc4 complexes; YLR224W is not an 
essential gene 
0.60 1.516 
YML070W DAK1 Dihydroxyacetone kinase, required for 
detoxification of dihydroxyacetone (DHA); 
involved in stress adaptation 
0.60 1.516 
YOR111W  Putative protein of unknown function 0.60 1.516 
YPL135W ISU1 Conserved protein of the mitochondrial 
matrix, performs a scaffolding function during 
assembly of iron-sulfur clusters, interacts 
physically and functionally with yeast frataxin 
(Yfh1p); isu1 isu2 double mutant is inviable 
0.60 1.516 
YBL020W RFT1 Essential integral membrane protein that is 
required for translocation of Man5GlcNac2-
PP-Dol from the cytoplasmic side to the 
lumenal side of the ER membrane but is not 
the flippase; mutation is suppressed by 
expression of human p53 protein 
0.57 1.481 
YDL179W PCL9 Cyclin, forms a functional kinase complex 
with Pho85p cyclin-dependent kinase (Cdk), 
expressed in late M/early G1 phase, 
activated by Swi5p 
0.57 1.481 
YIL048W NEO1 Putative aminophospholipid translocase 
(flippase) involved in endocytosis and 
vacuolar biogenesis; localizes to endosomes 
and the Golgi aparatus 
0.57 1.481 
YJL171C  GPI-anchored cell wall protein of unknown 
function; induced in response to cell wall 
damaging agents and by mutations in genes 
involved in cell wall biogenesis; sequence 
similarity to YBR162C/TOS1, a covalently 
bound cell wall protein 
0.57 1.481 
YLR300W EXG1 Major exo-1,3-beta-glucanase of the cell 
wall, involved in cell wall beta-glucan 
assembly; exists as three differentially 
glycosylated isoenzymes 
0.57 1.481 
YOL164W BDS1 Bacterially-derived sulfatase required for use 
of alkyl- and aryl-sulfates as sulfur sources 
0.57 1.481 
YDR318W MCM21 Protein involved in minichromosome 
maintenance; component of the COMA 
complex (Ctf19p, Okp1p, Mcm21p, Ame1p) 
that bridges kinetochore subunits that are in 
contact with centromeric DNA and the 
subunits bound to microtubules 
0.57 1.481 
YGR134W CAF130 Part of the evolutionarily-conserved CCR4-
NOT transcriptional regulatory complex 
involved in controlling mRNA initiation, 
elongation, and degradation 
0.57 1.481 
YJL151C SNA3 Integral membrane protein localized to 
vacuolar intralumenal vesicles, 




protein-protein interaction data suggests a 
possible role in either cell wall synthesis or 
protein-vacuolar targeting 
YLR425W TUS1 Guanine nucleotide exchange factor (GEF) 
that functions to modulate Rho1p activity as 
part of the cell integrity signaling pathway; 
multicopy suppressor of tor2 mutation and 
ypk1 ypk2 double mutation; potential Cdc28p 
substrate 
0.57 1.481 
YML076C WAR1 Homodimeric Zn2Cys6 zinc finger 
transcription factor; binds to a weak acid 
response element to induce transcription of 
PDR12 and FUN34, encoding an acid 
transporter and a putative ammonia 
transporter, respectively 
0.57 1.481 
YBL093C ROX3 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme 
0.53 1.447 
YBL098W BNA4 Kynurenine 3-mono oxygenase, required for 
the de novo biosynthesis of NAD from 
tryptophan via kynurenine; expression 
regulated by Hst1p; putative therapeutic 
target for Huntington disease 
0.53 1.447 
YBR176W ECM31 Ketopantoate hydroxymethyltransferase, 
required for pantothenic acid biosynthesis, 
converts 2-oxoisovalerate into 2-
dehydropantoate 
0.53 1.447 
YDL141W BPL1 Biotin:apoprotein ligase, covalently modifies 
proteins with the addition of biotin, required 
for acetyl-CoA carboxylase (Acc1p) 
holoenzyme formation 
0.53 1.447 
YDR019C GCV1 T subunit of the mitochondrial glycine 
decarboxylase complex, required for the 
catabolism of glycine to 5,10-methylene-
THF; expression is regulated by levels of 
levels of 5,10-methylene-THF in the 
cytoplasm 
0.53 1.447 
YDR022C CIS1 Autophagy-specific protein required for 
autophagosome formation; may form a 
complex with Atg17p and Atg29p that 
localizes other proteins to the pre-
autophagosomal structure; high-copy 
suppressor of CIK1 deletion 
0.53 1.447 
YGL021W ALK1 Protein kinase; accumulation and 
phosphorylation are periodic during the cell 
cycle; phosphorylated in response to DNA 
damage; contains characteristic motifs for 
degradation via the APC pathway; similar to 
Alk2p and to mammalian haspins 
0.53 1.447 
YGR037C ACB1 Acyl-CoA-binding protein, transports newly 
synthesized acyl-CoA esters from fatty acid 
synthetase (Fas1p-Fas2p) to acyl-CoA-
consuming processes 
0.53 1.447 
YOL073C  Putative protein of unknown function 0.53 1.447 
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YPL138C SPP1 Subunit of COMPASS (Set1C), a complex 
which methylates histone H3 on lysine 4 and 
is required in telomeric transcriptional 
silencing; interacts with Orc2p; PHD finger 
domain protein similar to human CGBP, an 
unmethylated CpG binding protein 
0.53 1.447 
YPR037C ERV2 Flavin-linked sulfhydryl oxidase localized to 
the endoplasmic reticulum lumen, involved in 
disulfide bond formation within the ER 
0.53 1.447 
YDL117W CYK3 SH3-domain protein located in the mother-
bud neck and the cytokinetic actin ring; 
mutant phenotype and genetic interactions 
suggest a role in cytokinesis 
0.50 1.414 
YDR084C TVP23 Integral membrane protein localized to late 
Golgi vesicles along with the v-SNARE 
Tlg2p; green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm in a 
punctate pattern 
0.50 1.414 
YIL077C  Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-





YBR095C RXT2 Subunit of the histone deacetylase Rpd3L 
complex; possibly involved in cell fusion and 
invasive growth 
0.50 1.414 
YGL174W BUD13 Subunit of the RES complex, which is 
required for nuclear pre-mRNA retention and 
splicing; involved in bud-site selection; 
diploid mutants display a unipolar budding 
pattern instead of the wild-type bipolar 
pattern 
0.50 1.414 
YGR157W CHO2 Phosphatidylethanolamine methyltransferase 
(PEMT), catalyzes the first step in the 
conversion of phosphatidylethanolamine to 
phosphatidylcholine during the methylation 
pathway of phosphatidylcholine biosynthesis 
0.50 1.414 
YIL147C SLN1 Histidine kinase osmosensor that regulates a 
MAP kinase cascade; transmembrane 
protein with an intracellular kinase domain 
that signals to Ypd1p and Ssk1p, thereby 
forming a phosphorelay system similar to 
bacterial two-component regulators 
0.50 1.414 
YJL034W KAR2 ATPase involved in protein import into the 
ER, also acts as a chaperone to mediate 
protein folding in the ER and may play a role 
in ER export of soluble proteins; regulates 
the unfolded protein response via interaction 
with Ire1p 
0.50 1.414 
YJL222W VTH2 Putative membrane glycoprotein with strong 
similarity to Vth1p and Pep1p/Vps10p, may 
be involved in vacuolar protein sorting 
0.50 1.414 
YNL157W  Putative protein of unknown function; green 0.50 1.414 
176 
 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm and nucleus 
YDL142C CRD1 Cardiolipin synthase; produces cardiolipin, 
which is a phospholipid of the mitochondrial 
inner membrane that is required for normal 
mitochondrial membrane potential and 
function; also required for normal vacuolar 
ion homeostasis 
0.47 1.382 
YAL049C AIM2 Cytoplasmic protein involved in 
mitochondrial function or organization; null 
mutant displays reduced frequency of 
mitochondrial genome loss; potential Hsp82p 
interactor 
0.47 1.382 
YDL115C IWR1 Protein involved in transcription from 
polymerase II promoters; interacts with with 
most of the polymerase II subunits; nucleo-
cytoplasmic shuttling protein; deletion 
causes hypersensitivity to the K1 killer toxin 
0.47 1.382 
YDR349C YPS7 Putative GPI-anchored aspartic protease, 
located in the cytoplasm and endoplasmic 
reticulum 
0.47 1.382 
YIL129C TAO3 Component of the RAM signaling network 
that is involved in regulation of Ace2p activity 
and cellular morphogenesis, interacts with 
protein kinase Cbk1p and also with Kic1p 
0.47 1.382 
YLR209C PNP1 Purine nucleoside phosphorylase, 
specifically metabolizes inosine and 
guanosine nucleosides; involved in the 
nicotinamide riboside salvage pathway 
0.47 1.382 
YBL083C  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; overlaps verified ORF ALG3 
0.43 1.350 
YDL052C SLC1 1-acyl-sn-glycerol-3-phosphate 
acyltransferase, catalyzes the acylation of 
lysophosphatidic acid to form phosphatidic 
acid, a key intermediate in lipid metabolism; 
enzymatic activity detected in lipid particles 
and microsomes 
0.43 1.350 
YIL014W MNT3 Alpha-1,3-mannosyltransferase, adds the 
fourth and fifth alpha-1,3-linked mannose 
residues to O-linked glycans during protein 
O-glycosylation 
0.43 1.350 
YKL186C MTR2 mRNA transport regulator, essential nuclear 
protein; Mex67p and Mtr2p form a mRNA 
export complex which binds to RNA 
0.43 1.350 
YML041C VPS71 Nucleosome-binding component of the 
SWR1 complex, which exchanges histone 
variant H2AZ (Htz1p) for chromatin-bound 
histone H2A; required for vacuolar protein 
sorting 
0.43 1.350 
YML071C COG8 Component of the conserved oligomeric 
Golgi complex (Cog1p through Cog8p), a 
cytosolic tethering complex that functions in 




transport vesicles to Golgi compartments 
YMR226C  NADP(+)-dependent dehydrogenase; acts 
on serine, L-allo-threonine, and other 3-
hydroxy acids; green fluorescent protein 
fusion protein localizes to the cytoplasm and 
nucleus; may interact with ribosomes, based 
on co-purification experiments 
0.43 1.350 
YAL029C MYO4 One of two type V myosin motors (along with 
MYO2) involved in actin-based transport of 
cargos; required for mRNA transport, 
including ASH1 mRNA, and facilitating the 
growth and movement of ER tubules into the 
growing bud along with She3p 
0.43 1.350 
YGR275W RTT102 Component of both the SWI/SNF and RSC 
chromatin remodeling complexes, suggested 
role in chromosome maintenance; possible 
weak regulator of Ty1 transposition 
0.43 1.350 
YLR454W FMP27 Putative protein of unknown function; the 
authentic, non-tagged protein is detected in 
highly purified mitochondria in high-
throughput studies 
0.43 1.350 
YHL044W  Putative integral membrane protein, member 
of DUP240 gene family; green fluorescent 
protein (GFP)-fusion protein localizes to the 
plasma membrane in a punctate pattern 
0.40 1.320 
YHR179W OYE2 Widely conserved NADPH oxidoreductase 
containing flavin mononucleotide (FMN), 
homologous to Oye3p with slight differences 
in ligand binding and catalytic properties; 
may be involved in sterol metabolism 
0.40 1.320 
YHR192W  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm and is induced in 
response to the DNA-damaging agent MMS 
0.40 1.320 
YJL204C RCY1 F-box protein involved in recycling plasma 
membrane proteins internalized by 
endocytosis; localized to sites of polarized 
growth 
0.40 1.320 
YBL041W PRE7 Beta 6 subunit of the 20S proteasome 0.37 1.289 
YBR062C  Hypothetical protein 0.37 1.289 
YDR160W SSY1 Component of the SPS plasma membrane 
amino acid sensor system (Ssy1p-Ptr3p-
Ssy5p), which senses external amino acid 
concentration and transmits intracellular 
signals that result in regulation of expression 
of amino acid permease genes 
0.37 1.289 
YIR035C  Putative cytoplasmic protein of unknown 
function 
0.37 1.289 
YLR246W ERF2 Subunit of a palmitoyltransferase, composed 
of Erf2p and Shr5p, that adds a palmitoyl 
lipid moiety to heterolipidated substrates 
such as Ras1p and Ras2p through a 
thioester linkage; mutants partially 
mislocalize Ras2p to the vacuole 
0.37 1.289 
YGL221C NIF3 Protein of unknown function, similar to 0.37 1.289 
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Listeria monocytogenes major sigma factor 
(rpoD gene product); the authentic, non-
tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
YBL017C PEP1 Type I transmembrane sorting receptor for 
multiple vacuolar hydrolases; cycles 
between the late-Golgi and prevacuolar 
endosome-like compartments 
0.33 1.260 
YDR435C PPM1 Carboxyl methyltransferase, methylates the 
C terminus of the protein phosphatase 2A 
catalytic subunit (Pph21p or Pph22p), which 
is important for complex formation with 
regulatory subunits 
0.33 1.260 
YJR017C ESS1 Peptidylprolyl-cis/trans-isomerase (PPIase) 
specific for phosphorylated serine and 
threonine residues N-terminal to proline; 
regulates phosphorylation of the RNA 
polymerase II large subunit (Rpo21p) C-
terminal domain 
0.33 1.260 
YJR159W SOR1 Sorbitol dehydrogenase; expression is 
induced in the presence of sorbitol or xylose 
0.30 1.231 
YDL147W RPN5 Essential, non-ATPase regulatory subunit of 
the 26S proteasome lid, similar to 
mammalian p55 subunit and to another S. 
cerevisiae regulatory subunit, Rpn7p 
0.27 1.203 
YDR249C  Putative protein of unknown function 0.10 1.072 
YNL131W TOM22 Component of the TOM (translocase of outer 
mitochondrial membrane) complex 
responsible for initial import of 
mitochondrially directed proteins; acts as a 
receptor for precursor proteins and mediates 
interaction between TOM and TIM 
complexes 
-0.40 1.320 
YOL029C  Putative protein of unknown function; 
identified as interacting with Hsc82p and 
Hsp82p in high-throughput two-hybrid 
screens 
-0.43 1.350 
YMR242C RPL20A Protein component of the large (60S) 
ribosomal subunit, nearly identical to 
Rpl20Bp and has similarity to rat L18a 
ribosomal protein 
-0.47 1.382 
YNL067W RPL9B Protein component of the large (60S) 
ribosomal subunit, nearly identical to Rpl9Ap 
and has similarity to E. coli L6 and rat L9 
ribosomal proteins 
-0.47 1.382 
YNR024W MPP6 Nuclear exosome-associated RNA binding 
protein; involved in surveillance of pre-
rRNAs and pre-mRNAs, and the degradation 
of cryptic non-coding RNAs (ncRNA); 
copurifies with ribosomes 
-0.50 1.414 
YOR286W  Protein of unknown function; overexpression 
causes a cell cycle delay; the authentic, non-
tagged protein is detected in purified 
mitochondria in high-throughput studies; null 




mitochondrial genome loss 
YPL198W RPL7B Protein component of the large (60S) 
ribosomal subunit, nearly identical to Rpl7Ap 
and has similarity to E. coli L30 and rat L7 
ribosomal proteins; contains a conserved C-
terminal Nucleic acid Binding Domain 
(NDB2) 
-0.50 1.414 
YNL137C NAM9 Mitochondrial ribosomal component of the 
small subunit 
-0.53 1.447 
YOR091W TMA46 Protein of unknown function that associates 
with ribosomes; interacts with GTPase 
Rbg1p 
-0.53 1.447 
YNL280C ERG24 C-14 sterol reductase, acts in ergosterol 
biosynthesis; mutants accumulate the 
abnormal sterol ignosterol (ergosta-8,14 
dienol), and are viable under anaerobic 
growth conditions but inviable on rich 
medium under aerobic conditions 
-0.57 1.481 
YGR214W RPS0A Protein component of the small (40S) 
ribosomal subunit, nearly identical to 
Rps0Bp; required for maturation of 18S 
rRNA along with Rps0Bp; deletion of either 
RPS0 gene reduces growth rate, deletion of 
both genes is lethal 
-0.57 1.481 
YNR046W TRM112 Subunit of tRNA methyltransferase (MTase) 
complexes in combination with Trm9p and 
Trm11p; subunit of complex with Mtq2p that 
methylates Sup45p (eRF1) in the ternary 
complex eRF1-eRF3-GTP; deletion confers 
resistance to zymocin 
-0.57 1.481 
YOR101W RAS1 GTPase involved in G-protein signaling in 
the adenylate cyclase activating pathway, 
plays a role in cell proliferation; localized to 
the plasma membrane; homolog of 
mammalian RAS proto-oncogenes 
-0.57 1.481 
YGL255W ZRT1 High-affinity zinc transporter of the plasma 
membrane, responsible for the majority of 
zinc uptake; transcription is induced under 
low-zinc conditions by the Zap1p 
transcription factor 
-0.60 1.516 
YPL263C KEL3 Cytoplasmic protein of unknown function -0.60 1.516 
YPR110C RPC40 RNA polymerase subunit, common to RNA 
polymerase I and III 
-0.60 1.516 
YNL002C RLP7 Nucleolar protein with similarity to large 
ribosomal subunit L7 proteins; constituent of 
66S pre-ribosomal particles; plays an 
essential role in processing of precursors to 
the large ribosomal subunit RNAs 
-0.63 1.551 
YOL158C ENB1 Endosomal ferric enterobactin transporter, 
expressed under conditions of iron 
deprivation; member of the major facilitator 
superfamily; expression is regulated by 
Rcs1p and affected by chloroquine treatment 
-0.63 1.551 
YIL177C  Putative protein of unknown function; 




within subtelomeric Y' elements and induced 
in telomerase deficient survivors 
YMR233W TRI1 Non-essential sumoylated protein of 
unknown function with similarity to 
components of human SWI/SNF complex 
including SMRD3; green fluorescent protein 
(GFP)-fusion protein localizes to the 
cytoplasm, nucleus and nucleolus 
-0.63 1.551 
YHR147C MRPL6 Mitochondrial ribosomal protein of the large 
subunit 
-0.67 1.587 
YNL252C MRPL17 Mitochondrial ribosomal protein of the large 
subunit 
-0.67 1.587 
YPR041W TIF5 Translation initiation factor eIF-5; N-terminal 
domain functions as a GTPase-activating 
protein to mediate hydrolysis of ribosome-
bound GTP; C-terminal domain is the core of 
ribosomal preinitiation complex formation 
-0.67 1.587 
YER029C SMB1 Core Sm protein Sm B; part of 
heteroheptameric complex (with Smd1p, 
Smd2p, Smd3p, Sme1p, Smx3p, and 
Smx2p) that is part of the spliceosomal U1, 
U2, U4, and U5 snRNPs; homolog of human 
Sm B and Sm B' 
-0.70 1.625 
YGL032C AGA2 Adhesion subunit of a-agglutinin of a-cells, 
C-terminal sequence acts as a ligand for 
alpha-agglutinin (Sag1p) during 
agglutination, modified with O-linked 
oligomannosyl chains, linked to anchorage 
subunit Aga1p via two disulfide bonds 
-0.70 1.625 
YGL204C  Dubious open reading frame unlikely to 
encode a functional protein, based on 
available experimental and comparative 
sequence data 
-0.70 1.625 
YGR233C PHO81 Cyclin-dependent kinase (CDK) inhibitor, 
regulates Pho80p-Pho85p and Pcl7p-
Pho85p cyclin-CDK complexes in response 
to phosphate levels; inhibitory activity for 
Pho80p-Pho85p requires myo-D-inositol 
heptakisphosphate (IP7) generated by Vip1p 
-0.70 1.625 
YHR169W DBP8 ATPase, putative RNA helicase of the 
DEAD-box family; component of 90S 
preribosome complex involved in production 
of 18S rRNA and assembly of 40S small 
ribosomal subunit; ATPase activity 
stimulated by association with Esp2p 
-0.70 1.625 
YJR070C LIA1 Deoxyhypusine hydroxylase, a HEAT-repeat 
containing metalloenzyme that catalyzes 
hypusine formation; binds to and is required 
for the modification of Hyp2p (eIF5A); 
complements S. pombe mmd1 mutants 
defective in mitochondrial positioning 
-0.70 1.625 
YHR025W THR1 Homoserine kinase, conserved protein 
required for threonine biosynthesis; 
expression is regulated by the GCN4-





YGL040C HEM2 Aminolevulinate dehydratase, a homo-
octameric enzyme, catalyzes the conversion 
of 5-aminolevulinate to porphobilinogen, the 
second step in heme biosynthesis; 
enzymatic activity is zinc-dependent; 
localizes to the cytoplasm and nucleus 
-0.73 1.662 
YGR155W CYS4 Cystathionine beta-synthase, catalyzes 
synthesis of cystathionine from serine and 
homocysteine, the first committed step in 
cysteine biosynthesis; responsible for 
hydrogen sulfide generation; mutations in 
human ortholog cause homocystinuria 
-0.73 1.662 
YJR025C BNA1 3-hydroxyanthranilic acid dioxygenase, 
required for the de novo biosynthesis of NAD 
from tryptophan via kynurenine; expression 
regulated by Hst1p 
-0.73 1.662 
YLR372W SUR4 Elongase, involved in fatty acid and 
sphingolipid biosynthesis; synthesizes very 
long chain 20-26-carbon fatty acids from 
C18-CoA primers; involved in regulation of 
sphingolipid biosynthesis 
-0.73 1.662 
YML056C IMD4 Inosine monophosphate dehydrogenase, 
catalyzes the first step of GMP biosynthesis, 
member of a four-gene family in S. 
cerevisiae, constitutively expressed 
-0.73 1.662 
YMR131C RRB1 Essential nuclear protein involved in early 
steps of ribosome biogenesis; physically 
interacts with the ribosomal protein Rpl3p 
-0.73 1.662 
YMR310C  Putative protein of unknown function; 
predicted to be involved in ribosome 
biogenesis; green fluorescent protein (GFP)-
fusion protein localizes to the nucleus; 
YMR310C is not an essential gene 
-0.73 1.662 
YNL282W POP3 Subunit of both RNase MRP, which cleaves 
pre-rRNA, and nuclear RNase P, which 
cleaves tRNA precursors to generate mature 
5' ends 
-0.73 1.662 
YOL092W  Putative protein of unknown function; 
predicted to contain six transmembrane 
domains and is 58% similar to the 
uncharacterized ORF YBR147W 
-0.73 1.662 
YOL111C MDY2 Protein required for efficient mating; involved 
in shmoo formation and nuclear migration in 
the pre-zygote; associates with ribosomes 
and interacts with Get4p; has a possible role 
in insertion of tail-anchored proteins into the 
ER membrane 
-0.73 1.662 
YOR294W RRS1 Essential protein that binds ribosomal protein 
L11 and is required for nuclear export of the 
60S pre-ribosomal subunit during ribosome 
biogenesis; mouse homolog shows altered 
expression in Huntington's disease model 
mice 
-0.73 1.662 
YEL021W URA3 Orotidine-5'-phosphate (OMP) -0.77 1.701 
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decarboxylase, catalyzes the sixth enzymatic 
step in the de novo biosynthesis of 
pyrimidines, converting OMP into uridine 
monophosphate (UMP); converts 5-FOA into 
5-fluorouracil, a toxic compound 
YIL070C MAM33 Acidic protein of the mitochondrial matrix 
involved in oxidative phosphorylation; related 
to the human complement receptor gC1q-R 
-0.77 1.701 
YJL063C MRPL8 Mitochondrial ribosomal protein of the large 
subunit 
-0.77 1.701 
YOL097C WRS1 Cytoplasmic tryptophanyl-tRNA synthetase, 
aminoacylates tryptophanyl-tRNA 
-0.77 1.701 
YOL124C TRM11 Catalytic subunit of an adoMet-dependent 
tRNA methyltransferase complex (Trm11p-
Trm112p), required for the methylation of the 
guanosine nucleotide at position 10 (m2G10) 
in tRNAs; contains a THUMP domain and a 
methyltransferase domain 
-0.77 1.701 
YOR309C  Dubious open reading frame unlikely to 
encode a protein, based on available 
experimental and comparative sequence 
data; partially overlaps the verified gene 
NOP58 
-0.80 1.741 
YDR347W MRP1 Mitochondrial ribosomal protein of the small 
subunit; MRP1 exhibits genetic interactions 
with PET122, encoding a COX3-specific 
translational activator, and with PET123, 
encoding a small subunit mitochondrial 
ribosomal protein 
-0.80 1.741 
YGL232W TAN1 Putative tRNA acetyltransferase, RNA-
binding protein required for the formation of 
the modified nucleoside N(4)-acetylcytidine 
in serine and leucine tRNAs but not required 
for the same modification in 18S rRNA 
-0.80 1.741 
YNR021W  Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the endoplasmic reticulum; 
YNR021W is not an essential gene 
-0.80 1.741 
YPR145W ASN1 Asparagine synthetase, isozyme of Asn2p; 
catalyzes the synthesis of L-asparagine from 
L-aspartate in the asparagine biosynthetic 
pathway 
-0.80 1.741 
YHL026C  Putative protein of unknown function; 
YHL026C is not an essential gene; in 2005 
the start site was moved 141 nt upstream 
(see Locus History) 
-0.80 1.741 
YER025W GCD11 Gamma subunit of the translation initiation 
factor eIF2, involved in the identification of 
the start codon; binds GTP when forming the 
ternary complex with GTP and tRNAi-Met 
-0.83 1.782 
YGR145W ENP2 Essential nucleolar protein of unknown 
function; contains WD repeats, interacts with 
Mpp10p and Bfr2p, and has homology to 
Spb1p 
-0.83 1.782 
YHR170W NMD3 Protein involved in nuclear export of the -0.83 1.782 
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large ribosomal subunit; acts as a Crm1p-
dependent adapter protein for export of 
nascent ribosomal subunits through the 
nuclear pore complex 
YKL113C RAD27 5' to 3' exonuclease, 5' flap endonuclease, 
required for Okazaki fragment processing 
and maturation as well as for long-patch 
base-excision repair; member of the S. 
pombe RAD2/FEN1 family 
-0.83 1.782 
YMR033W ARP9 Component of both the SWI/SNF and RSC 
chromatin remodeling complexes; actin-
related protein involved in transcriptional 
regulation 
-0.83 1.782 
YMR243C ZRC1 Vacuolar membrane zinc transporter, 
transports zinc from the cytosol into the 
vacuole for storage; also has a role in 
resistance to zinc shock resulting from a 
sudden influx of zinc into the cytoplasm 
-0.83 1.782 
YNL075W IMP4 Component of the SSU processome, which 
is required for pre-18S rRNA processing; 
interacts with Mpp10p; member of a 
superfamily of proteins that contain a 
sigma(70)-like motif and associate with 
RNAs 
-0.83 1.782 
YNL096C RPS7B Protein component of the small (40S) 
ribosomal subunit, nearly identical to 
Rps7Ap; interacts with Kti11p; deletion 
causes hypersensitivity to zymocin; has 
similarity to rat S7 and Xenopus S8 
ribosomal proteins 
-0.83 1.782 
YNR050C LYS9 Saccharopine dehydrogenase (NADP+, L-
glutamate-forming); catalyzes the formation 
of saccharopine from alpha-aminoadipate 6-
semialdehyde, the seventh step in lysine 
biosynthesis pathway; exhibits genetic and 
physical interactions with TRM112 
-0.83 1.782 
YOR310C NOP58 Protein involved in pre-rRNA processing, 
18S rRNA synthesis, and snoRNA synthesis; 
component of the small subunit processome 
complex, which is required for processing of 
pre-18S rRNA 
-0.83 1.782 
YGL171W ROK1 ATP-dependent RNA helicase of the DEAD 
box family; required for 18S rRNA synthesis 
-0.87 1.823 
YKR006C MRPL13 Mitochondrial ribosomal protein of the large 
subunit, not essential for mitochondrial 
translation 
-0.87 1.823 
YOR340C RPA43 RNA polymerase I subunit A43 -0.87 1.823 
YNL110C NOP15 Constituent of 66S pre-ribosomal particles, 
involved in 60S ribosomal subunit 
biogenesis; localizes to both nucleolus and 
cytoplasm 
-0.90 1.866 
YNR053C NOG2 Putative GTPase that associates with pre-
60S ribosomal subunits in the nucleolus and 





YEL016C NPP2 Nucleotide 
pyrophosphatase/phosphodiesterase family 
member; mediates extracellular nucleotide 
phosphate hydrolysis along with Npp1p and 
Pho5p; activity and expression enhanced 
during conditions of phosphate starvation 
-0.90 1.866 
YJR105W ADO1 Adenosine kinase, required for the utilization 
of S-adenosylmethionine (AdoMet); may be 
involved in recycling adenosine produced 
through the methyl cycle 
-0.90 1.866 
YMR239C RNT1 RNAase III; involved in rDNA transcription 
and rRNA processing; also cleaves a stem-
loop structure at the 3' end of U2 snRNA to 
ensure formation of the correct U2 3' end 
-0.90 1.866 
YFL026W STE2 Receptor for alpha-factor pheromone; seven 
transmembrane-domain GPCR that interacts 
with both pheromone and a heterotrimeric G 
protein to initiate the signaling response that 
leads to mating between haploid a and alpha 
cells 
-0.93 1.910 
YLR056W ERG3 C-5 sterol desaturase, catalyzes the 
introduction of a C-5(6) double bond into 
episterol, a precursor in ergosterol 
biosynthesis; mutants are viable, but cannot 
grow on non-fermentable carbon sources 
-0.93 1.910 
YMR217W GUA1 GMP synthase, an enzyme that catalyzes 
the second step in the biosynthesis of GMP 
from inosine 5'-phosphate (IMP); 
transcription is not subject to regulation by 
guanine but is negatively regulated by 
nutrient starvation 
-0.93 1.910 
YDR398W UTP5 Subunit of U3-containing Small Subunit 
(SSU) processome complex involved in 
production of 18S rRNA and assembly of 
small ribosomal subunit 
-0.97 1.954 
YGR280C PXR1 Essential protein involved in rRNA and 
snoRNA maturation; competes with TLC1 
RNA for binding to Est2p, suggesting a role 
in negative regulation of telomerase; human 
homolog inhibits telomerase; contains a G-
patch RNA interacting domain 
-0.97 1.954 
YDR194C MSS116 DEAD-box protein required for efficient 
splicing of mitochondrial Group I and II 
introns; non-polar RNA helicase that also 
facilities strand annealing 
-0.97 1.954 
YGL078C DBP3 Putative ATP-dependent RNA helicase of 
the DEAD-box family involved in ribosomal 
biogenesis 
-0.97 1.954 
YKL120W OAC1 Mitochondrial inner membrane transporter, 
transports oxaloacetate, sulfate, thiosulfate, 
and isopropylmalate; member of the 
mitochondrial carrier family 
-0.97 1.954 
YLR382C NAM2 Mitochondrial leucyl-tRNA synthetase, also 
has a direct role in splicing of several 




required for mitochondrial genome 
maintenance 
YLR197W NOP56 Essential evolutionarily-conserved nucleolar 
protein component of the box C/D snoRNP 
complexes that direct 2'-O-methylation of 
pre-rRNA during its maturation; 
overexpression causes spindle orientation 
defects 
-0.97 1.954 
YGR082W TOM20 Component of the TOM (translocase of outer 
membrane) complex responsible for 
recognition and initial import steps for all 
mitochondrially directed proteins; acts as a 
receptor for incoming precursor proteins 
-1.00 2.000 
YNL151C RPC31 RNA polymerase III subunit C31; contains 
HMG-like C-terminal domain 
-1.00 2.000 
YNL182C IPI3 Essential component of the Rix1 complex 
(Rix1p, Ipi1p, Ipi3p) that is required for 
processing of ITS2 sequences from 35S pre-
rRNA; highly conserved and contains WD40 
motifs; Rix1 complex associates with Mdn1p 
in pre-60S ribosomal particles 
-1.00 2.000 
YGR131W  Protein of unknown function; expression 
induced in response to ketoconazole; 
promoter region contains a sterol regulatory 
element motif, which has been identified as a 
Upc2p-binding site 
-1.03 2.047 
YNL145W MFA2 Mating pheromone a-factor, made by a cells; 
interacts with alpha cells to induce cell cycle 
arrest and other responses leading to 
mating; biogenesis involves C-terminal 
modification, N-terminal proteolysis, and 
export; also encoded by MFA1 
-1.03 2.047 
YOR187W TUF1 Mitochondrial translation elongation factor 
Tu; comprises both GTPase and guanine 
nucleotide exchange factor activities, while 
these activities are found in separate 
proteins in S. pombe and humans 
-1.03 2.047 
YGR187C HGH1 Nonessential protein of unknown function; 
predicted to be involved in ribosome 
biogenesis; green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm; 
similar to mammalian BRP16 (Brain protein 
16) 
-1.07 2.095 
YIR026C YVH1 Protein phosphatase involved in vegetative 
growth at low temperatures, sporulation, and 
glycogen accumulation; transcription induced 
by low temperature and nitrogen starvation; 
member of the dual-specificity family of 
protein phosphatases 
-1.07 2.095 
YJL218W  Putative protein of unknown function, similar 
to bacterial galactoside O-
acetyltransferases; induced by oleate in an 
OAF1/PIP2-dependent manner; promoter 
contains an oleate response element 




YMR215W GAS3 Putative 1,3-beta-glucanosyltransferase, has 
similarity to Gas1p; localizes to the cell wall 
-1.07 2.095 
YNL248C RPA49 RNA polymerase I subunit A49 -1.07 2.095 
YDR494W RSM28 Mitochondrial ribosomal protein of the small 
subunit; genetic interactions suggest a 
possible role in promoting translation 
initiation 
-1.13 2.194 
YMR241W YHM2 Mitochondrial DNA-binding protein, 
component of the mitochondrial nucleoid 
structure, involved in mtDNA replication and 
segregation of mitochondrial genomes; 
member of the mitochondrial carrier protein 
family 
-1.13 2.194 
YMR246W FAA4 Long chain fatty acyl-CoA synthetase, 
regulates protein modification during growth 
in the presence of ethanol, functions to 
incorporate palmitic acid into phospholipids 
and neutral lipids 
-1.13 2.194 
YNL301C RPL18B Protein component of the large (60S) 
ribosomal subunit, identical to Rpl18Ap and 
has similarity to rat L18 ribosomal protein 
-1.13 2.194 
YDL182W LYS20 Homocitrate synthase isozyme, catalyzes 
the condensation of acetyl-CoA and alpha-
ketoglutarate to form homocitrate, which is 
the first step in the lysine biosynthesis 
pathway; highly similar to the other isozyme, 
Lys21p 
-1.17 2.245 
YJL133W MRS3 Iron transporter that mediates Fe2+ transport 
across the inner mitochondrial membrane; 
mitochondrial carrier family member, similar 
to and functionally redundant with Mrs4p; 
active under low-iron conditions; may 
transport other cations 
-1.17 2.245 
YJL012C VTC4 Vacuolar membrane polyphosphate 
polymerase; subunit of the vacuolar 
transporter chaperone (VTC) complex 
involved in synthesis and transfer of polyP to 
the vacuole; regulates membrane trafficking; 
role in non-autophagic vacuolar fusion 
-1.20 2.297 
YKL172W EBP2 Essential protein required for the maturation 
of 25S rRNA and 60S ribosomal subunit 
assembly, localizes to the nucleolus; 
constituent of 66S pre-ribosomal particles 
-1.20 2.297 
YNL112W DBP2 Essential ATP-dependent RNA helicase of 
the DEAD-box protein family, involved in 
nonsense-mediated mRNA decay and rRNA 
processing 
-1.20 2.297 
YNL246W VPS75 NAP family histone chaperone; binds to 
histones and Rtt109p, stimulating histone 
acetyltransferase activity; possesses 
nucleosome assembly activity in vitro; 
proposed role in vacuolar protein sorting and 
in double-strand break repair 
-1.20 2.297 
YKR092C SRP40 Nucleolar, serine-rich protein with a role in 




function as a chaperone of small nucleolar 
ribonucleoprotein particles (snoRNPs); 
immunologically and structurally to rat 
Nopp140 
YML010W SPT5 Protein involved in regulating Pol I and Pol II 
transcription and pre-mRNA processing; 
forms a complex with Spt4p; contains a C-
terminal repeat domain that is a target for 
phosphorylation by Sgv1p 
-1.23 2.351 
YPL019C VTC3 Subunit of the vacuolar transporter 
chaperone (VTC) complex involved in 
membrane trafficking, vacuolar 
polyphosphate accumulation, 
microautophagy and non-autophagic 
vacuolar fusion 
-1.23 2.351 
YHR137W ARO9 Aromatic aminotransferase II, catalyzes the 
first step of tryptophan, phenylalanine, and 
tyrosine catabolism 
-1.27 2.406 
YLR243W  Putative protein of unknown function; 
YLR243W is an essential gene 
-1.27 2.406 
YDR324C UTP4 Subunit of U3-containing 90S preribosome 
and Small Subunit (SSU) processome 
complexes involved in production of 18S 
rRNA and assembly of small ribosomal 
subunit; member of t-Utp subcomplex 
involved with transcription of 35S rRNA 
transcript 
-1.30 2.462 
YBL002W HTB2 Histone H2B, core histone protein required 
for chromatin assembly and chromosome 
function; nearly identical to HTB1; Rad6p-
Bre1p-Lge1p mediated ubiquitination 
regulates transcriptional activation, meiotic 
DSB formation and H3 methylation 
-1.30 2.462 
YOR108W LEU9 Alpha-isopropylmalate synthase II (2-
isopropylmalate synthase), catalyzes the first 
step in the leucine biosynthesis pathway; the 
minor isozyme, responsible for the residual 
alpha-IPMS activity detected in a leu4 null 
mutant 
-1.30 2.462 
YPL043W NOP4 Nucleolar protein, essential for processing 
and maturation of 27S pre-rRNA and large 
ribosomal subunit biogenesis; constituent of 
66S pre-ribosomal particles; contains four 
RNA recognition motifs (RRMs) 
-1.30 2.462 
YKL082C RRP14 Essential protein, constituent of 66S pre-
ribosomal particles; interacts with proteins 
involved in ribosomal biogenesis and cell 
polarity; member of the SURF-6 family 
-1.37 2.579 
YMR195W ICY1 Protein of unknown function, required for 
viability in rich media of cells lacking 
mitochondrial DNA; mutants have an 
invasive growth defect with elongated 
morphology; induced by amino acid 
starvation 
-1.37 2.579 
YMR290C HAS1 ATP-dependent RNA helicase; localizes to -1.37 2.579 
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both the nuclear periphery and nucleolus; 
highly enriched in nuclear pore complex 
fractions; constituent of 66S pre-ribosomal 
particles 
YDR384C ATO3 Plasma membrane protein, regulation 
pattern suggests a possible role in export of 
ammonia from the cell; phosphorylated in 
mitochondria; member of the TC 9.B.33 
YaaH family of putative transporters 
-1.40 2.639 
YGL077C HNM1 Choline/ethanolamine transporter; involved 
in the uptake of nitrogen mustard and the 
uptake of glycine betaine during hypersaline 
stress; co-regulated with phospholipid 
biosynthetic genes and negatively regulated 
by choline and myo-inositol 
-1.40 2.639 
YDR380W ARO10 Phenylpyruvate decarboxylase, catalyzes 
decarboxylation of phenylpyruvate to 
phenylacetaldehyde, which is the first 
specific step in the Ehrlich pathway 
-1.43 2.701 
YHR184W SSP1 Protein involved in the control of meiotic 
nuclear division and coordination of meiosis 
with spore formation; transcription is induced 
midway through meiosis 
-1.43 2.701 
YKL081W TEF4 Translation elongation factor EF-1 gamma -1.47 2.764 
YML123C PHO84 High-affinity inorganic phosphate (Pi) 
transporter and low-affinity manganese 
transporter; regulated by Pho4p and Spt7p; 
mutation confers resistance to arsenate; exit 
from the ER during maturation requires 
Pho86p 
-1.50 2.828 
YNL141W AAH1 Adenine deaminase (adenine 
aminohydrolase), converts adenine to 
hypoxanthine; involved in purine salvage; 
transcriptionally regulated by nutrient levels 
and growth phase; Aah1p degraded upon 
entry into quiescence via SCF and the 
proteasome 
-1.53 2.895 
YKL029C MAE1 Mitochondrial malic enzyme, catalyzes the 
oxidative decarboxylation of malate to 
pyruvate, which is a key intermediate in 
sugar metabolism and a precursor for 
synthesis of several amino acids 
-1.60 3.031 
YHR143W DSE2 Daughter cell-specific secreted protein with 
similarity to glucanases, degrades cell wall 
from the daughter side causing daughter to 
separate from mother; expression is 
repressed by cAMP 
-1.63 3.102 
YLR452C SST2 GTPase-activating protein for Gpa1p, 
regulates desensitization to alpha factor 
pheromone; also required to prevent 
receptor-independent signaling of the mating 
pathway; member of the RGS (regulator of 
G-protein signaling) family 
-1.67 3.175 
YMR058W FET3 Ferro-O2-oxidoreductase required for high-




resistance to copper ion toxicity, belongs to 
class of integral membrane multicopper 
oxidases 
YOL014W  Putative protein of unknown function -1.80 3.482 
YAR068W  Fungal-specific protein of unknown function; 
induced in respiratory-deficient cells 
-1.87 3.647 
YMR006C PLB2 Phospholipase B (lysophospholipase) 
involved in phospholipid metabolism; 
displays transacylase activity in vitro; 
overproduction confers resistance to 
lysophosphatidylcholine 
-2.17 4.490 
YJR147W HMS2 Protein with similarity to heat shock 
transcription factors; overexpression 
suppresses the pseudohyphal filamentation 
defect of a diploid mep1 mep2 homozygous 
null mutant 
-2.37 5.157 
YIL119C RPI1 Putative transcriptional regulator; 
overexpression suppresses the heat shock 
sensitivity of wild-type RAS2 overexpression 
and also suppresses the cell lysis defect of 
an mpk1 mutation 
-2.70 6.498 
YDR281C PHM6 Protein of unknown function, expression is 
regulated by phosphate levels 
-2.77 6.805 
YBR093C PHO5 Repressible acid phosphatase (1 of 3) that 
also mediates extracellular nucleotide-
derived phosphate hydrolysis; secretory 
pathway derived cell surface glycoprotein; 
induced by phosphate starvation and 
coordinately regulated by PHO4 and PHO2 
-3.50 11.314 
YHR136C SPL2 Protein with similarity to cyclin-dependent 
kinase inhibitors; downregulates low-affinity 
phosphate transport during phosphate 
limitation; overproduction suppresses a plc1 
null mutation; GFP-fusion protein localizes to 
the cytoplasm 
-3.67 12.699 
YAR071W PHO11 One of three repressible acid phosphatases, 
a glycoprotein that is transported to the cell 
surface by the secretory pathway; induced 
by phosphate starvation and coordinately 
regulated by PHO4 and PHO2 
-3.97 15.635 
YLR242C ARV1 Protein functioning in transport of 
glycosylphosphatidylinositol intermediates 
into the ER lumen; required for normal 
intracellular sterol distribution and for 
sphingolipid metabolism; similar to Nup120p 





Appendix 4. Gene ontology (GO) categories enriched in the arv1Δ  condition. 







GO Category Information 
GO:0003735 141 <1E-16 -18.48 <1E-16 structural constituent of 
ribosome 
GO:0042254 438 <1E-16 -18.09 <1E-16 ribosome biogenesis 
GO:0006412 283 <1E-16 -17.09 <1E-16 translation 
GO:0030529 197 <1E-16 -16.39 <1E-16 ribonucleoprotein complex 
GO:0006364 129 <1E-16 -14.29 <1E-16 rRNA processing 
GO:0005730 149 <1E-16 -13.64 <1E-16 nucleolus 
GO:0015935 11 2.41E-08 -13.02 2.83E-03 small ribosomal subunit 
GO:0032543 55 <1E-16 -12.99 6.51E-13 mitochondrial translation 
GO:0030686 55 <1E-16 -12.35 6.61E-15 90S preribosome 
GO:0022627 43 1.67E-16 -12.34 4.92E-09 cytosolic small ribosomal 
subunit 
GO:0030687 25 1.04E-11 -11.82 4.80E-11 preribosome, large subunit 
precursor 
GO:0005762 28 7.05E-12 -11.04 2.24E-08 mitochondrial large 
ribosomal subunit 
GO:0032040 34 8.34E-13 -10.94 1.12E-10 small-subunit processome 
GO:0030515 14 4.42E-08 -10.72 3.47E-05 snoRNA binding 
GO:0005840 215 <1E-16 -10.67 <1E-16 ribosome 
GO:0000447 26 4.06E-11 -10.63 2.51E-07 endonucleolytic cleavage in 
ITS1 to separate SSU-rRNA 
from 5.8S rRNA and LSU-
rRNA from tricistronic rRNA 
transcript (SSU-rRNA, 5.8S 
rRNA, LSU-rRNA) 
GO:0000027 28 6.02E-11 -10.16 7.10E-09 ribosomal large subunit 
assembly and maintenance 
GO:0022625 50 2.48E-13 -9.68 1.31E-09 cytosolic large ribosomal 
subunit 
GO:0000462 34 2.52E-11 -9.62 2.53E-09 maturation of SSU-rRNA 
from tricistronic rRNA 
transcript (SSU-rRNA, 5.8S 
rRNA, LSU-rRNA) 
GO:0000472 20 1.55E-08 -9.1 3.28E-06 endonucleolytic cleavage to 
generate mature 5'-end of 
SSU-rRNA from (SSU-rRNA, 
5.8S rRNA, LSU-rRNA) 
GO:0019843 18 5.28E-08 -8.92 2.21E-05 rRNA binding 
GO:0000480 18 6.50E-08 -8.83 8.34E-06 endonucleolytic cleavage in 
5'-ETS of tricistronic rRNA 
transcript (SSU-rRNA, 5.8S 
rRNA, LSU-rRNA) 
GO:0005736 12 4.60E-06 -8.13 8.89E-05 DNA-directed RNA 
polymerase I complex 
GO:0015934 11 7.90E-06 -8.12 8.11E-04 large ribosomal subunit 
GO:0042273 22 6.27E-08 -8.06 3.25E-08 ribosomal large subunit 
biogenesis 
GO:0003723 228 3.74E-13 -7.65 4.11E-14 RNA binding 
GO:0006417 275 1.02E-11 -7.04 3.21E-07 regulation of translation 
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GO:0005666 16 3.50E-06 -7.02 8.12E-05 DNA-directed RNA 
polymerase III complex 
GO:0000463 13 1.48E-05 -6.9 6.11E-05 maturation of LSU-rRNA 
from tricistronic rRNA 
transcript (SSU-rRNA, 5.8S 
rRNA, LSU-rRNA) 
GO:0003899 33 7.34E-08 -6.86 8.25E-06 DNA-directed RNA 
polymerase activity 
GO:0016072 220 3.81E-10 -6.53 5.25E-10 rRNA metabolic process 
GO:0005634 1395 4.06E-10 -6.27 6.14E-09 nucleus 
GO:0005763 24 8.30E-06 -5.66 6.78E-05 mitochondrial small 
ribosomal subunit 
GO:0004812 28 5.56E-06 -5.59 9.13E-05 aminoacyl-tRNA ligase 
activity 
GO:0006418 26 1.18E-05 -5.41 1.11E-04 tRNA aminoacylation for 
protein translation 
GO:0030150 18 4.44E-05 -5.41 6.43E-05 protein import into 
mitochondrial matrix 
GO:0004004 20 6.81E-05 -5.05 1.06E-04 ATP-dependent RNA 
helicase activity 
GO:0008026 40 1.02E-05 -5.04 1.11E-04 ATP-dependent helicase 
activity 
GO:0005622 279 4.98E-06 -4.64 2.63E-08 intracellular 
GO:0003743 34 5.45E-05 -4.61 1.49E-04 translation initiation factor 
activity 
GO:0003676 182 2.61E-05 -4.31 3.44E-06 nucleic acid binding 
GO:0006511 127 6.45E-05 4.12 3.83E-04 ubiquitin-dependent protein 
catabolic process 
GO:0016192 106 3.81E-05 4.29 5.92E-05 vesicle-mediated transport 
GO:0007039 74 5.30E-05 4.29 1.38E-06 vacuolar protein catabolic 
process 
GO:0005789 204 1.18E-05 4.48 5.41E-05 endoplasmic reticulum 
membrane 
GO:0000139 89 2.15E-05 4.48 6.54E-06 Golgi membrane 
GO:0030433 32 7.91E-05 4.53 2.14E-05 ER-associated protein 
catabolic process 
GO:0005783 293 3.42E-06 4.72 4.10E-06 endoplasmic reticulum 
GO:0005575 440 1.77E-06 4.84 1.61E-09 cellular_component 
GO:0003674 1326 8.94E-07 4.93 2.77E-08 molecular_function 
GO:0005794 150 1.87E-07 5.45 1.07E-07 Golgi apparatus 
GO:0005768 80 3.84E-07 5.5 4.06E-06 endosome 
GO:0006914 158 4.56E-09 6.19 5.13E-13 autophagy 
GO:0008150 802 4.77E-11 6.65 1.69E-13 biological_process 
GO:0016021 813 1.63E-12 7.15 1.55E-15 integral to membrane 
GO:0016020 1136 3.01E-15 7.96 <1E-16 membrane 




Appendix 5. UPR induction in ARV1 mutants does not reflect a generalized response to 
alterations in lipid metabolism.  Complete list of lipid-metabolic mutants and hypomorphic 
(DAmP) alleles screened for UPR induction by HAC1 splicing assay.  Mutants with a 
HAC1i/(HAC1i+HAC1u) score ≥ 3 were rescreened by qRT-PCR analyses of canonical UPR 








ACB1 YGR037C Deletion 
Strain 
2 Acyl-CoA-binding protein, transports newly 
synthesized acyl-CoA esters from fatty acid 
synthetase (Fas1p-Fas2p) to acyl-CoA-
consuming processes; subject to starvation-
induced, Grh1p-mediated unconventional 
secretion 
ACC1 YNR016C DAmP 
Allele 
1 Acetyl-CoA carboxylase, biotin containing 
enzyme that catalyzes the carboxylation of 
acetyl-CoA to form malonyl-CoA; required for 
de novo biosynthesis of long-chain fatty 
acids 
ACP1 YKL192C DAmP 
Allele 
1 Mitochondrial matrix acyl carrier protein, 
involved in biosynthesis of octanoate, which 
is a precursor to lipoic acid; activated by 
phosphopantetheinylation catalyzed by 
Ppt2p 
ARE1 YCR048W Deletion 
Strain 
0 Acyl-CoA:sterol acyltransferase, isozyme of 
Are2p; endoplasmic reticulum enzyme that 
contributes the major sterol esterification 
activity in the absence of oxygen 
ARE2 YNR019W Deletion 
Strain 
1 Acyl-CoA:sterol acyltransferase, isozyme of 
Are1p; endoplasmic reticulum enzyme that 
contributes the major sterol esterification 
activity in the presence of oxygen 
ARV1 YLR242C Deletion 
Strain 
21 Protein functioning in transport of 
glycosylphosphatidylinositol intermediates 
into the ER lumen; required for normal 
intracellular sterol distribution and for 
sphingolipid metabolism; similar to Nup120p 
and C. elegans R05H5.5 protein 
AUS1 YOR011W Deletion 
Strain 
0 Transporter of the ATP-binding cassette 
family, involved in uptake of sterols and 
anaerobic growth 
CEM1 YER061C Deletion 
Strain 
1 Mitochondrial beta-keto-acyl synthase with 
possible role in fatty acid synthesis; required 
for mitochondrial respiration 
CSG2 YBR036C Deletion 
Strain 
0 Endoplasmic reticulum membrane protein, 
required for mannosylation of 
inositolphosphorylceramide and for growth at 
high calcium concentrations 
CSH1 YBR161W Deletion 
Strain 
0 Probable catalytic subunit of a 
mannosylinositol phosphorylceramide 
(MIPC) synthase, forms a complex with 
probable regulatory subunit Csg2p; function 
in sphingolipid biosynthesis is overlapping 
with that of Sur1p 
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DGA1 YOR245C Deletion 
Strain 
2 Diacylglycerol acyltransferase, catalyzes the 
terminal step of triacylglycerol (TAG) 
formation, acylates diacylglycerol using acyl-
CoA as an acyl donor, localized to lipid 
particles 
DPL1 YDR294C Deletion 
Strain 
-2 Dihydrosphingosine phosphate lyase, 
regulates intracellular levels of sphingolipid 
long-chain base phosphates (LCBPs), 
degrades phosphorylated long chain bases, 
prefers C16 dihydrosphingosine-l-phosphate 
as a substrate 
ELO1 YJL196C Deletion 
Strain 
2 Elongase I, medium-chain acyl elongase, 
catalyzes carboxy-terminal elongation of 
unsaturated C12-C16 fatty acyl-CoAs to 
C16-C18 fatty acids 
EPT1 YHR123W Deletion 
Strain 
-4 sn-1,2-diacylglycerol ethanolamine- and 
cholinephosphotranferase; not essential for 
viability 
ERG1 YGR175C DAmP 
Allele 
2 Squalene epoxidase, catalyzes the 
epoxidation of squalene to 2,3-
oxidosqualene; plays an essential role in the 
ergosterol-biosynthesis pathway and is the 
specific target of the antifungal drug 
terbinafine 
ERG10 YPL028W DAmP 
Allele 
1 Acetyl-CoA C-acetyltransferase (acetoacetyl-
CoA thiolase), cytosolic enzyme that 
transfers an acetyl group from one acetyl-
CoA molecule to another, forming 
acetoacetyl-CoA; involved in the first step in 
mevalonate biosynthesis 
ERG11 YHR007C Deletion 
Strain 
4 Lanosterol 14-alpha-demethylase, catalyzes 
the C-14 demethylation of lanosterol to form 
4,4''-dimethyl cholesta-8,14,24-triene-3-beta-
ol in the ergosterol biosynthesis pathway; 
member of the cytochrome P450 family 
ERG12 YMR208W DAmP 
Allele 
2 Mevalonate kinase, acts in the biosynthesis 
of isoprenoids and sterols, including 
ergosterol, from mevalonate 
ERG13 YML126C DAmP 
Allele 
0 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) 
synthase, catalyzes the formation of HMG-
CoA from acetyl-CoA and acetoacetyl-CoA; 
involved in the second step in mevalonate 
biosynthesis 
ERG19 YNR043W DAmP 
Allele 
0 Mevalonate pyrophosphate decarboxylase, 
essential enzyme involved in the 
biosynthesis of isoprenoids and sterols, 
including ergosterol; acts as a homodimer 
ERG2 YMR202W Deletion 
Strain 
5 C-8 sterol isomerase, catalyzes the 
isomerization of the delta-8 double bond to 
the delta-7 position at an intermediate step in 
ergosterol biosynthesis 
ERG20 YJL167W DAmP 
Allele 
-1 Farnesyl pyrophosphate synthetase, has 
both dimethylallyltranstransferase and 
geranyltranstransferase activities; catalyzes 
the formation of C15 farnesyl pyrophosphate 
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units for isoprenoid and sterol biosynthesis 
ERG24 YNL280C Deletion 
Strain 
7 C-14 sterol reductase, acts in ergosterol 
biosynthesis; mutants accumulate the 
abnormal sterol ignosterol (ergosta-8,14 
dienol), and are viable under anaerobic 
growth conditions but inviable on rich 
medium under aerobic conditions 
ERG25 YGR060W DAmP 
Allele 
0 C-4 methyl sterol oxidase, catalyzes the first 
of three steps required to remove two C-4 
methyl groups from an intermediate in 
ergosterol biosynthesis; mutants accumulate 
the sterol intermediate 4,4-
dimethylzymosterol 
ERG26 YGL001C DAmP 
Allele 
2 C-3 sterol dehydrogenase, catalyzes the 
second of three steps required to remove 
two C-4 methyl groups from an intermediate 
in ergosterol biosynthesis 
ERG28 YER044C Deletion 
Strain 
14 Endoplasmic reticulum membrane protein, 
may facilitate protein-protein interactions 
between the Erg26p dehydrogenase and the 
Erg27p 3-ketoreductase and/or tether these 
enzymes to the ER, also interacts with Erg6p 
ERG29 YMR134W DAmP 
Allele 
1 Protein of unknown function that may be 
involved in iron metabolism; mutant bm-8 
has a growth defect on iron-limited medium 
that is complemented by overexpression of 
Yfh1p; shows localization to the ER; highly 
conserved in ascomycetes 
ERG3 YLR056W Deletion 
Strain 
0 C-5 sterol desaturase, catalyzes the 
introduction of a C-5(6) double bond into 
episterol, a precursor in ergosterol 
biosynthesis; mutants are viable, but cannot 
grow on non-fermentable carbon sources 
ERG4 YGL012W Deletion 
Strain 
1 C-24(28) sterol reductase, catalyzes the final 
step in ergosterol biosynthesis; mutants are 
viable, but lack ergosterol 
ERG5 YMR015C Deletion 
Strain 
3 C-22 sterol desaturase, a cytochrome P450 
enzyme that catalyzes the formation of the 
C-22(23) double bond in the sterol side chain 
in ergosterol biosynthesis; may be a target of 
azole antifungal drugs 
ERG6 YML008C Deletion 
Strain 
6 Delta(24)-sterol C-methyltransferase, 
converts zymosterol to fecosterol in the 
ergosterol biosynthetic pathway by 
methylating position C-24; localized to both 
lipid particles and mitochondrial outer 
membrane 
ERG8 YMR220W DAmP 
Allele 
1 Phosphomevalonate kinase, an essential 
cytosolic enzyme that acts in the 
biosynthesis of isoprenoids and sterols, 
including ergosterol, from mevalonate 
ETR1 YBR026C Deletion 
Strain 
0 2-enoyl thioester reductase, member of the 
medium chain dehydrogenase/reductase 
family; localized to in mitochondria, where it 
has a probable role in fatty acid synthesis 
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FAS1 YKL182W DAmP 
Allele 
1 Beta subunit of fatty acid synthetase, which 
catalyzes the synthesis of long-chain 
saturated fatty acids; contains 
acetyltransacylase, dehydratase, enoyl 
reductase, malonyl transacylase, and 
palmitoyl transacylase activities 
FAS2 YPL231W DAmP 
Allele 
9 Alpha subunit of fatty acid synthetase, which 
catalyzes the synthesis of long-chain 
saturated fatty acids; contains the acyl-
carrier protein domain and beta-ketoacyl 
reductase, beta-ketoacyl synthase and self-
pantetheinylation activities 
FEN1 YCR034W Deletion 
Strain 
2 Fatty acid elongase, involved in sphingolipid 
biosynthesis; acts on fatty acids of up to 24 
carbons in length; mutations have regulatory 
effects on 1,3-beta-glucan synthase, 
vacuolar ATPase, and the secretory pathway 
HFA1 YMR207C Deletion 
Strain 
1 Mitochondrial acetyl-coenzyme A 
carboxylase, catalyzes the production of 
malonyl-CoA in mitochondrial fatty acid 
biosynthesis 
HMG1 YML075C Deletion 
Strain 
3 One of two isozymes of HMG-CoA reductase 
that catalyzes the conversion of HMG-CoA 
to mevalonate, which is a rate-limiting step in 
sterol biosynthesis; localizes to the nuclear 
envelope; overproduction induces the 
formation of karmellae 
HMG2 YLR450W Deletion 
Strain 
1 One of two isozymes of HMG-CoA reductase 
that convert HMG-CoA to mevalonate, a 
rate-limiting step in sterol biosynthesis; 
overproduction induces assembly of 
peripheral ER membrane arrays and short 
nuclear-associated membrane stacks 
HTD2 YHR067W Deletion 
Strain 
2 Mitochondrial 3-hydroxyacyl-thioester 
dehydratase involved in fatty acid 
biosynthesis, required for respiratory growth 
and for normal mitochondrial morphology 
IDI1 YPL117C DAmP 
Allele 
2 Isopentenyl diphosphate:dimethylallyl 
diphosphate isomerase (IPP isomerase), 
catalyzes an essential activation step in the 
isoprenoid biosynthetic pathway; required for 
viability 
IPT1 YDR072C Deletion 
Strain 
1 Inositolphosphotransferase, involved in 
synthesis of mannose-(inositol-P)2-ceramide 
(M(IP)2C), the most abundant sphingolipid;, 
can mutate to resistance to the antifungals 
syringomycin E and DmAMP1 and to K. 
lactis zymocin 
ISC1 YER019W Deletion 
Strain 
1 Mitochondrial membrane localized inositol 
phosphosphingolipid phospholipase C, 
hydrolyzes complex sphingolipids to produce 
ceramide; activated by phosphatidylserine, 
cardiolipin, and phosphatidylglycerol; 
mediates Na+ and Li+ halotolerance 
LAC1 YKL008C Deletion 0 Ceramide synthase component, involved in 
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Strain synthesis of ceramide from C26(acyl)-
coenzyme A and dihydrosphingosine or 
phytosphingosine, functionally equivalent to 
Lag1p 
LAG1 YHL003C Deletion 
Strain 
-1 Ceramide synthase component, involved in 
synthesis of ceramide from C26(acyl)-
coenzyme A and dihydrosphingosine or 
phytosphingosine, functionally equivalent to 
Lac1p 
LCB2 YDR062W DAmP 
Allele 
0 Component of serine palmitoyltransferase, 
responsible along with Lcb1p for the first 
committed step in sphingolipid synthesis, 
which is the condensation of serine with 
palmitoyl-CoA to form 3-ketosphinganine 
LCB3 YJL134W Deletion 
Strain 
1 Long-chain base-1-phosphate phosphatase 
with specificity for dihydrosphingosine-1-
phosphate, regulates ceramide and long-
chain base phosphates levels, involved in 
incorporation of exogenous long chain bases 
in sphingolipids 
LCB4 YOR171C Deletion 
Strain 
-34 Sphingoid long-chain base kinase, 
responsible for synthesis of long-chain base 
phosphates, which function as signaling 
molecules, regulates synthesis of ceramide 
from exogenous long-chain bases, localizes 
to the Golgi and late endosomes 
LCB5 YLR260W Deletion 
Strain 
0 Minor sphingoid long-chain base kinase, 
paralog of Lcb4p responsible for few percent 
of the total activity, possibly involved in 
synthesis of long-chain base phosphates, 
which function as signaling molecules 
LRO1 YNR008W Deletion 
Strain 
5 Acyltransferase that catalyzes diacylglycerol 
esterification; one of several 
acyltransferases that contribute to 
triglyceride synthesis; putative homolog of 
human lecithin cholesterol acyltransferase 
MCT1 YOR221C Deletion 
Strain 
1 Predicted malonyl-CoA:ACP transferase, 
putative component of a type-II mitochondrial 
fatty acid synthase that produces 
intermediates for phospholipid remodeling 
MGA2 YIR033W Deletion 
Strain 
0 ER membrane protein involved in regulation 
of OLE1 transcription, acts with homolog 
Spt23p; inactive ER form dimerizes and one 
subunit is then activated by 
ubiquitin/proteasome-dependent processing 
followed by nuclear targeting 
NCR1 YPL006W Deletion 
Strain 
0 Vacuolar membrane protein that transits 
through the biosynthetic vacuolar protein 
sorting pathway, involved in sphingolipid 
metabolism; glycoprotein and functional 
orthologue of human Niemann Pick C1 
(NPC1) protein 
OAR1 YKL055C Deletion 
Strain 
0 Mitochondrial 3-oxoacyl-[acyl-carrier-protein] 
reductase, may comprise a type II 




OLE1 YGL055W DAmP 
Allele 
0 Delta(9) fatty acid desaturase, required for 
monounsaturated fatty acid synthesis and for 
normal distribution of mitochondria 
OSH1 YAR042W Deletion 
Strain 
1 Protein similar to mammalian oxysterol-
binding protein; contains ankyrin repeats; 
localizes to the Golgi and the nucleus-
vacuole junction 
OSH2 YDL019C Deletion 
Strain 
0 Member of an oxysterol-binding protein 
family with seven members in S. cerevisiae; 
family members have overlapping, 
redundant functions in sterol metabolism and 
collectively perform a function essential for 
viability 
OSH3 YHR073W Deletion 
Strain 
2 Member of an oxysterol-binding protein 
family with seven members in S. cerevisiae; 
family members have overlapping, 
redundant functions in sterol metabolism and 
collectively perform a function essential for 
viability 
OSH4 YPL145C Deletion 
Strain 
1 Member of the oxysterol binding protein 
family, which includes seven yeast 
homologs; involved in negative regulation of 
Sec14p-dependent Golgi complex secretory 
functions, peripheral membrane protein that 
localizes to the Golgi complex 
OSH5 YOR237W Deletion 
Strain 
0 Protein implicated in the regulation of 
ergosterol biosynthesis; one of a seven 
member gene family with a common 
essential function and non-essential unique 
functions; similar to human oxysterol binding 
protein (OSBP) 
OSH6 YKR003W Deletion 
Strain 
1 Member of an oxysterol-binding protein 
family with overlapping, redundant functions 
in sterol metabolism and which collectively 
perform a function essential for viability; 
GFP-fusion protein localizes to the cell 
periphery 
OSH7 YHR001W Deletion 
Strain 
-2 Member of an oxysterol-binding protein 
family with seven members in S. cerevisiae; 
family members have overlapping, 
redundant functions in sterol metabolism and 
collectively perform a function essential for 
viability 
PDR11 YIL013C Deletion 
Strain 
4 ATP-binding cassette (ABC) transporter, 
multidrug transporter involved in multiple 
drug resistance; mediates sterol uptake 
when sterol biosynthesis is 
compromisedregulated by Pdr1p; required 
for anaerobic growth 
SCS7 YMR272C Deletion 
Strain 
2 Sphingolipid alpha-hydroxylase, functions in 
the alpha-hydroxylation of sphingolipid-
associated very long chain fatty acids, has 
both cytochrome b5-like and 
hydroxylase/desaturase domains, not 
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essential for growth 
SKN1 YGR143W Deletion 
Strain 
1 Protein involved in sphingolipid biosynthesis; 
type II membrane protein with similarity to 
Kre6p 
SLC1 YDL052C Deletion 
Strain 
-2 1-acyl-sn-glycerol-3-phosphate 
acyltransferase, catalyzes the acylation of 
lysophosphatidic acid to form phosphatidic 
acid, a key intermediate in lipid metabolism; 
enzymatic activity detected in lipid particles 
and microsomes 
SUR1 YPL057C Deletion 
Strain 
1 Probable catalytic subunit of a 
mannosylinositol phosphorylceramide 
(MIPC) synthase, forms a complex with 
probable regulatory subunit Csg2p; function 
in sphingolipid biosynthesis is overlapping 
with that of Csh1p 
SUR2 YDR297W Deletion 
Strain 
0 Sphinganine C4-hydroxylase, catalyses the 
conversion of sphinganine to 
phytosphingosine in sphingolipid biosyntheis 
SUR4 YLR372W Deletion 
Strain 
1 Elongase, involved in fatty acid and 
sphingolipid biosynthesis; synthesizes very 
long chain 20-26-carbon fatty acids from 
C18-CoA primers; involved in regulation of 
sphingolipid biosynthesis 
TSC10 YBR265W DAmP 
Allele 
1 3-ketosphinganine reductase, catalyzes the 
second step in phytosphingosine synthesis, 
essential for growth in the absence of 
exogenous dihydrosphingosine or 
phytosphingosine, member of short chain 
dehydrogenase/reductase protein family 
TSC11 YER093C Deletion 
Strain 
1 Subunit of TORC2 (Tor2p-Lst8p-Avo1-Avo2-
Tsc11p-Bit61p), a membrane-associated 
complex that regulates actin cytoskeletal 
dynamics during polarized growth and cell 
wall integrity; involved in sphingolipid 
metabolism; contains a RasGEFN domain 
TSC13 YDL015C DAmP 
Allele 
4 Enoyl reductase that catalyzes the last step 
in each cycle of very long chain fatty acid 
elongation, localizes to the ER, highly 
enriched in a structure marking nuclear-
vacuolar junctions, coimmunoprecipitates 
with elongases Fen1p and Sur4p 
TSC3 YBR058C-A Deletion 
Strain 
0 Protein that stimulates the activity of serine 
palmitoyltransferase (Lcb1p, Lcb2p) several-
fold; involved in sphingolipid biosynthesis 
YDC1 YPL087W Deletion 
Strain 
1 Alkaline dihydroceramidase, involved in 
sphingolipid metabolism; preferentially 
hydrolyzes dihydroceramide to a free fatty 
acid and dihydrosphingosine; has a minor 
reverse activity 
YPC1 YBR183W Deletion 
Strain 
-1 Alkaline ceramidase that also has reverse 
(CoA-independent) ceramide synthase 
activity, catalyzes both breakdown and 
synthesis of phytoceramide; overexpression 
confers fumonisin B1 resistance 
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YSR3 YKR053C Deletion 
Strain 
0 Dihydrosphingosine 1-phosphate 
phosphatase, membrane protein involved in 
sphingolipid metabolism; has similarity to 
Lcb3p 
 
